Methods for treating cancer with PD-1 axis binding antagonist, antimetabolite and platinum formulation

Combining PD-1 axis binding antagonists with pemetrexed and platinum agents in NSCLC treatment enhances progression-free and overall survival, addressing the limitations of current therapies by improving survival rates and reducing toxicity.

JP2024161372APending Publication Date: 2024-11-19GENENTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024114391
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-09-21
Filing Date
2024-07-18
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Current treatment regimens for non-small cell lung cancer (NSCLC), particularly non-squamous NSCLC, are associated with significant toxicities and limited survival benefits, with platinum-based chemotherapy offering only a stable response rate of about 20% and a 1-year survival rate ranging from 31% to 36%, and targeted therapies face challenges with acquired resistance.

Method used

Administering a combination of a PD-1 axis binding antagonist, such as atezolizumab, with an antimetabolite like pemetrexed and a platinum agent, either carboplatin or cisplatin, to treat chemotherapy-naïve patients with stage IV non-squamous NSCLC, enhancing progression-free and overall survival.

Benefits of technology

The combination therapy significantly improves progression-free survival by approximately 7.6 months and overall survival by 18.1 months compared to chemotherapy alone, with no new safety signals identified, providing a more effective treatment option for NSCLC patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161372000022
    Figure 2024161372000022
  • Figure 2024161372000023
    Figure 2024161372000023
  • Figure 2024161372000024
    Figure 2024161372000024
Patent Text Reader

Abstract

To provide methods for treating lung cancer, e.g., Stage IV non-squamous epithelial non-small cell lung cancer in an individual.SOLUTION: A method comprises administering to an individual, a PD-1 axis binding antagonist (such as an anti-PD-L1 antibody, e.g., atezolizumab), an antimetabolite (e.g., pemetrexed), and a platinum agent (e.g., cisplatin or carboplatin).SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 700,184, filed July 18, 2018, and U.S. Provisional Application No. 62 / 734,936, filed September 21, 2018, the contents of each of which are incorporated by reference in their entirety herein.

[0002] Submitting a sequence listing as an ASCII text file The following submission in an ASCII text file is incorporated by reference in its entirety: Sequence Listing in computer readable form (CRF) (Filename: 146392045140SEQLIST.TXT, Recorded: July 12, 2019, Size: 37KB). [Technical field]

[0003] The present disclosure relates to methods of treating cancer by administering a PD-1 axis binding antagonist (e.g., atezolizumab) in combination with an antimetabolite (e.g., pemetrexed) and a platinum agent (e.g., carboplatin or cisplatin). [Background technology]

[0004] Lung cancer remains the leading cause of cancer deaths worldwide. It is the most common cancer in men, accounting for approximately 13% of new cancers in 2008 (Jemal et al. (2011) CA Cancer J. Clin 61:69-90). In 2012, it was estimated that there were 313,000 new cases of lung cancer and 268,000 deaths from lung cancer in Europe (GLOBOCAN (2012). Estimated cancer incidence: mortality and prevalence Worldwide in 2012., accessed at: globocan(dot)iarc(dot)fr / Pages / fact_sheets_cancer.aspx.). Similar data from the United States estimated that there would be 221,200 new cases of lung cancer and 158,040 deaths from lung cancer in 2015 (Siegel et al. 2015 CA Cancer J Clin. 65:5-29).

[0005] Non-small cell lung cancer (NSCLC) is the major subtype of lung cancer, accounting for approximately 85% of all cases (Molina et al. (2008) Mayo Clin Proc 83:584:94; Howlader et al. (2011) SEER cancer statistics review, 1975-2011, National Cancer Institute). NSCLC can be divided into two major histological types: adenocarcinoma and squamous cell carcinoma (Travis et al. (2011) J Thorac Oncol 6:244-85). Adenocarcinoma histology accounts for more than half of all NSCLC cases, and squamous cell histology accounts for approximately 25% (Langer et al. (2010) J Clin Oncol 28:5311-20). The remaining cases of NSCLC are represented by large cell carcinoma, neuroendocrine tumors, sarcomatoid carcinoma, and poorly differentiated histology.

[0006] The overall 5-year survival rate for advanced disease is 2%-4%, depending on geographic location (Cetin et al. (2011) Clin Epidemiol 3:139-48). Poor prognostic factors for survival in patients with NSCLC include advanced stage disease at presentation, poor performance status, and a history of unintentional weight loss. More than half of patients with NSCLC are diagnosed with distant disease, which directly contributes to poor survival prospects.

[0007] Platinum-based regimens remain the standard first-line treatment for patients with locally advanced or metastatic NSCLC who do not harbor EGFR mutations or ALK gene rearrangements. In particular, for newly diagnosed advanced non-squamous NSCLC, the standard of care is a platinum doublet with either cisplatin or carboplatin and either a taxane or pemetrexed, with or without bevacizumab. However, current treatment regimens are associated with many toxicities (such as febrile neutropenia, myelosuppression, nausea, alopecia, nephropathy, and neuropathy) and are generally not tolerated by elderly and poor performance status patients. Moreover, the survival benefit provided by cytotoxic chemotherapy has plateaued, with an overall response rate of approximately 20% and 1-year survival rates ranging from 31% to 36% (Schiller et al. (2002) N Engl J Med. 346:92-98).

[0008] Differences in disease characteristics are observed between adenocarcinoma and squamous NSCLC. First, squamous tumors commonly reside in the central airways and typically remain confined to the bronchial epithelium (Hirsch et al. (2008) J Thorac Oncol. 3:1468-1481), whereas nonsquamous tumors are more commonly located in the lung parenchyma distal to the central airways. Evaluation of NSCLC tumor tissue typically reveals cytologic differences between squamous cell types (keratinization, intracellular bridges, central necrosis) and adenocarcinoma (glandular architecture). When tumor samples are poorly differentiated or limited tissue is available, immunohistochemical markers may aid the histologic diagnosis. Thyroid transcription factor 1 is rarely expressed in squamous cells and strongly expressed in adenocarcinoma. In contrast, p63, CK5 / 6, and 34βE12 are highly expressed in squamous cell carcinomas and less frequently expressed in adenocarcinomas (Travis et al. (2011) J Thorac Oncol. 6:244-85).

[0009] Genetic alterations of prognostic and / or predictive significance in NSCLC include epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, and GTPase Kras (KRAS) gene mutations. The rates of these mutations differ between squamous cell carcinoma and adenocarcinoma. For example, EGFR kinase domain mutations have been reported in 10%-40% of patients with adenocarcinoma NSCLC, but are rarely observed in patients with squamous cell NSCLC (Herbst et al. (2008) N Engl J Med. 359:1367-80). Similarly, ALK fusion oncogenes, recognized as drivers of lung tumorigenesis, are observed in approximately 7% of patients with adenocarcinoma but are very rare in squamous histology (Herbst et al. (2008) N Engl J Med. 359:1367-80; Langer et al. (2010) J Clin Oncol 28:5311-20). In addition, KRAS mutations are very rare in squamous NSCLC but can be observed in up to 30% of adenocarcinoma NSCLC cases (Travis et al. (2011) J Thorac Oncol. 6:244-85).

[0010] Genotype-directed therapy may dramatically improve the balance between benefit and toxicity for selected patients with NSCLC (mainly non-squamous histology) characterized by driver oncogenic alterations, including sensitizing EGFR mutations and ALK rearrangements. However, these mutations are more common in squamous NSCLC and very rare in adenocarcinoma NSCLC. Randomized phase III trials of gefitinib (IPASS), erlotinib (EURTAC), and afatinib (LUX-Lung 3) showed significant improvements in PFS and ORR compared with platinum doublet chemotherapy (Fukuoka et al. (2011) J Clin Oncol. 29:2866-2874; Rosell et al. (2012) Lancet Oncol. 13:239-246; Yang et al. (2012) Lancet Oncol. 13:539-548). Similarly, the ALK inhibitors crizotinib and ceritinib have shown efficacy in patients with NSCLC positive for ALK rearrangements as defined by fluorescence in situ hybridization (Crino et al. (2011) J Clin Oncol. 29: Abstract 7514; Camidge et al. (2012) Lancet Oncol. 13: 1011-1019; Shaw et al. (2012) European Society of Medical Oncology Meeting. Abstract LBA1 PR; Shaw et al. (2014) N Engl J Med. 370: 2537-2539; XALKORI® USPI; ZYKADIA™ USPI).

[0011] Despite the progress of new targeted therapy and new chemotherapy combination, the survival rate of advanced NSCLC disease remains low, and acquired resistance to targeted drugs is a major clinical problem.Therefore, there is a need in the art for alternative treatment options that improve the prognosis of patients with this disease, such as treatment methods that prolong survival.

[0012] All references cited herein, including patent applications, patent publications, and UniProtKB / Swiss-Prot accession numbers, are hereby incorporated by reference in their entirety as if each individual reference was specifically and individually indicated to be incorporated by reference. Summary of the Invention

[0013] Provided herein are methods and uses of anti-PD-L1 antibodies for treating lung cancer patients. In particular, the methods and uses are based on data from a randomized Phase III clinical trial of atezolizumab (TECETRIQ®) in combination with pemetrexed and a platinum agent (e.g., carboplatin or cisplatin) in untreated individuals (e.g., chemotherapy-naive individuals) with stage IV non-squamous non-small cell lung cancer (NSCLC). This study showed that initial (first-line) treatment with a combination of TECENTRIQ® (atezolizumab) and chemotherapy (pemetrexed + carboplatin or pemetrexed + cisplatin) reduced the risk of disease progression or death (PFS) compared to chemotherapy alone. In addition, patients receiving TECENTRIQ® (atezolizumab) plus chemotherapy (pemetrexed + carboplatin or pemetrexed + cisplatin) demonstrated a numerical improvement in overall survival compared to chemotherapy alone. The safety of the combination of TECENTRIQ and chemotherapy appeared to be consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with this combination.

[0014] In one aspect, provided herein is a method of treating an individual having lung cancer comprising administering to the individual an effective amount of an anti-PD-L1 antibody, an antimetabolite, and a platinum agent, wherein the treatment extends the progression free survival (PFS) of the individual. In some embodiments, the treatment extends the overall survival (OS) of the individual. In some embodiments, the treatment increases the progression free survival (PFS) of the individual by at least one of about 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 months (including any ranges therebetween). In some embodiments, the treatment increases the progression free survival (PFS) of the individual by at least about 7.6 months. In some embodiments, the treatment increases the individual's PFS by at least one of about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 months (including any ranges between these values) compared to an individual with lung cancer (non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer) who has been treated with an antimetabolite (e.g., pemetrexed) and a platinum agent (e.g., carboplatin or cisplatin).

[0015] In another aspect, provided herein is a method of treating an individual with lung cancer, comprising administering to the individual an effective amount of an anti-PD-L1 antibody, an antimetabolite, and a platinum agent, wherein the treatment increases the overall survival (OS) of the individual. In some embodiments, the overall survival (OS) is measured as the time from the start of treatment to death. In some embodiments, the treatment increases the OS of the individual by at least any one of about 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 months (including any ranges between these values). In some embodiments, the treatment increases the OS of the individual by at least about 18.1 months. In some embodiments, the treatment increases the OS of the individual by at least any one of about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, or 7 months (including any ranges between these values) compared to an individual with lung cancer (non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer) who has been treated with an antimetabolite (e.g., pemetrexed) and a platinum agent (e.g., carboplatin or cisplatin).

[0016] In some embodiments, the anti-PD-L1 antibody comprises: (a) a heavy chain variable region (VH) comprising HVR-H1 (SEQ ID NO: 1) consisting of the amino acid sequence of GFTFSDSWIH, HVR-2 (SEQ ID NO: 2) consisting of the amino acid sequence of AWISPYGGSTYYADSVKG, and HVR-3 (SEQ ID NO: 3) consisting of the amino acid sequence of RHWPGGFDY, and (b) a light chain variable region (VL) comprising HVR-L1 (SEQ ID NO: 4) consisting of the amino acid sequence of RASQDVSTAVA, HVR-L2 (SEQ ID NO: 5) consisting of the amino acid sequence of SASFLYS, and HVR-L3 (SEQ ID NO: 6) consisting of the amino acid sequence of QQYLYHPAT. In some embodiments, the anti-PD-L1 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-PD-L1 antibody is atezolizumab.

[0017] In some embodiments, the antimetabolite is pemetrexed, 5-fluorouracil, 6-mercaptopurine, capecitabine, cytarabine, floxuridine, fludarabine, hydroxycarbamide, or methotrexate. In some embodiments, the antimetabolite is pemetrexed. In some embodiments, the platinum agent is carboplatin. In some embodiments, the platinum agent is cisplatin.

[0018] In some embodiments, the anti-PD-L1 antibody is administered at a dose of 1200 mg, where the platinum agent is carboplatin and is administered at a dose sufficient to achieve an AUC=6 mg / mL / min, and where the antimetabolite is pemetrexed and is administered at a dose sufficient to achieve an AUC=500 mg / mL. 2 In some embodiments, the anti-PD-L1 antibody is administered at a dose of 1200 mg, where the platinum agent is cisplatin and is 75 mg / m 2 and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m 2 In some embodiments, the anti-PD-L1 antibody, the antimetabolite, and the platinum agent are administered in four 21-day cycles, where the anti-PD-L1 antibody is atezolizumab and is administered on day 1 at a dose of 1200 mg, and where the antimetabolite is pemetrexed and is administered on day 1 at a dose of 500 mg / m 2 and where the platinum agent is carboplatin and is administered at a dose sufficient to achieve an AUC=6 mg / mL / min on day 1 of each 21-day cycle for cycles 1-4. In some embodiments, the anti-PD-L1 antibody, the antimetabolite, and the platinum agent are administered in four 21-day cycles, where the anti-PD-L1 antibody is atezolizumab and is administered at a dose of 1200 mg on day 1, and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m 2 on day 1, where the platinum agent is cisplatin and is administered at a dose of 75 mg / m on day 1 of each 21-day cycle for cycles 1-4. 2In some embodiments, the anti-PD-L1 antibody, antimetabolite, and platinum agent are administered sequentially on day 1 of cycles 1-4. In some embodiments, the anti-PD-L1 antibody is administered prior to the antimetabolite, where the antimetabolite is administered prior to the platinum agent on day 1 of cycles 1-4. In some embodiments, the anti-PD-L1 antibody and the antimetabolite are further administered after cycle 4, where the anti-PD-L1 antibody is atezolizumab and is administered at a dose of 1200 mg on day 1, and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 4. 2 In some embodiments, the anti-PD-L1 antibody and the antimetabolite are administered consecutively on day 1 of each 21-day cycle for all cycles after Cycle 4. In some embodiments, the anti-PD-L1 antibody is administered prior to the antimetabolite on day 1 after Cycle 4.

[0019] In some embodiments, the anti-PD-L1 antibody, the antimetabolite, and the platinum agent are administered in four 21 day cycles, where the anti-PD-L1 antibody is atezolizumab and is administered on day 1 at a dose of 1200 mg, and where the antimetabolite is pemetrexed and is administered on day 1 at a dose of 500 mg / m 2 and where the platinum agent is carboplatin and is administered at a dose sufficient to achieve an AUC=6 mg / mL / min on day 1 of each 21-day cycle for cycles 1-6. In some embodiments, the anti-PD-L1 antibody, the antimetabolite, and the platinum agent are administered in four 21-day cycles, where the anti-PD-L1 antibody is atezolizumab and is administered at a dose of 1200 mg on day 1, and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m 2 on day 1, where the platinum agent is cisplatin and is administered at a dose of 75 mg / m on day 1 of each 21-day cycle for cycles 1-6. 2In some embodiments, the anti-PD-L1 antibody, antimetabolite, and platinum agent are administered sequentially on day 1 of cycles 1-6. In some embodiments, the anti-PD-L1 antibody is administered prior to the antimetabolite, where the antimetabolite is administered prior to the platinum agent on day 1 of cycles 1-6. In some embodiments, the anti-PD-L1 antibody and the antimetabolite are further administered after cycle 6, where the anti-PD-L1 antibody is atezolizumab and is administered at a dose of 1200 mg on day 1, and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 6. 2 In some embodiments, the anti-PD-L1 antibody and the antimetabolite are administered consecutively on day 1 of each 21-day cycle for all cycles after cycle 6. In some embodiments, the anti-PD-L1 antibody is administered prior to the antimetabolite on day 1 of each 21-day cycle for all cycles after cycle 6.

[0020] In some embodiments, the anti-PD-L1 antibody, the platinum agent, and the antimetabolite inhibitor are each administered intravenously. In some embodiments, the lung cancer is non-small cell lung cancer (NSCLC). In some embodiments, the NSCLC is stage IV non-squamous NSCLC. In some embodiments, the individual is treatment naive for stage IV non-squamous NSCLC. In some embodiments, the individual is chemotherapy naive for stage IV non-squamous NSCLC. In some embodiments, the individual is Asian or of Asian descent. In some embodiments, the individual is at least 65 years old. In some embodiments, the individual is a non-smoker. In some embodiments, the individual is PD-L1 high. In some embodiments, the individual is PD-L1 negative. In some embodiments, the individual is human.

[0021] In another aspect, described herein is a method of treating an individual with stage IV non-squamous non-small cell lung cancer (NSCLC), comprising administering to the individual effective amounts of atezolizumab, pemetrexed, and carboplatin, where the atezolizumab is administered at a dose of 1200 mg and the pemetrexed is administered at a dose of 500 mg / m. 2and the carboplatin is administered at a dose sufficient to achieve an AUC=6 mg / mL / min, wherein the treatment extends progression-free survival (PFS). In some embodiments, the treatment extends the overall survival (OS) of the individual. In some embodiments, the treatment increases the progression-free survival (PFS) of the individual by at least any one of about 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 months (including any ranges between these values). In some embodiments, the treatment increases the progression-free survival (PFS) of the individual by at least about 7.6 months. In some embodiments, the treatment increases the individual's PFS by at least one of about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 months (including any range between these values) compared to an individual with lung cancer (non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer) treated with pemetrexed and carboplatin. In some embodiments, the treatment extends the individual's overall survival (OS). In some embodiments, the overall survival (OS) is measured as the time from the start of treatment to death. In some embodiments, the treatment increases the individual's OS by at least one of about 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 months (including any range between these values). In some embodiments, the treatment increases the individual's OS by at least about 18.1 months. In some embodiments, the treatment increases the OS of the individual by at least any one of about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, or 7 months (including any ranges between these values) compared to an individual with lung cancer (non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer) who has been treated with pemetrexed and carboplatin.In some embodiments, atezolizumab, pemetrexed, and carboplatin are administered in four 21-day cycles, and atezolizumab and pemetrexed are further administered in a 21-day cycle after cycle 4, where atezolizumab is administered at a dose of 1200 mg on day 1 of each 21-day cycle for cycles 1-4, and pemetrexed is administered at 500 mg / m on day 1 of each 21-day cycle for cycles 1-4. 2 and carboplatin is administered at a dose sufficient to achieve an AUC=6 mg / mL / min on day 1 of each 21-day cycle for cycles 1-4, and wherein atezolizumab is further administered at a dose of 1200 mg on day 1 of each 21-day cycle for all cycles after cycle 4, and pemetrexed is further administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 4. 2 In some embodiments, atezolizumab, pemetrexed, and carboplatin are administered consecutively on day 1 of cycles 1-4. In some embodiments, atezolizumab is administered prior to pemetrexed, where pemetrexed is administered prior to carboplatin on day 1 of cycles 1-4. In some embodiments, atezolizumab and pemetrexed are administered consecutively on day 1 of each 21-day cycle for all cycles after cycle 4. In some embodiments, atezolizumab is administered prior to pemetrexed on day 1 of each 21-day cycle for all cycles after cycle 4. In some embodiments, atezolizumab, pemetrexed, and carboplatin are administered in six 21-day cycles, and atezolizumab and pemetrexed are further administered in a 21-day cycle after cycle 6, where atezolizumab is administered at a dose of 1200 mg on day 1 of each 21-day cycle for cycles 1-6, and pemetrexed is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for cycles 1-6. 2and carboplatin is administered at a dose sufficient to achieve an AUC=6 mg / mL / min on day 1 of each 21-day cycle for cycles 1-6, and wherein atezolizumab is further administered at a dose of 1200 mg on day 1 of each 21-day cycle for all cycles after cycle 6, and pemetrexed is further administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 6. 2 In some embodiments, atezolizumab, pemetrexed, and carboplatin are administered consecutively on day 1 of cycles 1-6. In some embodiments, atezolizumab is administered prior to pemetrexed, where pemetrexed is administered prior to carboplatin on day 1 of cycles 1-6. In some embodiments, atezolizumab and pemetrexed are administered consecutively on day 1 of each 21-day cycle for all cycles after cycle 6. In some embodiments, atezolizumab is administered prior to pemetrexed on day 1 of each 21-day cycle for all cycles after cycle 6. In some embodiments, the atezolizumab, the pemetrexed, and the carboplatin are each administered intravenously.

[0022] In another aspect, described herein is a method of treating an individual with stage IV non-squamous non-small cell lung cancer (NSCLC), comprising administering to the individual effective amounts of atezolizumab, pemetrexed, and cisplatin, where the atezolizumab is administered at a dose of 1200 mg and the pemetrexed is administered at a dose of 500 mg / m. 2 and the cisplatin is administered at a dose of 75 mg / m 2wherein the treatment extends the progression-free survival (PFS) of the individual. In some embodiments, the treatment extends the overall survival (OS) of the individual. In some embodiments, the treatment increases the progression-free survival (PFS) of the individual by at least any one of about 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 months (including any ranges between these values). In some embodiments, the treatment increases the progression-free survival (PFS) of the individual by at least about 7.6 months. In some embodiments, the treatment increases the individual's PFS by at least one of about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 months (including any range between these values) compared to an individual with lung cancer (non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer) treated with pemetrexed and cisplatin. In some embodiments, the treatment extends the individual's overall survival (OS). In some embodiments, the overall survival (OS) is measured as the time from the start of treatment to death. In some embodiments, the treatment increases the individual's OS by at least one of about 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 months (including any range between these values). In some embodiments, the treatment increases the individual's OS by at least about 18.1 months. In some embodiments, the treatment increases the OS of the individual by at least any one of about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, or 7 months (including any ranges between these values) compared to an individual with lung cancer (non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer) who has been treated with pemetrexed and cisplatin.In some embodiments, atezolizumab, pemetrexed, and cisplatin are administered in four 21-day cycles, and atezolizumab and pemetrexed are further administered in a 21-day cycle after cycle 4, where atezolizumab is administered at a dose of 1200 mg on day 1 of each 21-day cycle for cycles 1-4, and pemetrexed is administered at 500 mg / m on day 1 of each 21-day cycle for cycles 1-4. 2 and cisplatin was administered at a dose of 75 mg / m on day 1 of each 21-day cycle in cycles 1 to 4. 2 and where atezolizumab is further administered at a dose of 1200 mg on day 1 of each 21-day cycle for all cycles after cycle 4, and pemetrexed is further administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 4. 2 In some embodiments, atezolizumab, pemetrexed, and cisplatin are administered consecutively on day 1 of cycles 1-4. In some embodiments, atezolizumab is administered prior to pemetrexed, where pemetrexed is administered prior to cisplatin on day 1 of cycles 1-4. In some embodiments, atezolizumab and pemetrexed are administered consecutively on day 1 of each 21-day cycle for all cycles after cycle 4. In some embodiments, atezolizumab is administered prior to pemetrexed on day 1 of each 21-day cycle for all cycles after cycle 4. In some embodiments, atezolizumab, pemetrexed, and cisplatin are administered in six 21-day cycles, and atezolizumab and pemetrexed are further administered in a 21-day cycle after cycle 6, where atezolizumab is administered at a dose of 1200 mg on day 1 of each 21-day cycle for cycles 1-6, and pemetrexed is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for cycles 1-6. 2 and cisplatin was administered at a dose of 75 mg / m on day 1 of each 21-day cycle in cycles 1 to 6. 2and where atezolizumab is further administered at a dose of 1200 mg on day 1 of each 21-day cycle for all cycles after cycle 6, and pemetrexed is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 6. 2 In some embodiments, atezolizumab, pemetrexed, and cisplatin are administered consecutively on day 1 of cycles 1-6. In some embodiments, atezolizumab is administered prior to pemetrexed, where pemetrexed is administered prior to cisplatin on day 1 of cycles 1-6. In some embodiments, atezolizumab and pemetrexed are administered consecutively on day 1 of each 21-day cycle for all cycles after cycle 6. In some embodiments, atezolizumab is administered prior to pemetrexed on day 1 of each 21-day cycle for all cycles after cycle 6. In some embodiments, the atezolizumab, the pemetrexed, and the cisplatin are each administered intravenously.

[0023] In some embodiments, the individual is treatment naive for stage IV non-squamous NSCLC. In some embodiments, the individual is chemotherapy naive for stage IV non-squamous NSCLC. In some embodiments, the individual is Asian or of Asian descent. In some embodiments, the individual is at least 65 years old. In some embodiments, the individual is a non-smoker. In some embodiments, the individual is PD-L1 high. In some embodiments, the individual is PD-L1 negative. In some embodiments, the individual is human.

[0024] In another aspect, the present disclosure provides a kit comprising an anti-PD-L1 antibody for use in combination with an antimetabolite and a platinum agent to treat an individual having lung cancer according to the methods disclosed herein. In some embodiments, the present disclosure provides a kit comprising atezolizumab for use in combination with pemetrexed and carboplatin to treat an individual having lung cancer according to the methods disclosed herein. In some embodiments, the present disclosure provides a kit comprising atezolizumab for use in combination with pemetrexed and cisplatin to treat an individual having lung cancer according to the methods disclosed herein.

[0025] In another aspect, there is provided a composition comprising an anti-PD-L1 antibody for use in a method of treating lung cancer in an individual comprising administering to the individual an effective amount of an anti-PD-L1 antibody, an antimetabolite, and a platinum drug, wherein the treatment extends the progression-free survival (PFS) of the individual. In some embodiments, the treatment extends the overall survival (OS) of the individual. In some embodiments, a composition comprises an anti-PD-L1 antibody for use in accordance with the methods disclosed herein.

[0026] In another embodiment, a composition comprising atezolizumab for use in a method of treating stage IV non-squamous non-small cell lung cancer (NSCLC) comprising administering to an individual effective amounts of atezolizumab, pemetrexed, and carboplatin, wherein the atezolizumab is administered at a dose of 1200 mg and the pemetrexed is administered at a dose of 500 mg / m 2 and the carboplatin is administered at a dose sufficient to achieve AUC=6 mg / mL / min, wherein the treatment extends the progression-free survival (PFS) of the individual. In some embodiments, the treatment extends the overall survival (OS) of the individual. In some embodiments, the composition is for use in accordance with the methods disclosed herein.

[0027] In another embodiment, a composition comprising atezolizumab for use in a method of treating stage IV non-squamous non-small cell lung cancer (NSCLC) comprising administering to an individual effective amounts of atezolizumab, pemetrexed, and cisplatin, wherein the atezolizumab is administered at a dose of 1200 mg and the pemetrexed is administered at a dose of 500 mg / m 2 and the cisplatin is administered at a dose of 75 mg / m 2 wherein the treatment extends the progression-free survival (PFS) of the individual. In some embodiments, the treatment extends the overall survival (OS) of the individual. In some embodiments, the composition is for use in accordance with the methods disclosed herein.

[0028] It should be understood that one, some, or all of the features of the various embodiments described herein may be combined to form other embodiments of the present invention. These and other aspects of the present invention will be apparent to those skilled in the art. These and other embodiments of the present invention are further described in the detailed description that follows. [Brief description of the drawings]

[0029] [Figure 1] Figure 1 provides a schematic of the study design of the clinical trial described in Example 1. 578 patients were enrolled. Group A included 292 patients and Group B included 286 patients. Patients in Group A were treated until progressive disease (PD) or loss of clinical benefit, and patients in Group B were treated until PD.

[0030] [Diagram 2] Figure 2 provides a Kaplan-Meier plot of progression-free survival (PFS) of patients in group A (atezolizumab + pemetrexed + carboplatin or cisplatin) versus group B (pemetrexed + carboplatin or cisplatin).

[0031] [Diagram 3] Figure 3 provides a Kaplan-Meier plot of overall survival (OS) of patients in group A (atezolizumab + pemetrexed + carboplatin or cisplatin) versus group B (pemetrexed + carboplatin or cisplatin).

[0032] [Figure 4] Figure 4 provides a comparison of patient confirmed overall response rates (ORR) in Group A versus Group B. (CR=complete response; CR / PR=complete / partial response; SD=stable disease; PD=progressive disease.) ORR was assessed according to RECIST version 1.1 criteria.

[0033] [Figure 5A] Figure 5A provides a forest plot showing subgroup analysis of PFS for patients with various baseline risk factors in group A (APP) versus group B (PP). (APP = atezolizumab + pemetrexed + carboplatin or cisplatin; PP = pemetrexed + carboplatin or cisplatin.)

[0034] [Figure 5B] Figure 5B provides a forest plot showing subgroup analysis of PFS for patients with various baseline risk factors in group A (APP) versus group B (PP). (APP = atezolizumab + pemetrexed + carboplatin or cisplatin; PP = pemetrexed + carboplatin or cisplatin.)

[0035] [Figure 6] Figure 6 provides a forest plot showing subgroup analysis of OS of patients with various baseline risk factors in group A (APP) versus group B (PP). (APP = atezolizumab + pemetrexed + carboplatin or cisplatin; PP = pemetrexed + carboplatin or cisplatin.)

[0036] [Figure 7A] Figure 7A provides a Kaplan-Meier plot of progression-free survival (PFS) for “PD-L1 high” patients in group A (atezolizumab + pemetrexed + carboplatin or cisplatin) versus group B (pemetrexed + carboplatin or cisplatin).

[0037] [Figure 7B] Figure 7B provides a Kaplan-Meier plot of progression-free survival (PFS) for “low PD-L1” patients in group A (atezolizumab + pemetrexed + carboplatin or cisplatin) versus group B (pemetrexed + carboplatin or cisplatin).

[0038] [Figure 7C] Figure 7C is a plot of progression-free survival (PFS) of "PD-L1 negative" patients in group A (atezolizumab + pemetrexed + carboplatin or cisplatin) versus group B (pemetrexed + carboplatin or cisplatin). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] I. Definition Before describing the present invention in detail, it is to be understood that this invention is not limited to particular compositions or biological systems, which can, of course, vary widely. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0040] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a "molecule" includes any combination of two or more such molecules, and so forth.

[0041] The term "about" as used herein refers to a normal range of error for the respective value, which would be readily appreciated by one of ordinary skill in the art. Reference herein to "about" a value or parameter includes (and describes) embodiments that are directed to the value or parameter itself.

[0042] It is understood that aspects and embodiments of the invention described herein include "comprising," "consisting," and "consisting essentially of" aspects and embodiments.

[0043] The term "PD-1 axis binding antagonist" refers to a molecule that inhibits the interaction of a PD-1 axis binding partner with any one or more of its binding partners to eliminate T cell dysfunction resulting from signaling on the PD-1 signaling axis, thereby restoring or enhancing T cell function (e.g., proliferation, cytokine production, target cell killing). As used herein, PD-1 axis binding antagonists include PD-1 binding antagonists, PD-L1 binding antagonists, and PD-L2 binding antagonists.

[0044] The term "PD-1 binding antagonist" refers to a molecule that reduces, blocks, inhibits, abrogates, or prevents signaling resulting from the interaction of PD-1 with one or more of its binding partners, e.g., PD-L1, PD-L2. In some embodiments, a PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to one or more of its binding partners. In a specific aspect, a PD-1 binding antagonist inhibits the binding of PD-1 to PD-L1 and / or PD-L2. For example, PD-1 binding antagonists include anti-PD-1 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, abrogate, or prevent signaling resulting from the interaction of PD-1 with PD-L1 and / or PD-L2. In one embodiment, the PD-1 binding antagonist reduces the negative costimulatory signal mediated by or through cell surface proteins expressed on T lymphocytes that mediated signaling through PD-1, rendering dysfunctional T cells less dysfunctional (e.g., enhancing the effector response to antigen recognition). In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody. Specific examples of PD-1 binding antagonists are provided below.

[0045] The term "PD-L1 binding antagonist" refers to a molecule that reduces, blocks, inhibits, abrogates, or prevents signaling resulting from the interaction of PD-L1 with any one or more of its binding partners, e.g., PD-1, B7-1. In some embodiments, a PD-L1 binding antagonist is a molecule that inhibits the binding of PD-L1 to its binding partners. In a specific aspect, a PD-L1 binding antagonist inhibits the binding of PD-L1 to PD-1 and / or B7-1. In some embodiments, PD-L1 binding antagonists include anti-PD-L1 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, abrogate, or prevent signaling resulting from the interaction of PD-L1 with one or more of its binding partners, e.g., PD-1, B7-1. In one embodiment, the PD-L1 binding antagonist reduces the negative costimulatory signal mediated by or through cell surface proteins expressed on T lymphocytes that mediated signaling through PD-L1, rendering dysfunctional T cells less dysfunctional (e.g., enhancing the effector response to antigen recognition). In some embodiments, the PD-L1 binding antagonist is an anti-PD-L1 antibody. Specific examples of PD-L1 binding antagonists are provided below.

[0046] The term "PD-L2 binding antagonist" refers to a molecule that reduces, blocks, inhibits, abrogates, or prevents signaling resulting from the interaction of PD-L2 with any one or more of its binding partners, e.g., PD-1. In some embodiments, a PD-L2 binding antagonist is a molecule that inhibits the binding of PD-L2 to one or more of its binding partners. In a specific aspect, a PD-L2 binding antagonist inhibits the binding of PD-L2 to PD-1. In some embodiments, PD-L2 antagonists include anti-PD-L2 antibodies, antigen-binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides, and other molecules that reduce, block, inhibit, abrogate, or prevents signaling resulting from the interaction of PD-L2 with any one or more of its binding partners, e.g., PD-1. In one embodiment, the PD-L2 binding antagonist reduces the negative costimulatory signal mediated by or through cell surface proteins expressed on T lymphocytes that mediated signaling through PD-L2, rendering dysfunctional T cells less dysfunctional (e.g., enhancing the effector response to antigen recognition). In some embodiments, the PD-L2 binding antagonist is an immunoadhesin.

[0047] "Sustained response" refers to a sustained effect on reducing tumor growth after treatment is stopped. For example, the tumor size may remain the same or may be smaller compared to the size at the beginning of the administration period. In some embodiments, the sustained response has a duration of at least the same as the treatment period, or at least 1.5, 2.0, 2.5, or 3.0 times the treatment period.

[0048] The term "pharmaceutical formulation" refers to a preparation in which the biological activity of the active ingredient is effective and which does not contain additional ingredients that are unacceptably toxic to the subject to which the formulation is administered. Such formulations are sterile. A "pharmaceutical acceptable" excipient (vehicle, additive) is one that can be competently administered to a mammalian subject to provide an effective dose of the active ingredient employed.

[0049] As used herein, the term "treatment" refers to a clinical intervention designed to change the natural course of the individual or cells being treated during the course of clinical pathology. The desired effects of treatment include reducing the rate of disease progression, reversing or alleviating the disease state, and remission or improvement of prognosis. For example, an individual is successfully "treated" if one or more symptoms associated with cancer are reduced or eliminated, including, but not limited to, reducing (or destroying) the proliferation of cancer cells, reducing symptoms caused by the disease, improving the quality of life of those suffering from the disease, reducing the dose of other drugs required to treat the disease, and / or prolonging the survival of the individual.

[0050] As used herein, "delaying disease progression" means to postpone, prevent, slow down, delay, stabilize, and / or prolong the onset of a disease (such as cancer). This delay can be of varying duration depending on the history of the disease and / or the individual being treated. As will be apparent to one of skill in the art, a sufficient or significant delay can in effect encompass prevention, in that the individual does not develop the disease. For example, late-stage cancer, such as the onset of metastases, can be delayed.

[0051] An "effective amount" is at least the minimum amount required to achieve a measurable improvement or prevention of a particular disorder. The effective amount herein may vary depending on factors such as the disease state, age, sex, and weight of the patient, and the ability of the antibody to elicit a desired response in the individual. An effective amount is also one in which any toxic or adverse effects of the treatment are outweighed by the therapeutically beneficial effects. In the case of prophylactic use, beneficial or desired results include results such as eliminating or reducing the risk of disease, reducing the severity of disease, or delaying the onset of disease, including biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes manifested during the development of the disease. In the case of therapeutic use, beneficial or desired results include clinical results such as reducing one or more symptoms caused by the disease, improving the quality of life of a person suffering from the disease, reducing the dose of other drugs required to treat the disease, enhancing the effect of another drug (e.g., by targeting), delaying the progression of the disease, and / or prolonging survival. In the case of cancer or tumor, an effective amount of a drug may have the effect of reducing the number of cancer cells, reducing tumor size, inhibiting (i.e., slowing or preferably stopping to some extent) the invasion of cancer cells into peripheral organs, inhibiting (i.e., slowing or preferably stopping to some extent) tumor metastasis, inhibiting tumor growth to some extent, and / or alleviating to some extent one or more of the symptoms associated with the disorder. An effective amount may be administered in one or more administrations. In the present invention, an effective amount of a drug, compound, or pharmaceutical composition is an amount sufficient to directly or indirectly achieve prophylactic or therapeutic treatment. As understood in the clinical field, an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an "effective amount" may be considered in the context of administration of one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desired result can be achieved or is achieved.

[0052] As used herein, "in combination" refers to the administration of one therapy in addition to another. Thus, "in combination" refers to the administration of one therapy before, during, or after the administration of another therapy to an individual.

[0053] A "disorder" is any condition that would benefit from treatment, including, but not limited to, chronic and acute disorders or diseases, including pathological conditions that predispose a mammal to the disorder in question.

[0054] The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer. In one embodiment, the cell proliferative disorder is a tumor.

[0055] "Tumor," as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder," and "tumor" are not mutually exclusive as referred to herein.

[0056] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More specific examples of such cancers include squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer, e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma and lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastric cancer or stomach cancer, e.g., gastrointestinal cancer and gastrointestinal stromal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, urinary tract cancer, liver cancer, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, kidney cancer or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, melanoma, superficial spreading melanoma, lentigo maligna melanoma, acral lentigo melanoma, nodular melanoma, multiple myeloma, and B-cell lymphoma (low-grade / follicular non-Hodgkin's lymphoma). lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade / follicular NHL, intermediate grade diffuse NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small noncleaved cell NHL, bulky disease NHL, mantle cell lymphoma, AIDS-related lymphoma, and Waldenstrom's macroglobulinemia), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, chronic myeloblastic leukemia, and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal blood vessel proliferation associated with phacomatosis, edema (such as that associated with brain tumors), Meigs' syndrome, brain cancer, and head and neck cancer, and associated metastases.In certain embodiments, cancers suitable for treatment with the antibodies of the invention include breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, glioblastoma, non-Hodgkin's lymphoma (NHL), renal cell carcinoma, prostate cancer, liver cancer, pancreatic cancer, soft tissue sarcoma, Kaposi's sarcoma, carcinoid cancer, head and neck cancer, ovarian cancer, mesothelioma, and multiple myeloma. In some embodiments, the cancer is selected from small cell lung cancer, glioblastoma, neuroblastoma, melanoma, breast cancer, gastric cancer, colorectal cancer (CRC), and hepatocellular carcinoma.

[0057] The term "cytotoxic agent" as used herein refers to any agent that is detrimental to cells (e.g., causes cell death, inhibits proliferation, or otherwise interferes with cell function).Cytotoxic agents include, but are not limited to, radioisotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212, and radioisotopes of Lu); chemotherapeutic agents; growth inhibitors; enzymes and their fragments, such as nucleases; and toxins, such as small molecule toxins or enzymatically active toxins (including their fragments and / or variants) of bacterial, fungal, plant, or animal origin. Exemplary cytotoxic agents may be selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormone analogs, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutics, proapoptotic agents, LDH-A inhibitors, fatty acid biosynthesis inhibitors, cell cycle signaling inhibitors, HDAC inhibitors, proteasome inhibitors, and cancer metabolism inhibitors. In one embodiment, the cytotoxic agent is a taxane. In one embodiment, the taxane is paclitaxel or docetaxel. In one embodiment, the cytotoxic agent is a platinum agent. In one embodiment, the cytotoxic agent is an antagonist of EGFR. In one embodiment, the antagonist of EGFR is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (e.g., erlotinib). In one embodiment, the cytotoxic agent is a RAF inhibitor. In one embodiment, the RAF inhibitor is a BRAF and / or CRAF inhibitor. In one embodiment, the RAF inhibitor is vemurafenib. In one embodiment, the cytotoxic agent is a PI3K inhibitor.

[0058] "Chemotherapeutic agents" include compounds useful in the treatment of cancer. Examples of chemotherapeutic agents include erlotinib (TARCEVA®, Genentech / OSI Pharm.), bortezomib (VELCADE®, Millennium Pharm.), disulfiram, epigallocatechin gallate, salinosporamide A, carfilzomib, 17-AAG (geldanamycin), radicicol, lactate dehydrogenase A (LDH-A), fulvestrant (FASLODEX®, AstraZeneca), sunitib (SUTENT®, Pfizer / Sugen), letrozole (FEMARA®, Novartis). , imatinib mesylate (GLEEVEC®, Novartis), finasunate (VATALANIB®, Novartis), oxaliplatin (ELOXATIN®, Sanofi), 5-FU (5-fluorouracil), leucovorin, rapamycin (Sirolimus, RAPAMUNE®, Wyeth), lapatinib (TYKERB®, GSK572016, Glaxo Smith Kline), lonafarnib (SCH 66336), sorafenib (NEXAVAR®, Bayer Labs), gefitinib (IRESSA®, AstraZeneca), AG1478, alkylating agents such as thiotepa and CYTOXAN®, cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; althlateamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylmelamine; acetogenins (especially bullatacin and bullatasinone); camptothecins (including topotecan and irinotecan); bryostatin; kallistatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (especially cryptophycin 1 and cryptophycin 8); corticosteroids (including prednisone and prednisolone); cyproterone acetate;5α-reductase (including finasteride and dutasteride); vorinostat, romidepsin, panobinostat, valproic acid, mocetinostat, dolastatins; aldesleukin, talc, duocarmycins (including synthetic analogs, KW-2189, and CB1-TM1); eleutherobin; pancratistatin; sarcodictiin; spongistatins; nitrogen mustards, such as chlorambucil, chlomaphazine, chlorophosphatidylserine, chloro ... amides, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, nobembikine, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics, such as enediyne antibiotics (e.g., calicheamicins, especially calicheamicin γ1I and calicheamicin ω1I ("Angew Chem. Intl. Ed. Engl. (1994) 33, 183-186); dynemycins including dynemycin A; bisphosphonates such as clodronate; esperamicin; and neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomycins, actinomycin, ausramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazole-5-oxo-L-norleucine, ADRIAMYCI N® (doxorubicin), morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcelomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, queramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU);Folic acid analogues, such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogues, such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogues, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens, such as calsterone, dromostanolone propionate, epithiostanol, mepitiostane, testolactone; antiadrenal agents, such as aminoglutethimide, mitotane, trilostane; folic acid supplements, such as floric acid; aceglatone; Ludophosphamide glycosides; Aminolevulinic acid; Eniluracil; Amsacrine; Bestravcil; Bisantrene; Edatraxate; Defofamine; Demecolcine; Diazicon; Elfornithine; Elliptinium acetate; Epothilone; Etoglucide; Gallium nitrate; Hydroxyurea; Lentinan; Lonidynin; Maytansinoids, such as maytansine and ansamitocins; Mitoguazone; Mitoxantrone; Mopidamol; Nitraerin; Pentostatin; Phenamet; Pirarubicin; Rosoxantrone; Podophyllic acid; 2-Ethylhydrazide; Procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; schizofuran; spirogermanium; tenuazonic acid; triazicon; 2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2 toxin, veracrine A, roridin A, and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids such as TAXOL (paclitaxel; Bristol-Myers Squibb Oncology, Princeton, NJ), ABRAXANE® (Cremophor-free), albumin engineered nanoparticle preparations of paclitaxel (American Pharmaceutical Partners, Schaumburg, Ill.), and TAXOTERE® (docetaxel;Sanofi-Aventis; chlorambucil; GEMZAR® (gemcitabine); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE® (vinorelbine); novantrone; teniposide; edatrexate; daunomycin; aminopterin; capecitabine (XELODA®); ibandronate; CPT-11; topoisomerase inhibitors RFS2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; and pharma- ceutically acceptable salts, acids, and derivatives of any of the above.

[0059] Chemotherapeutic agents also include (i) antihormonal agents that act to modulate or inhibit hormone action on tumors, such as antiestrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (NOLVADEX®; including tamoxifen citrate), raloxifene, droloxifene, iodoxyfene, 4-hydroxytamoxifen, trioxyfene, ketoxifene, LY117018, onapristone, and FARESTON® (toremifene citrate); and (ii) anti-tumor agents, such as, for example, 4(5)-imidazole, aminoglutethimide, MEGASE® (megestrol acetate), AROMASIN® (exemestane, Pf (iii) aromatase inhibitors, such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; buserelin, tripterelin, medroxyprogesterone acetate, diethylstilbestrol, premarin, fluoxymesterone, all transretionic acid, erythritol, squalene ... (iv) protein kinase inhibitors; (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, such as PKC-α, Ralf, and H-Ras, which inhibit the expression of genes, particularly in signal transduction pathways involved in abnormal cell proliferation; (vii) ribozymes, such as VEGF expression inhibitors (e.g., ANGIOZYME®) and HER2 expression inhibitors; (viii) for example, ALLOVECTIN®, LEUVECTIN®, and VAXID®; PROLEUKIN®, rIL-2; topoisomerase 1 inhibitors, such as LURTOTECAN®;(ix) pharmaceutically acceptable salts, acids, and derivatives of any of the above;

[0060] Chemotherapeutic agents also include antibodies, such as alemtuzumab (Campath), bevacizumab (AVASTIN®, Genentech), cetuximab (ERBITUX®, Imclone), panitumumab (VECTIBIX®, Amgen), rituximab (RITUXAN®, Genentech / Biogen Idec), pertuzumab (OMNITARG®, 2C4, Genentech), trastuzumab (HERCEPTIN®, Genentech), tositumomab (Bexxar, Corixia), and the antibody-drug conjugate, gemtuzumab ozogamicin (MYLOTARG®, Wyeth). Additional humanized monoclonal antibodies that have therapeutic potential as drugs in combination with the compounds of the invention include apolizumab, acelizumab, atlizumab, bapineuzumab, bivatuzumab mertansine,mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizu mab, numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan These include tetraxetan, tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab, ustekinumab, visilizumab, and anti-interleukin-12 (ABT-874 / J695, Wyeth Research and Abbott Laboratories), an exclusively human sequence recombinant full-length IgG1 lambda antibody genetically modified to recognize the interleukin-12 p40 protein.

[0061] Chemotherapeutic agents also include "EGFR inhibitors," which refer to compounds that bind to or otherwise directly interact with EGFR and block or reduce its signaling activity, also referred to as "EGFR antagonists." Examples of such agents include antibodies and small molecules that bind to EGFR. Examples of antibodies that bind to EGFR include MAb579 (ATCC CRL HB8506), MAb455 (ATCC CRL HB8507), MAb225 (ATCC CRL8508), MAb528 (ATCC CRL8509) (see U.S. Pat. No. 4,943,533 (Mendelsohn et al.)), and variants thereof, such as chimeric 225 (C225 or Cetuximab; ERBUTIX®) and reshaped human 225 (H225) (see International Publication No. WO 96 / 40210 (Imclone Systems, Inc.) Inc.); IMC-11F8, a fully human, EGFR-targeted antibody (Imclone); antibodies that bind type II mutant EGFR (U.S. Pat. No. 5,212,290); humanized and chimeric antibodies that bind EGFR as described in U.S. Pat. No. 5,891,996; and human antibodies that bind EGFR, such as ABX-EGF or panitumumab (see International Publication No. WO 98 / 50433 (Abgenix / Amgen)); EMD55900 (Stragliotto et al., "Eur. J. Catalogs, vol. 143, pp. 1111-1115, 2003); 32A, 636-640 (1996); EMD7200 (matuzumab), a humanized EGFR antibody against EGFR that competes with both EGF and TGF-α for EGFR binding (EMD / Merck); the human EGFR antibody, HuMax-EGFR (GenMab); the fully human antibodies known as E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 and E7.6.3 and described in U.S. Pat. No. 6,235,883; MDX-447 (Medarex Inc); and mAb806 or humanized mAb806 (Johns et al., J. Biol. Chem. 279(29), 30375-30384 (2004)).Anti-EGFR antibodies can be conjugated to cytotoxic drugs to generate immunoconjugates (see, e.g., European Patent Application Publication No. EP659439A2, Merck Patent GmbH). EGFR antagonists include those described in U.S. Patents Nos. 5,616,582, 5,457,105, 5,475,001, 5,654,307, 5,679,683, 6,084,095, 6,265,410, 6,455,534, 6,521,620, 6,596,726, 6,713,484, 5,770,599, 6,140,332, 6,152,416, and 6,265,420. Nos. 5,866,572, 6,399,602, 6,344,459, 6,602,863, 6,391,874, 6,344,455, 5,760,041, 6,002,008, and 5,747,498, and the following PCT publications, WO 98 / 14451, WO 98 / 50038, WO 99 / 09016, and WO 99 / 24037.Specific small molecule EGFR antagonists include OSI-774 (CP-358774, erlotinib, TARCEVA® Genentech / OSI Pharmaceuticals); PD 183805 (CI 1033, 2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, dihydrochloride, Pfizer Inc.; ZD1839, gefitinib (IRESSA®) 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, AstraZeneca; ZM105180 ((6-amino-4-(3-methylphenyl-amino)-quinazoline, Zeneca); BIBX-1382 (N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methyl-piperidin-4-yl)-pyrimido[5,4-d]pyrimidine-2,8-diamine, Boehringer Ingelheim;PKI-166((R)-4-[4-[(1-phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yl]-phenol;(R)-6-(4-hydroxyphenyl)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine;CL-387785(N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide);EKB-569(N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinazolinyl]-4-(dimethylamino)-2-butynamide)(Wyeth);AG1478(Pfizer);AG1571(SU 5271, Pfizer); dual EGFR / HER2 tyrosine kinase inhibitors, such as lapatinib (TYKERB®, GSK572016 or N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6[5[[[2 methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine).

[0062] Chemotherapeutic agents also include "tyrosine kinase inhibitors", such as the EGFR targeted drugs described in the previous paragraph; small molecule HER2 tyrosine kinase inhibitors, such as TAK165 available from Takeda; CP-724,714, an oral selective inhibitor of ErbB2 receptor tyrosine kinase (Pfizer and OSI); dual HER inhibitors, such as EKB-569 (available from Wyeth), which preferentially binds to EGFR but inhibits both HER2 and EGFR overexpressing cells; lapatinib (GSK572016, available from Glaxo-SmithKline); oral HER2 and EGFR tyrosine kinase inhibitors; PKI-166 (available from Novartis); pan-HER inhibitors, such as canertinib (CI-1033, Pharmacia); Raf-1 inhibitors, such as ISIS, which inhibits Raf-1 signaling. antisense drug ISIS-5132 available from Pharmaceuticals; non-HER targeted TK inhibitors such as imatinib mesylate (GLEEVEC® available from Glaxo SmithKline); multi-targeted tyrosine kinase inhibitors such as sunitinib (SUTENT® available from Pfizer); VEGF receptor tyrosine kinase inhibitors such as vatalanib (PTK787 / ZK222584 available from Novartis / Schering AG); MAPK extracellular regulated kinase I inhibitor CI-1040 (available from Pharmacia); quinazolines such as PD 153035, 4-(3-chloroanilino)quinazoline; pyridopyrimidines; pyrimidopyrimidines; pyrrolopyrimidines such as CGP 59326, CGP 60261, and CGP 62706; pyrazolopyrimidine, 4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidine; curcumin (diferuloylmethane, 4,5-bis(4-fluoroanilino)phthalimide); tyrphostins containing a nitrothiophene moiety; PD-0183805 (Warner-Lamber); antisense molecules (e.g., those that bind to HER-encoding nucleic acids), quinoxalines (U.S. Patent No. 5,804,396); tryphostins (U.S. Patent No. 5,804,396); ZD6474 (Astra Zeneca);PTK-787 (Novartis / Schering AG); pan-HER inhibitors, such as CI-1033 (Pfizer); Affinitac (ISIS 3521, Isis / Lilly); imatinib mesylate (GLEEVEC®); PKI 166 (Novartis); GW2016 (Glaxo SmithKline); CI-1033 (Pfizer); EKB-569 (Wyeth); Semaxinib (Pfizer); ZD6474 (AstraZeneca); PTK-787 (Novartis / Schering AG); INC-1C11 (Imclone), rapamycin (sirolimus, RAPAMUNE®); or the following patent publications: U.S. Pat. No. 5,804,396; International Publication No. WO 1999 / 09016 (American Cyanamid); International Publication No. WO 1998 / 43960 (American Cyanamid); WO1997 / 38983 (Warner Lambert); WO1999 / 06378 (Warner Lambert); WO1999 / 06396 (Warner Lambert); WO1996 / 30347 (Pfizer, Inc); WO1996 / 33978 (Zeneca); WO1996 / 3397 (Zeneca), and WO1996 / 33980 (Zeneca).

[0063] Chemotherapeutic agents include dexamethasone, interferon, colchicine, metoprine, cyclosporine, amphotericin, metronidazole, alemtuzumab, alitretinoin, allopurinol, amifostine, arsenic trioxide, asparaginase, BCG live, bevacizumab, bexarotene, cladribine, clofarabine, darbepoetin alfa, denileukin, dexrazoxane, epoetin alfa, erlotinib, filgrastim, histrelin acetate, ibritumomab, interferon alfa-2a, and interferon alfa. Also included are benzodiazepine, benzodiazepine, benzocaine, benzoyl pertuzumab, benzocaine-2b, lenalidomide, levamisole, mesna, methoxsalen, nandrolone, nelarabine, nofetumomab, oprelvekin, palifermin, pamidronate, pegademase, pegaspargase, pegfilgrastim, pemetrexed disodium, plicamycin, porfimer sodium, quinacrine, rasburicase, sargramostim, temozolomide, VM-26, 6-TG, toremifene, tretinoin, ATRA, valrubicin, zoledronate, and zoledronic acid, and pharmaceutically acceptable salts thereof.

[0064] Chemotherapeutic agents include hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-butyrate ... thizone-17-valerate, aclomethasone propionate, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasone-17-propionate, fluocortolone caproate, fluocortolone pivalate and fluprednidene acetate; immunoselective anti-inflammatory peptides (ImSAIDs), such as phenylalanine-glutamine-glycine (FEG) and its D-form (feG) (IMULAN BioTherapeutics, LLC; antirheumatic drugs such as azathioprine, cyclosporine (cyclosporine A), D-penicillamine, gold salts, hydroxychloroquine, leflunomide, minocycline, sulfasalazine, tumor necrosis factor alpha (TNFα) blockers such as etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), cetrizumab pegol (Cimzia), golimumab (Si mponi), interleukin 1 (IL-1) blockers such as anakinra (Kineret), T cell costimulation blockers such as abatacept (Orencia), interleukin 6 (IL-6) blockers, tocilizumab (ACTEMERA®); interleukin 13 (IL-13) blockers such as lebrikizumab; interferon alpha (IFN) blockers such as rontalizumab; beta 7 integrin blockers such as rhuMAb Beta7; IgE pathway blockers such as anti-M1 prime; secreted homotrimeric LTa3 and membrane-bound heterotrimeric LTa1 / β2 blockers such as anti-lymphotoxin alpha (LTa); radioisotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212, and radioisotopes);Various investigational agents, such as thioplatin, PS-341, phenylbutyrate, ET-18-OCH3, or farnesyltransferase inhibitors (L-739749, L-744832); polyphenols, such as quercetin, resveratrol, piceatannol, epigallocatechin gallate, theaflavins, flavanols, procyanidins, betulinic acid and its derivatives; autophagy inhibitors, such as chloroquine; delta-9-tetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone; lapachol; colchicine; betulinic acid; acetylcamptothecin, scopolectin, and 9-aminocamptothecin; podophyllotoxin; tegafur (UFTORAL®); bexarotene (TARGRETIN®); bisphosphonates, such as clodronate (e.g., BONEFOS®, (R) or OSTAC®), etidronate (DIDROCAL®), NE-58095, zoledronic acid / zoledronate (ZOMETA®), alendronate (FOSAMAX®), pamidronate (AREDIA®), tiludronate (SKELID®), or risedronate (ACTONEL®); as well as epidermal growth factor receptor (EGF-R); vaccines, such as the THERATOOPE® vaccine; perifosine, COX-2 inhibitors (e.g., celecoxib or etoricoxib), proteosome inhibitors (e.g., PS341); CCI-779; tipifarnib (R11577); orafenib, ABT510; Bcl-2 inhibitors such as oblimersen sodium (GENASENSE®); pixantrone; lonafarnib (SCH 6636, SARASAR™); and pharma- ceutically acceptable salts, acids, or derivatives of any of the above; and combinations of two or more of the above, such as CHOP (short for cyclophosphamide, doxorubicin, vincristine, and prednisolone); and combinations of two or more of the above, such as FOLFOX (short for a treatment regimen that combines 5-FU and leucovorin with oxaliplatin (ELOXATIN™));

[0065] Chemotherapeutic agents may also include nonsteroidal anti-inflammatory drugs that have analgesic, antipyretic and anti-inflammatory effects.NSAIDs include nonselective inhibitors of the enzyme cyclooxygenase.Specific examples of NSAIDs include aspirin, propionic acid derivatives such as ibuprofen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin and naproxen, acetic acid derivatives such as indomethacin, sulindac, etodolac, diclofenac, enolic acid derivatives such as piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam and isoxicam, fenamic acid derivatives such as mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, and COX-2 inhibitors such as celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, rofecoxib and valdecoxib. Indications for NSAIDs can be symptomatic relief of conditions such as rheumatoid arthritis, osteoarthritis, inflammatory arthropathy, ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome, acute gout, dysmenorrhea, metastatic bone pain, headaches and migraines, post-operative pain, mild to moderate pain due to inflammation and tissue injury, fever, ileus, and renal colic.

[0066] As used herein, a "growth inhibitor" refers to a compound or composition that inhibits cell growth either in vitro or in vivo. In one embodiment, the growth inhibitor is a growth inhibitory antibody that prevents or reduces the proliferation of cells expressing the antigen to which the antibody binds. In another embodiment, the growth inhibitor can be one that significantly reduces the percentage of cells in S phase. Examples of growth inhibitors include agents that block cell cycle progression (outside of S phase), such as agents that induce G1 arrest and M-phase arrest. Classical M-phase blockers include vincas (vincristine and vinblastine), taxanes, and topoisomerase II inhibitors, such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Drugs that arrest G1 phase, such as DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C, also extend to S-phase arrest. Further information can be found in "The Molecular Basis of Cancer", edited by Mendelsohn and Israel, Chapter 1, entitled "Cell cycle regulation, oncogenes, and antitineoplastic drugs", Murakami et al., WB Saunders, Philadelphia (1995), e.g., p. 13. Taxanes (paclitaxel and docetaxel) are anticancer drugs, both derived from the yew tree. Docetaxel (TAXOTERE®, Rhone-Poulenc Rorer), derived from the European yew tree, is a semisynthetic analogue of paclitaxel (TAXOL®, Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers, stabilize microtubules by preventing depolymerization, and inhibit mitosis in cells.

[0067] "Radiation therapy" refers to the use of directed gamma or beta radiation to induce sufficient damage to cells to limit their ability to function normally or to destroy the cells completely. It is understood that there are many methods known in the art for determining various dosages and durations of treatment. A typical treatment is given as a single dose, with typical dosages ranging from 10 to 200 units (grays) per day.

[0068] A "subject" or "individual" for purposes of treatment refers to any animal classified as a mammal, e.g., humans, domestic and farm animals, and zoo, sport, or pet animals, e.g., dogs, horses, cats, cows, etc. Preferably, the mammal is a human.

[0069] The term "antibody" as used herein is used in the broadest sense and specifically includes monoclonal antibodies (such as full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity.

[0070] An "isolated" antibody is one that has been identified and separated and / or recovered from a component of its natural environment. Contaminant components of its natural environment are substances that would interfere with the antibody's experimental, diagnostic, or therapeutic uses, including enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, the antibody is purified (1) to greater than 95%, and in some embodiments, greater than 99%, by weight, of the antibody, e.g., as determined by the Lowry method; (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, e.g., using a spinning cup sequenator; or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions, e.g., using Coomassie blue or silver staining. An isolated antibody includes the antibody in situ within recombinant cells, since at least one component of the antibody's natural environment will not be present. Ordinarily, however, an isolated antibody will be prepared by at least one purification step.

[0071] A "native antibody" is usually a heterotetrameric glycoprotein of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide bonds varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced interchain disulfide bridges. Each heavy chain has a variable domain (VH) at one end followed by several constant domains. Each light chain has a variable domain (VL) at one end; and a constant domain at its other end, with the constant domain of the light chain aligned with the first constant domain of the heavy chain, and the variable domain of the light chain aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light-chain variable domain and the heavy-chain variable domain.

[0072] The term "constant domain" refers to the portion of an immunoglobulin molecule that has a more conserved amino acid sequence compared to the other portions of the immunoglobulin, the variable domains, which contain the antigen binding sites. The constant domains contain the CH1, CH2, and CH3 domains of the heavy chain (collectively, CH) and the CHL (or CL) domain of the light chain.

[0073] The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy or light chain of the antibody. A heavy chain variable domain may be referred to as "VH". A light chain variable domain may be referred to as "VL". These domains are generally the most variable parts of an antibody and contain the antigen binding sites.

[0074] The term "variable" refers to the fact that the sequence of certain parts of the variable domains varies widely among antibodies and is used in the binding and specificity of each particular antibody to its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called hypervariable regions (HVRs) in both the light and heavy chain variable domains. The more highly conserved parts of the variable domains are called framework regions (FRs). Natural heavy and light chain variable domains each contain four FR regions that largely adopt a beta-sheet configuration connected by three HVRs that form loops that connect and, in some cases, form part of the beta-sheet structure. The HVRs within each chain are held in close proximity to each other by the FR regions and, together with the HVRs of the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., "Sequences of Immunological Interest," 5th ed., National Institute of Health, Bethesda, Md., 1991). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participating in antibody-dependent cellular toxicity.

[0075] The "light chains" of antibodies (immunoglobulins) from any mammalian species can be assigned to one of two clearly distinct types, called kappa ("κ") and lambda ("λ"), based on the amino acid sequences of their constant domains.

[0076] The term IgG "isotype" or "subclass" as used herein means any of the subclasses of immunoglobulins defined by the chemical and antigenic properties of their constant regions.

[0077] Depending on the amino acid sequence of the constant domain of their heavy chains, antibodies (immunoglobulins) can be assigned to different classes. There are five main classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, γ, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known and are generally described, for example, in Abbas et al., Cellular and Mol. Immunology, 4th Edition (WB Saunders, Co. (2000). An antibody may be part of a larger fusion molecule formed by covalent or non-covalent association of the antibody with one or more other proteins or peptides.

[0078] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody in its substantially intact form, rather than an antibody fragment as described below. These terms specifically refer to antibodies having heavy chains that contain an Fc region.

[0079] A "naked antibody" for purposes herein is an antibody that is not conjugated to a cytotoxic moiety or radiolabel.

[0080] An "antibody fragment" includes a portion of an intact antibody, preferably including its antigen-binding region. In some embodiments, the antibody fragments described herein are antigen-binding fragments. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

[0081] Papain digestion of antibodies produces two identical antigen-binding fragments called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, a name reflecting its ability to crystallize readily. Pepsin treatment yields an F(ab')2 fragment that has two antigen-binding sites and is still capable of cross-linking antigen.

[0082] "Fv" is the smallest antibody fragment that contains a complete antigen-binding site. In one embodiment, a two-chain Fv species consists of a dimer of one heavy-chain variable domain and one light-chain variable domain in tight non-covalent association. In a single-chain Fv (scFv) species, one heavy-chain variable domain and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric" structure similar to that in the two-chain Fv species. It is in this configuration that the three HVRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six HVRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv containing only three antigen-specific HVRs) has the ability to recognize and bind to an antigen, albeit with a lower affinity than the entire binding site.

[0083] Fab fragments contain heavy and light chain variable domains, and also contain a light chain constant domain and the first heavy chain constant domain (CH1). Fab' fragments differ from Fab fragments in that they have a few additional residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine ​​residue(s) of the constant domains bear a free thiol group. F(ab')2 antibody fragments were originally produced as pairs of Fab' fragments with hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

[0084] "Single-chain Fv" or "scFv" antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding. For a general review of scFvs, see, e.g., Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, Eds. Rosenburg and Moore (Springer-Verlag, New York (1994)), pp. 269-315.

[0085] The term "diabody" refers to an antibody fragment having two antigen-binding sites, which fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH-VL). By using a linker that is too short to allow pairing between the two domains on the same chain, these domains are forced to pair with complementary domains on another chain, creating two antigen-binding sites. Diabodies can be bivalent or bispecific. Diabodies are described in more detail, for example, in EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).

[0086] The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogenous antibodies, e.g., the individual antibodies that make up the population are identical except for possible mutations that may be present in minor amounts, e.g., naturally occurring mutations. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of separate antibodies. In certain embodiments, such monoclonal antibodies typically include antibodies that include a polypeptide sequence that binds to a target, the target-binding polypeptide sequence being obtained by a process that includes selection of the target-binding polypeptide sequence from a plurality of polypeptide sequences. For example, the selection process can be selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, or recombinant DNA clones. It is understood that the selected target-binding sequence may be further modified, e.g., to improve affinity to the target, humanize the target-binding sequence, improve its production in cell culture, reduce its immunogenicity in vivo, and create a multispecific antibody, and an antibody that includes a modified target-binding sequence is also a monoclonal antibody of the present invention. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. In addition to their specificity, monoclonal antibody preparations are advantageous in that they are typically uncontaminated by other immunoglobulins.

[0087] The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies to be used in accordance with the present invention may be produced using techniques such as the hybridoma method (e.g., Kohler and Milstein, Nature 256:495-97 (1975); Hongo et al., Hybridoma 14:3:253-260 (1995); Harlow et al., Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 2nd ed., 1988); Hammerling et al., Monoclonal Antibodies and T-Cell Immunotherapy (1997), 12:111-113 (1997)). Hybridomas, 563-681 (Elsevier, New York, 1981)), recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567), phage display methods (see, e.g., Clackson et al., Nature, 352:624-628 (1991); Marks et al., J. Mol. Biol. 222:581-597 (1992); Sidhu et al., J. Mol. Biol., 338:299-310 (2004); Lee et al., J. Mol. Biol., 340:5:1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA, 101:34:12467-12472 (2004); and Lee et al., J. Immunol. Methods, Vol. 284, No. 1-2, pp. 119-132 (2004)), as well as techniques for producing human antibodies or human-like antibodies in animals that have some or all of the human immunoglobulin loci or genes encoding human immunoglobulin sequences (see, e.g., International Publication Nos. WO 1998 / 24893; WO 1996 / 34096; WO 1996 / 33735; WO 1991 / 10741; Jakobovits et al., Proc. Natl. Acad. Sci. USA, Vol. 90, p. 2551 (1993); Jakobovits et al., Nature, Vol. 362, p. 255-258 (1993); Bruggemann et al., Year in Immunol.7, 33 (1993); U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016; Marks et al., Bio / Technology 10, 779-783 (1992); Lonberg et al., Nature 368, 856-859 (1994); Morrison, Nature 368, 812-813 (1994); Fishwild et al., Nature Biotechnol. 14, 845-851 (1996); Neuberger, Nature Biotechnol. 14, 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).

[0088] The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and / or light chain is identical or homologous to a corresponding sequence in an antibody from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical or homologous to a corresponding sequence in an antibody from another species or belonging to another antibody class or subclass, so long as the desired biological activity is exhibited (see, e.g., U.S. Pat. No. 4,816,567, and Morrison et al., Proc. Natl. Acad. Sci. USA, vol. 81, pp. 6851-6855 (1984)). Chimeric antibodies include PRIMATTZED® antibodies, whose antigen-binding regions are derived from, for example, antibodies produced by immunizing macaque monkeys with an antigen of interest.

[0089] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. In one embodiment, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from an HVR of the recipient are replaced by residues from an HVR of a non-human species (donor antibody) such as mouse, rat, rabbit, or non-human primate having the desired specificity, affinity, and / or capacity. In some instances, FR residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient or donor antibody. These modifications can be made to further refine antibody performance. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, with all or substantially all of the hypervariable loops corresponding to those of a non-human immunoglobulin and all or substantially all of the FRs being those of a human immunoglobulin sequence. The humanized antibody optionally also comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see, e.g., Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See also, e.g., Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998); Harris, Biochem. Soc. Transactions 23:1035-1038 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428-433 (1994); and U.S. Pat. Nos. 6,982,321 and 7,087,409.

[0090] A "human antibody" is an antibody having an amino acid sequence that corresponds to that of an antibody produced by a human and / or produced using any of the techniques for producing human antibodies disclosed herein. This definition of a human antibody specifically excludes humanized antibodies that contain non-human antigen-binding residues. Human antibodies can be produced using a variety of techniques known in the art, such as phage display libraries. Hoogenboom and Winter, J. Mol. Biol. 227:381 (1991); Marks et al., J. Mol. Biol. 222:581 (1991). The methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J. Immunol. 147:1:86-95 (1991) are also available for the preparation of human monoclonal antibodies. See also van Dijk and van de Winkel, Curr Opin Pharmacol. 5:368-74 (2001). Human antibodies can be prepared by administering antigen to transgenic animals, e.g., immunized xenomouse, that have been engineered to produce such antibodies in response to antigen challenge, but whose endogenous loci have been disabled (see, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 for XENOMOUSE™ technology). See, e.g., Li et al., Proc. Natl. Acad. Sci. USA 103:3557-3562 (2006), also for human antibodies produced by human B cell hybridoma technology.

[0091] A "species-dependent antibody" is an antibody that has a stronger binding affinity for an antigen from a first mammalian species than for a homologue of the antigen from a second mammalian species. Typically, a species-dependent antibody "specifically binds" to a human antigen (e.g., has a binding affinity (Kd) value of about 1×10-7M or less, preferably about 1×10-8M or less, preferably about 1×10-9M or less), but has a binding affinity for a homologue of the antigen from a second non-human mammalian species that is at least about 50-fold, or at least about 500-fold, or at least about 1000-fold weaker than the binding affinity for the human antigen. A species-dependent antibody can be any of the various types of antibodies defined above, but is preferably a humanized or human antibody.

[0092] The term "hypervariable region", "HVR", or "HV" as used herein refers to a region of an antibody variable domain that is sequence hypervariable and / or forms structurally defined loops. Generally, antibodies contain six HVRs, three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3). In natural antibodies, H3 and L3 represent the highest diversity of the six HVRs, and H3 in particular is believed to play a unique role in conferring fine specificity to antibodies. See, for example, Xu et al., Immunity 13:37-45 (2000); Johnson and Wu, Methods in Molecular Biology 248:1-25 (ed. Lo, Human Press, Totowa, NJ (2003)). In fact, naturally occurring camelid antibodies consisting only of heavy chains are functional and stable in the absence of light chains. See, e.g., Hamers-Casterman et al., Nature 363:446-448 (1993); Sheriff et al., Nature Struct. Biol. 3:733-736 (1996).

[0093] Several HVR delineations are used and encompassed herein. The Kabat complementarity determining regions (CDRs) are based on sequence variability and are the most commonly used (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Leland (1991)). Chothia, instead, refers to the location of structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). The AbM HVRs represent a compromise between the Kabat HVRs and the Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software. The "contact" HVRs are based on analysis of available complex crystal structures. Residues from each of these HVRs are described below. Loop Kabat AbM Chothia Contact L1 L24-L34 L24-L34 L26-L32 L30-L36 L2 L50-L56 L50-L56 L50-L52 L46-L55 L3 L89-L97 L89-L97 L91-L96 L89-L96 H1 H31-H35B H26-H35B H26-H32 H30-H35B (Kabat numbering) H1 H31-H35 H26-H35 H26-H32 H30-H35 (Chothia numbering) H2 H50-H65 H50-H58 H53-H55 H47-H58 H3 H95-H102 H95-H102 H96-H101 H93-H101

[0094] HVRs may include the following "extended HVRs": in the VL, 24-36 or 24-34 (L1), 46-56 or 50-56 (L2), and 89-97 or 89-96 (L3), and in the VH, 26-35 (H1), 50-65 or 49-65 (H2), and 93-102, 94-102, or 95-102 (H3). The variable domain residues are numbered according to Kabat et al. (see above) for each of these definitions.

[0095] HVRs may include the following "extended HVRs": in the VL, 24-36 or 24-34 (L1), 46-56 or 50-56 (L2), and 89-97 or 89-96 (L3), and in the VH, 26-35 (H1), 50-65 or 49-65 (H2), and 93-102, 94-102, or 95-102 (H3). The variable domain residues are numbered according to Kabat et al. (see above) for each of these definitions.

[0096] "Framework" or "FR" residues are those variable domain residues other than HVR residues as herein defined.

[0097] The terms "variable domain residue numbering as in Kabat" or "amino acid position numbering as in Kabat", and variations thereof, refer to the numbering system used for the heavy or light chain variable domains of the compilation of antibodies in Kabat et al. (see above). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, the FR or HVR of the variable domain. For example, a heavy chain variable domain may contain a single amino acid insertion after residue 52 of H2 (residue 52a according to Kabat) and may contain inserted residues after heavy chain FR residue 82 (e.g., residues 82a, 82b, and 82c, etc. according to Kabat). The Kabat numbering of residues may be determined for a given antibody by alignment of the antibody's sequence with the "standard" Kabat numbered sequence at the regions of homology.

[0098] The Kabat numbering system is commonly used when referring to residues within the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) (e.g., Kabat et al., "Sequences of Immunological Interest." 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). The "EU numbering system" or "EU index" is commonly used when referring to residues in immunoglobulin heavy chain constant regions (e.g., the EU index reported in Kabat et al., supra). "EU index as in Kabat" refers to the residue numbering of the human IgG1 EU antibody.

[0099] The term "linear antibody" refers to the antibodies described in Zapata et al. (Protein Eng. 8(10):1057-1062 (1995)). Briefly, these antibodies comprise a pair of tandem Fd segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen-binding regions. Linear antibodies may be bispecific or monospecific.

[0100] As used herein, the terms "bind", "specifically bind to", or "specific for" refer to a measurable and reproducible interaction, such as binding between a target and an antibody, that determines the presence of the target in the presence of a heterogeneous population of molecules, such as biological molecules. For example, an antibody that binds to or specifically binds to a target (which may be an epitope) is an antibody that binds to this target with higher affinity, avidity, more readily, and / or for longer than it binds to other targets. In one embodiment, the extent to which an antibody binds to an unrelated target is less than about 10% of the binding of the antibody to the target, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that specifically binds to a target has a dissociation constant (Kd) of 1 μM or less, 100 nM or less, 10 nM or less, 1 nM or less, or 0.1 nM or less. In certain embodiments, an antibody specifically binds to an epitope on a protein that is conserved among proteins from different species. In another embodiment, specific binding can include, but does not require, exclusive binding.

[0101] The term "sample" as used herein refers to a composition obtained or derived from a subject and / or individual of interest that contains a cellular and / or other molecular entity to be characterized and / or identified, for example, based on physical, biochemical, chemical, and / or physiological properties. For example, the phrase "disease sample" and variations thereof refer to any sample obtained from a subject of interest that is expected to contain or is known to contain the cellular and / or molecular entity to be characterized. Samples include, but are not limited to, primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous fluid, lymphatic fluid, synovial fluid, follicular fluid, semen, amniotic fluid, milk, whole blood, cells from blood, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tumor lysates, and tissue culture media, tissue extracts (such as homogenized tissue), tumor tissue, cell extracts, and combinations thereof.

[0102] "Tissue sample" or "cell sample" refers to a collection of similar cells obtained from the tissue of a subject or individual. The source of the tissue or cell sample may be solid tissue, such as from fresh, frozen, and / or preserved organs, tissue samples, biopsies, and / or aspirates; blood or any blood constituents, such as plasma; bodily fluids, such as cerebrospinal fluid, amniotic fluid, peritoneal fluid, or interstitial fluid; cells from any time during the subject's pregnancy or development. The tissue sample may also be primary or cultured cells or cell lines. Optionally, the tissue or cell sample is obtained from a diseased tissue / organ. The tissue sample may contain compounds that are not naturally mixed with the native tissue, such as preservatives, anticoagulants, buffers, fixatives, nutrients, or antibiotics.

[0103] A "reference sample", "reference cell", "reference tissue", "control sample", "control cell", or "control tissue" as used herein refers to a sample, cell, tissue, standard, or level used for comparison purposes. In one embodiment, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy and / or non-diseased part (e.g., tissue or cell) of the body of the same subject or individual. For example, a healthy and / or non-diseased cell or tissue adjacent to a diseased cell or tissue (e.g., a cell or tissue adjacent to a tumor). In another embodiment, the reference sample is obtained from an untreated tissue and / or cell of the body of the same subject or individual. In yet another embodiment, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy and / or non-diseased part (e.g., tissue or cell) of the body of an individual that is not the subject or individual. In yet another embodiment, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from an untreated tissue and / or cell of the body of an individual that is not the subject or individual.

[0104] An "effective response" of a patient to treatment with a pharmaceutical agent or a patient's "responsiveness" and similar words refer to a clinical or therapeutic benefit conferred on a patient at risk for or suffering from a disease or disorder, such as cancer. In one embodiment, such benefit includes one or more of: extending survival (including overall survival and progression-free survival), producing an objective response (including a complete or partial response), or ameliorating the signs or symptoms of cancer.

[0105] A patient who "does not respond effectively" to a treatment is one who does not have any of the following: prolonged survival (including overall survival and progression-free survival), failed to produce an objective response (including a complete or partial response), or failed to improve the signs or symptoms of cancer.

[0106] A "functional Fc region" has an "effector function" of a native sequence Fc region. Exemplary "effector functions" include C1q binding; CDC; Fc receptor binding; ADCC; phagocytosis; downregulation of cell surface receptors (e.g., B cell receptor; BCR), and the like. Such effector functions generally require that the Fc region be combined with a binding domain (e.g., an antibody variable domain) and can be assessed, for example, using various assays as disclosed in the definitions herein.

[0107] "Human effector cells" refers to leukocytes that express one or more FcRs and perform effector function. In certain embodiments, these cells express at least FcγRIII and perform ADCC effector function(s). Examples of human leukocytes that mediate ADCC include peripheral blood mononuclear cells (PBMCs), natural killer (NK) cells, monocytes, cytotoxic T cells, and neutrophils. Effector cells can be isolated from a natural source, e.g., blood.

[0108] A cancer or biological sample "having human effector cells" is one that has human effector cells (eg, infiltrating human effector cells) present in the sample in a diagnostic test.

[0109] A cancer or biological sample "having FcR-expressing cells" is one that has FcR expression (e.g., infiltrating FcR-expressing cells) present in the sample in a diagnostic test. In some embodiments, the FcR is an FcγR. In some embodiments, the FcR is an activating FcγR.

[0110] II. Overview Provided herein is a method for treating or delaying the progression of lung cancer (such as non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer) in an individual, comprising administering to the individual an effective amount of a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab), an antimetabolite (e.g., pemetrexed), and a platinum agent (e.g., carboplatin or cisplatin). Also provided herein is a method for improving immune function in an individual with lung cancer (such as non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer), comprising administering to the individual an effective amount of a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab), an antimetabolite (e.g., pemetrexed), and a platinum agent (e.g., carboplatin or cisplatin). In some embodiments, the treatment extends the progression-free survival (PFS) and / or overall survival (OS) of the individual. In some embodiments, the treatment extends the individual's progression-free survival (PFS) and / or overall survival (OS) as compared to a treatment comprising administration of an antimetabolite (e.g., pemetrexed) and a platinum agent (e.g., carboplatin or cisplatin).

[0111] In some embodiments, the methods include treating an individual with stage IV lung cancer, e.g., stage IV non-squamous NSCLC, by administering atezolizumab in combination with pemetrexed and carboplatin to the individual, wherein the administration includes an induction phase and a maintenance phase, the induction phase including administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1. 2 and carboplatin administered at a dose sufficient to achieve an AUC=6 mg / mL / min on day 1 of each 21-day cycle for cycles 1-4, wherein the maintenance phase comprises atezolizumab administered at a dose of 1200 mg on day 1 and pemetrexed administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 4. 2 and administering to the individual a dose of 0.1 mg / kg / day of 10 ... of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of In some embodiments, the treatment increases the OS of the individual by at least any one of about 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 months (including any ranges between these values). In some embodiments, the treatment increases the OS of the individual by at least about 18.1 months.

[0112] In some embodiments, the methods include treating an individual with stage IV lung cancer, e.g., stage IV non-squamous NSCLC, by administering atezolizumab in combination with pemetrexed and cisplatin to the individual, wherein the administration includes an induction phase and a maintenance phase, the induction phase including administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1. 2 and cisplatin at 75 mg / m on day 1 of each 21-day cycle for cycles 1 to 4. 2 and the maintenance phase comprises administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 4. 2 and administering to the individual a dose of 0.1 mg / kg / day of 10 ... of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of In some embodiments, the treatment increases the OS of the individual by at least any one of about 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 months (including any ranges between these values). In some embodiments, the treatment increases the OS of the individual by at least about 18.1 months.

[0113] In some embodiments, the methods include treating an individual with stage IV lung cancer, e.g., stage IV non-squamous NSCLC, by administering atezolizumab in combination with pemetrexed and carboplatin to the individual, wherein the administration includes an induction phase and a maintenance phase, the induction phase including administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1. 2 and carboplatin administered at a dose sufficient to achieve an AUC=6 mg / mL / min on day 1 of each 21-day cycle for cycles 1-6, wherein the maintenance phase comprises atezolizumab administered at a dose of 1200 mg on day 1 and pemetrexed administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 6. 2 and administering to the individual a dose of 0.1 mg / kg / day of 10 ... of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of In some embodiments, the treatment increases the OS of the individual by at least any one of about 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 months (including any ranges between these values). In some embodiments, the treatment increases the OS of the individual by at least about 18.1 months.

[0114] In some embodiments, the methods include treating an individual with stage IV non-small cell lung cancer (NSCLC), e.g., stage IV non-squamous NSCLC, by administering atezolizumab in combination with pemetrexed and cisplatin to the individual, wherein the administration includes an induction phase and a maintenance phase, the induction phase including administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1. 2 and cisplatin at 75 mg / m on day 1 of each 21-day cycle for cycles 1 to 6. 2 and the maintenance phase comprises administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 6. 2 and administering to the individual a dose of 0.1 mg / kg / day of 10 ... of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of 100 mg / kg of In some embodiments, the treatment increases the OS of the individual by at least any one of about 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 months (including any ranges between these values). In some embodiments, the treatment increases the OS of the individual by at least about 18.1 months.

[0115] III. PD-1 axis binding antagonists For example, PD-1 axis binding antagonists include PD-1 binding antagonists, PDL1 binding antagonists, and PDL2 binding antagonists. Alternative names for "PD-1" include CD279 and SLEB2. Alternative names for "PDL1" include B7-H1, B7-4, CD274, and B7-H. Alternative names for "PDL2" include B7-DC, Btdc, and CD273. In some embodiments, PD-1, PDL1, and PDL2 are human PD-1, PDL1, and PDL2.

[0116] In some embodiments, the PD-1 binding antagonist is a molecule that inhibits the binding of PD-1 to its ligand binding partner(s). In a specific aspect, the ligand binding partner of PD-1 is PDL1 and / or PDL2. In another embodiment, the PDL1 binding antagonist is a molecule that inhibits the binding of PDL1 to its binding partner(s). In a specific aspect, the binding partner(s) of PDL1 is PD-1 and / or B7-1. In another embodiment, the PDL2 binding antagonist is a molecule that inhibits the binding of PDL2 to its binding partner(s). In a specific aspect, the binding partner of PDL2 is PD-1. The antagonist may be an antibody, an antigen-binding fragment thereof, an immunoadhesin, a fusion protein, or an oligopeptide.

[0117] In some embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody (eg, a human antibody, a humanized antibody, or a chimeric antibody).

[0118] In some embodiments, the anti-PD-1 antibody is nivolumab (CAS Registry Number 946414-94-4). Nivolumab (Bristol-Myers Squibb / Ono), also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558, and OPDIVO®, is an anti-PD-1 antibody described in International Publication No. WO 2006 / 121168. In some embodiments, the anti-PD-1 antibody comprises heavy and light chain sequences, wherein: (a) the heavy chain has the amino acid sequence: QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWY DGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 11); and (b) the light chain comprises the amino acid sequence: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 12).

[0119] In some embodiments, the anti-PD-1 antibody comprises six HVR sequences from SEQ ID NO:11 and SEQ ID NO:12 (e.g., three heavy chain HVRs from SEQ ID NO:11 and three light chain HVRs from SEQ ID NO:12). In some embodiments, the anti-PD-1 antibody comprises a heavy chain variable domain from SEQ ID NO:11 and a light chain variable domain from SEQ ID NO:12.

[0120] In some embodiments, the anti-PD-1 antibody is pembrolizumab (CAS Registry Number 1374853-91-4). Pembrolizumab (Merck), also known as MK-3475, Merck 3475, lambrolizumab, KEYTRUDA®, and SCH-900475, is an anti-PD-1 antibody described in WO2009 / 114335. In some embodiments, the anti-PD-1 antibody comprises heavy and light chain sequences, wherein: (a) the heavy chain has the amino acid sequence: QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGG INPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYW GQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTK PREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK GQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 13), and (b) the light chain has the amino acid sequence: Contains EIVLTQSPAT LSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLES GVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 14).

[0121] In some embodiments, the anti-PD-1 antibody comprises six HVR sequences from SEQ ID NO: 13 and SEQ ID NO: 14 (e.g., three heavy chain HVRs from SEQ ID NO: 13 and three light chain HVRs from SEQ ID NO: 14). In some embodiments, the anti-PD-1 antibody comprises a heavy chain variable domain from SEQ ID NO: 13 and a light chain variable domain from SEQ ID NO: 14.

[0122] In some embodiments, the anti-PD-1 antibody is MEDI-0680 (AMP-514; AstraZeneca). MEDI-0680 is a humanized IgG4 anti-PD-1 antibody.

[0123] In some embodiments, the anti-PD-1 antibody is PDR001 (CAS Registry No. 1859072-53-9; Novartis). PDR001 is a humanized IgG4 anti-PD1 antibody that blocks the binding of PDL1 and PDL2 to PD-1.

[0124] In some embodiments, the anti-PD-1 antibody is REGN2810 (Regeneron). REGN2810 is a human anti-PD1 antibody.

[0125] In some embodiments, the anti-PD-1 antibody is BGB-108 (BeiGene). In some embodiments, the anti-PD-1 antibody is BGB-A317 (BeiGene).

[0126] In some embodiments, the anti-PD-1 antibody is JS-001 (Shanghai Junshi). JS-001 is a humanized anti-PD1 antibody.

[0127] In some embodiments, the anti-PD-1 antibody is STI-A1110 (Sorrento). STI-A1110 is a human anti-PD1 antibody.

[0128] In some embodiments, the anti-PD-1 antibody is INCSHR-1210 (Incyte). INCSHR-1210 is a human IgG4 anti-PD1 antibody.

[0129] In some embodiments, the anti-PD-1 antibody is PF-06801591 (Pfizer).

[0130] In some embodiments, the anti-PD-1 antibody is TSR-042 (also known as ANB011; Tesaro / AnaptysBio).

[0131] In some embodiments, the anti-PD-1 antibody is AM0001 (ARMO Biosciences).

[0132] In some embodiments, the anti-PD-1 antibody is ENUM244C8 (Enumeral Biomedical Holdings). ENUM244C8 is an anti-PD-1 antibody that inhibits PD-1 function without blocking the binding of PDL1 to PD-1.

[0133] In some embodiments, the anti-PD-1 antibody is ENUM388D4 (Enumeral Biomedical Holdings). ENUM388D4 is an anti-PD1 antibody that competitively inhibits the binding of PDL1 to PD-1.

[0134] In some embodiments, the PD-1 antibody comprises six HVR sequences (e.g., three heavy chain HVRs and three light chain HVRs) and / or the HVR sequences described in International Publication Nos. WO2015 / 112800 (applicant: Regeneron), WO2015 / 112805 (applicant: Regeneron), WO2015 / 112900 (applicant: Novartis), U.S. Patent Application Publication No. US20150210769 (assigned to Novartis), International Publication No. WO2016 / 089873 (applicant: Celgene), WO2015 / 035606 (applicant: Beigene), WO2015 / 085847 (applicant: Shanghai Hengrui Pharmaceutical / Jiangsu Hengrui), and / or the HVR sequences described in International Publication Nos. WO2015 ... Shanghai Hengrui Pharmaceutical / Jiangsu Hengrui), and / or the HVR sequences described in International Publication Nos. WO2015 / 089873 (applicant: Shanghai Hengrui Pharmaceutical / Jiangsu Hengrui), WO201 Medicine), and WO2014 / 206107 (applicant: Shanghai Junshi Biosciences / Junmeng No. WO2012 / 145493 (applicant: Amplimmune), U.S. Patent No. US9205148 (assigned to MedImmune), International Publication No. WO2015 / 119930 (applicant: Pfizer / Merck), WO2015 / 119923 (applicant: Pfizer / Merck), WO2016 / 032927 (applicant: Pfizer / Merck), WO2014 / 179664 (applicant: AnaptysBio), WO2016 / 106160 (applicant: Enumeral), and WO2014 / 194302 (applicant: Sorrento).

[0135] In some embodiments, the PD-1 binding antagonist is an immunoadhesin (e.g., an immunoadhesin that includes an extracellular or PD-1 binding portion of PDL1 or PDL2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence). In some embodiments, the PD-1 binding antagonist is AMP-224. AMP-224 (CAS Registry Number 1422184-00-6; GlaxoSmithKline / MedImmune), also known as B7-DCIg, is a PDL2-Fc fusion soluble receptor described in International Publication Nos. WO2010 / 027827 and WO2011 / 066342.

[0136] In some embodiments, the PD-1 binding antagonist is a peptide or a small molecule compound. In some embodiments, the PD-1 binding antagonist is AUNP-12 (PierreFabre / Aurigene). See, e.g., International Publication Nos. WO2012 / 168944, WO2015 / 036927, WO2015 / 044900, WO2015 / 033303, WO2013 / 144704, WO2013 / 132317, and WO2011 / 161699.

[0137] In some embodiments, the PDL1 binding antagonist is a small molecule that inhibits PD-1. In some embodiments, the PDL1 binding antagonist is a small molecule that inhibits PDL1. In some embodiments, the PDL1 binding antagonist is a small molecule that inhibits PDL1 and VISTA. In some embodiments, the PDL1 binding antagonist is CA-170 (also known as AUPM-170). In some embodiments, the PDL1 binding antagonist is a small molecule that inhibits PDL1 and TIM3. In some embodiments, the small molecule is a compound described in International Publication Nos. WO2015 / 033301 and WO2015 / 033299.

[0138] In some embodiments, the PD-1 axis binding antagonist is an anti-PDL1 antibody. A variety of anti-PDL1 antibodies are contemplated and described herein. In any of the embodiments herein, the isolated anti-PDL1 antibody can bind to human PDL1, e.g., human PDL1 set forth in UniProtKB / Swiss-Prot Accession No. Q9NZQ7.1, or a variant thereof. In some embodiments, the anti-PDL1 antibody can inhibit the binding between PDL1 and PD-1 and / or between PDL1 and B7-1. In some embodiments, the anti-PDL1 antibody is a monoclonal antibody. In some embodiments, the anti-PDL1 antibody can be a Fab, Fab'-SH, Fv, scFv, and (Fab') 2 In some embodiments, the anti-PDL1 antibody is an antibody fragment selected from the group consisting of humanized antibody fragments. In some embodiments, the anti-PDL1 antibody is a human antibody. Examples of anti-PDL1 antibodies useful in the methods of the present invention and methods for making them are described in PCT Patent Application No. WO2010 / 077634A1 and U.S. Patent No. 8,217,149, which are incorporated herein by reference.

[0139] In some embodiments, the anti-PDL1 antibody comprises a heavy chain variable region sequence and a light chain variable region sequence, wherein: (a) the heavy chain variable region comprises the HVR-H1, HVR-H2, and HVR-H3 sequences of GFTFSDSWIH (SEQ ID NO: 1), AWISPYGGSTYYADSVKG (SEQ ID NO: 2), and RHWPGGFDY (SEQ ID NO: 3), respectively; and (b) the light chain variable region comprises the HVR-L1, HVR-L2, and HVR-L3 sequences, respectively, of RASQDVSTAVA (sequence number 4), SASFLYS (sequence number 5), and QQYLYHPAT (sequence number 6).

[0140] In some embodiments, the anti-PDL1 antibody is MPDL3280A, also known as atezolizumab and TECENTRIQ® (CAS Registry Number 1422185-06-5). In some embodiments, the anti-PDL1 antibody comprises heavy and light chain sequences, wherein: (a) the heavy chain variable region sequence comprises the amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS (SEQ ID NO: 7); and (b) the light chain variable region sequence comprises the amino acid sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR (SEQ ID NO:8).

[0141] In some embodiments, the anti-PDL1 antibody comprises heavy and light chain sequences, wherein: (a) the heavy chain has the amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 9); and (b) the light chain comprises the amino acid sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 10).

[0142] In some embodiments, the anti-PDL1 antibody is avelumab (CAS Registry Number 1537032-82-8). Avelumab, also known as MSB0010718C, is a human monoclonal IgG1 anti-PDL1 antibody (Merck KGaA, Pfizer). In some embodiments, the anti-PDL1 antibody comprises heavy and light chain sequences, wherein: (a) the heavy chain has the amino acid sequence: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 15); and (b) the light chain comprises the amino acid sequence: QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 16).

[0143] In some embodiments, the anti-PDL1 antibody comprises six HVR sequences from SEQ ID NO: 15 and SEQ ID NO: 16 (e.g., three heavy chain HVRs from SEQ ID NO: 15 and three light chain HVRs from SEQ ID NO: 16). In some embodiments, the anti-PDL1 antibody comprises a heavy chain variable domain from SEQ ID NO: 15 and a light chain variable domain from SEQ ID NO: 16.

[0144] In some embodiments, the anti-PDL1 antibody is durvalumab (CAS Registry Number 1428935-60-7). Durvalumab, also known as MEDI4736, is an Fc-optimized human monoclonal IgG1 kappa anti-PDL1 antibody (MedImmune, AstraZeneca) described in International Publication No. WO2011 / 066389 and US Patent Application Publication No. US2013 / 034559. In some embodiments, the anti-PDL1 antibody comprises heavy and light chain sequences, wherein: (a) the heavy chain has the amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC DKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 17); and (b) the light chain comprises the amino acid sequence: EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (sequence number 18).

[0145] In some embodiments, the anti-PDL1 antibody comprises six HVR sequences from SEQ ID NO: 17 and SEQ ID NO: 18 (e.g., three heavy chain HVRs from SEQ ID NO: 17 and three light chain HVRs from SEQ ID NO: 18). In some embodiments, the anti-PDL1 antibody comprises a heavy chain variable domain from SEQ ID NO: 17 and a light chain variable domain from SEQ ID NO: 18.

[0146] In some embodiments, the anti-PDL1 antibody is MDX-1105 (Bristol Myers Squibb). MDX-1105, also known as BMS-936559, is an anti-PDL1 antibody described in WO2007 / 005874.

[0147] In some embodiments, the anti-PDL1 antibody is LY3300054 (Eli Lilly).

[0148] In some embodiments, the anti-PDL1 antibody is STI-A1014 (Sorrento). STI-A1014 is a human anti-PDL1 antibody.

[0149] In some embodiments, the anti-PDL1 antibody is KN035 (Suzhou Alphamab), a single domain antibody (dAB) generated from a camel phage display library.

[0150] In some embodiments, the anti-PDL1 antibody comprises a cleavable moiety or linker that, when cleaved (e.g., by a protease in the tumor microenvironment), activates the antibody antigen-binding domain so that it can bind to its antigen, e.g., by removing unbound steric moieties. In some embodiments, the anti-PDL1 antibody is CX-072 (CytomX Therapeutics).

[0151] In some embodiments, the PDL1 antibody comprises six HVR sequences (e.g., three heavy chain HVRs and three light chain HVRs) and / or heavy and light chain variable domains from the PDL1 antibody described in U.S. Patent Application Publication No. US20160108123 (assigned to Novartis), International Publication No. WO2016 / 000619 (applicant: Beigene), International Publication No. WO2012 / 145493 (applicant: Amplimmune), U.S. Patent No. US9205148 (assigned to MedImmune), International Publication No. WO2013 / 181634 (applicant: Sorrento), and International Publication No. WO2016 / 061142 (applicant: Novartis).

[0152] In an even more specific aspect, the antibody further comprises a human or mouse constant region. In a still further aspect, the human constant region is selected from the group consisting of IgG1, IgG2, IgG2, IgG3, and IgG4. In an even more specific aspect, the human constant region is IgG1. In a still further aspect, the mouse constant region is selected from the group consisting of IgG1, IgG2A, IgG2B, and IgG3. In a still further aspect, the mouse constant region is IgG2A.

[0153] In a still further specific aspect, the antibody has reduced or minimal effector function. In a still further specific aspect, the minimal effector function is due to an "effectorless Fc mutation" or an aglycosylation mutation. In a still further embodiment, the effectorless Fc mutation is an N297A or D265A / N297A substitution in the constant region. In some embodiments, the isolated anti-PDL1 antibody is aglycosylated. Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are recognition sequences for enzymatic attachment of a carbohydrate moiety to the asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars, N-acetylgalactosamine, galactose, or xylose, to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. Removal of a glycosylation site from an antibody is conveniently accomplished by modifying the amino acid sequence such that one of the tripeptide sequences described above (for N-linked glycosylation sites) is removed. This modification may be made by replacing the asparagine, serine, or threonine residue in the glycosylation site with another amino acid residue (e.g., glycine, alanine, or a conservative substitution).

[0154] In yet a further embodiment, the present disclosure provides a composition comprising any of the above-mentioned anti-PDL1 antibodies in combination with at least one pharma- ceutically acceptable carrier.

[0155] In yet a further embodiment, the present disclosure provides a composition comprising an anti-PDL1, anti-PD-1, or anti-PDL2 antibody, or antigen-binding fragment thereof, provided herein, and at least one pharma- ceutically acceptable carrier. In some embodiments, the anti-PDL1, anti-PD-1, or anti-PDL2 antibody, or antigen-binding fragment thereof, administered to an individual is a composition comprising one or more pharma- ceutically acceptable carriers. Any of the pharma- ceutically acceptable carriers described herein or known in the art may be used.

[0156] IV. Antimetabolites and Platinum Preparations Antimetabolites Antimetabolites (e.g., pemetrexed, 5-fluorouracil, 6-mercaptopurine, capecitabine, cytarabine, floxuridine, fludarabine, hydroxycarbamide, and methotrexate, etc.) are widely used antitumor drugs that interfere with one or more enzymes required for DNA synthesis. Antimetabolites typically act by a variety of mechanisms, including, for example, inducing apoptosis by incorporation into nucleic acids, or competing for binding sites on enzymes involved in, for example, nucleotide synthesis, thereby depleting supplies necessary for DNA and / or RNA replication and cell proliferation.

[0157] Pemetrexed is an exemplary antimetabolite used in the methods described herein. Pemetrexed is a folic acid analog. The drug substance, pemetrexed disodium heptahydrate, has the chemical name L-glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl]benzoyl]-, disodium salt, C 20 H 19 N 5 Na 2 O 6 7H 2 It has a molecular formula of 0 and a molecular weight of 597.49 as a heptahydrate.

[0158] Pemetrexed disodium heptahydrate has the following structure: TIFF2024161372000001.tif37170

[0159] Pemetrexed inhibits several folate-dependent enzymes used in thymine and purine synthesis, namely thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) (see Shih et al. (1997) Cancer Res. 57:1116-23). ​​By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are necessary for the growth and survival of both normal and cancer cells. Pemetrexed is commercially available under the trademarks ALIMTA®, GIOPEM, PEXATE, PEMANAT, PEMEX, PEMMET, PEXATE, RELITREXED, and TEMERAN, CIAMBRA, among others.

[0160] Platinum drugs Platinum drugs (such as cisplatin, carboplatin, oxaliplatin, and satraplatin) are widely used antitumor drugs that cause DNA crosslinks as single adducts, interstrand crosslinks, intrastrand crosslinks, or DNA-protein crosslinks. Platinum drugs typically act at the adjacent N-7 position of guanine, forming 1,2 intrastrand crosslinks (Poklar et al. (1996) Proc. Natl. Acad. Sci. USA 93:15:7606-11; Rudd et al. (1995) Cancer Chemother. Pharmacol. 35:4:323-6). The resulting crosslinks inhibit DNA repair and / or DNA synthesis in cancer cells.

[0161] Carboplatin is an exemplary platinum coordination compound for use in the methods described herein. The chemical name of carboplatin is platinum, diamine [1,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2), and carboplatin has the following structural formula: TIFF2024161372000002.tif30170

[0162] Carboplatin is C 6 H 12 N 2 O 4 It is a crystalline powder with a molecular formula of Pt and a molecular weight of 371.25. It dissolves in water at a rate of approximately 14 mg / mL, with a pH of 5-7 for a 1% solution. It is practically insoluble in ethanol, acetone, and dimethylacetamide. Carboplatin primarily produces interstrand DNA crosslinks, and this effect is nonspecific to the cell cycle. Carboplatin is commercially available as PARAPLATIN®, BIOCARN, BLASTOCARB, BLASTOPLATIN, CARBOKEM, CARBOMAX, CARBOPA, CARBOPLAN, CARBOTEEN, CARBOTINAL, CYTOCARB, DUCARB, KARPLAT, KEMOCARB, NAPROPLAT, NEOPLATIN, NISCARBO, ONCOCARBIN, TEVACARB, and WOMASTIN.

[0163] Cisplatin is another exemplary platinum coordination compound for use in the methods described herein. Cisplatin's chemical name is dichloroplatinum diammoniate, and cisplatin has the following structural formula: TIFF2024161372000003.tif24170

[0164] Cisplatin is Pt(NH 3 ) 2 Cl 2Cisplatin is an inorganic and water-soluble platinum complex with a molecular formula of and a molecular weight of 300.046. After hydrolysis, it reacts with DNA to form both intrastrand and interstrand crosslinks. These crosslinks appear to inhibit DNA replication and transcription. The cytotoxicity of cisplatin correlates with cell arrest in the G2 phase of the cell cycle. Cisplatin is commercially available as PLATINOL®, PLATINOL®-AQ, CDDP, CISPLAN, CISPLAT, PLATIKEM, PLATIONCO, PRACTICIS, PLATICIS, BLASTOLEM, CISMAX, CISPLAN, CISPLATINUM, CISTEEN, DUPLAT, KEMOPLAT, ONCOPLATIN-AQ, PLATINEX, PLATIN, and TEVAPLATIN.

[0165] V. Antibody preparation The antibodies described herein are prepared using techniques available in the art for generating antibodies, exemplary methods of which are described in more detail in the following sections.

[0166] The antibody is directed to an antigen of interest (e.g., PD-L1, such as human PD-L1). Preferably, the antigen is a biologically important polypeptide, and administration of the antibody to a mammal suffering from a disorder can provide a therapeutic benefit to the mammal.

[0167] In certain embodiments, the antibodies provided herein have a concentration of 1 μM or less, 150 nM or less, 100 nM or less, 50 nM or less, 10 nM or less, 1 nM or less, 0.1 nM or less, 0.01 nM or less, or 0.001 nM or less (e.g., 10 -8 M or less, e.g. 10 -8 M~10 -13 M, for example 10 -9 M~10 -13 It has a dissociation constant (Kd) of 1 M.

[0168] In one embodiment, Kd is measured by a radiolabeled antigen binding assay (RIA) performed with a Fab version of the antibody of interest and its antigen, as illustrated by the following assay: The solution binding affinity of the Fab for the antigen is determined by the minimum concentration of ( 125 I) Fab is equilibrated with labeled antigen, and then bound antigen is measured by capturing it on a plate coated with anti-Fab antibody (see, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999)). To establish assay conditions, MICROTITER® multiwell plates (Thermo Scientific) are coated overnight with 5 μg / mL of capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), then blocked with 2% (w / v) bovine serum albumin in PBS for 2-5 hours at room temperature (approximately 23° C.). In non-adsorbent plates (Nunc #269620), 100 pM or 26 pM [ 125 I] The antigen is mixed with a serial dilution of the Fab of interest. The Fab of interest is then incubated overnight, although incubation can be continued for a longer period (e.g., about 65 hours) to ensure equilibrium is reached. The mixture is then transferred to the capture plate for incubation at room temperature (e.g., 1 hour). The solution is then removed and the plate is washed 8 times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. Once the plate has dried, 150 μL / well of scintillant (MICROSCINT-20™, Packard) is added and the plate is counted for 10 minutes on a TOPCOUNT™ gamma counter (Packard). The concentration of each Fab that results in 20% or less of maximum binding is selected for use in the competitive binding assay.

[0169] According to another embodiment, Kd is measured using a surface plasmon resonance assay using a BIACORE®-2000 or BIACORE®-3000 (BIAcore, Inc., Piscataway, NJ) at 25° C. with an immobilized antigen CM5 chip at approximately 10 response units (RU). Briefly, a carboxymethylated dextran biosensor chip (CM5, BIACORE, Inc.) is activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. The antigen is diluted to 5 μg / ml (approximately 0.2 μM) with 10 mM sodium acetate, pH 4.8, and then injected at a flow rate of 5 μl / min to achieve approximately 10 response units (RU) of coupled protein. After antigen injection, 1 M ethanolamine is injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN-20™) surfactant (PBST) at 25° C. with a flow rate of approximately 25 μL / min. Association rates (kon) and dissociation rates (koff) are calculated using a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensograms. The equilibrium dissociation constant (Kd) is calculated as the ratio koff / kon. See, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999). If the on-rate exceeds 106 M-1 s-1 by the surface plasmon resonance assay described above, the on-rate can be determined by using a fluorescence quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm, emission = 340 nm, 16 nm band pass) of 20 nM anti-antigen antibody (Fab form) in PBS (pH 7.2) at 25°C in the presence of increasing concentrations of antigen as measured with a spectrometer such as a spectrophotometer equipped with a stopped-flow (Aviv Instruments) or an 8000 series SLM-AMINCO™ spectrophotometer with a stirred cuvette (ThermoSpectronic).

[0170] (i) Antigen preparation Soluble antigens or fragments thereof, optionally conjugated to other molecules, can be used as immunogens to generate antibodies. In the case of transmembrane molecules such as receptors, fragments of these (e.g., the extracellular domain of the receptor) can be used as immunogens. Alternatively, cells expressing the transmembrane molecule can be used as immunogens. Such cells can be from natural sources (e.g., cancer cell lines) or can be cells transformed by recombinant techniques to express the transmembrane molecule. Other antigens and forms thereof useful for the preparation of antibodies will be apparent to those skilled in the art.

[0171] (ii) Exemplary Antibody-Based Methods Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. Bifunctional or derivatizing agents, such as maleimidobenzoyl sulfosuccinimide ester (conjugation via cysteine ​​residues), N-hydroxysuccinimide (via lysine residues), glutaraldehyde, succinic anhydride, SOCl 2 , or R 1 N=C=NR, where R and R 1 are different alkyl groups) to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, such as keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor.

[0172] For example, animals are immunized against the antigen, immunogenic conjugate, or derivative by combining 100 μg or 5 μg of protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later, the animals are boosted with 1 / 5 to 1 / 10 of the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later, the animals are bled and the serum is assayed for antibody titer. The animals are boosted until the titer plateaus. Preferably, the animals are boosted with a conjugate of the same antigen, but conjugated to a different protein and / or with a different cross-linking reagent. Conjugates can also be produced in recombinant cell culture as protein fusions. Agglutinating agents such as alum are also suitably used to enhance the immune response.

[0173] The monoclonal antibodies of the disclosure can be made using hybridoma methods first described by Kohler et al., Nature 256:495 (1975), and further described for human-human hybridomas in, for example, Hongo et al., Hybridoma 14:3:253-260 (1995), Harlow et al., Antibodies: A Laboratory Manual (Cold Spring Harbour Laboratory Press, 2nd ed. (1988)); Hammerling et al., Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, New York (1981)), and Ni, Xiandai Mianyixue 26:4:265-268 (2006). Further methods include those described, for example, in U.S. Patent No. 7,189,826 for the production of monoclonal human native IgM antibodies from hybridoma cell lines. Human hybridoma technology (trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, Vol. 20, No. 3, pp. 927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, Vol. 27, No. 3, pp. 185-91 (2005).

[0174] For various other hybridoma techniques, see, for example, US Patent Application Publication Nos. US2006 / 258841, US2006 / 183887 (fully human antibodies), US2006 / 059575, US2005 / 287149, US2005 / 100546, US2005 / 026229, and also U.S. Patent Nos. 7,078,492 and 7,153,507. An exemplary protocol for producing monoclonal antibodies using the hybridoma method is described below. In one embodiment, a mouse or other suitable host animal, e.g., a hamster, is immunized to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization. Antibodies are produced in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the polypeptides of the present disclosure or fragments thereof and an adjuvant, such as monophosphoryl lipid A (MPL) / trehalose diclinomycolate (TDM) (Ribi Immunochem Research, Inc. Hamilton, Montana). The polypeptides (e.g., antigens) of the present disclosure or fragments thereof can be prepared using methods well known in the art, such as recombinant methods, some of which are further described herein. Serum from the immunized animals is assayed for anti-antigen antibodies, and booster immunizations are optionally administered. Lymphocytes from the animals that produce anti-antigen antibodies are isolated. Alternatively, lymphocytes can be immunized in vitro.

[0175] The lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form hybridoma cells. See, for example, Goding, "Monoclonal Antibodies: Principles and Practice," pp. 59-103 (Academic Press, 1986). Myeloma cells that fuse efficiently, support stable high-level antibody production by selected antibody-producing cells, and are sensitive to media such as HAT medium may be used. Exemplary myeloma cells include, but are not limited to, mouse myeloma lines derived from, for example, MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center (San Diego, Calif., USA), and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection (Rockville, Md., USA). Human myeloma and mouse-human heteromyeloma cell lines have also been described for the production of human monoclonal antibodies (Kozbor, J. Immunol. 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, 51-63 (Marcel Dekker, Inc., New York, 1987)).

[0176] The hybridoma cells so prepared are seeded and grown in a suitable culture medium, e.g., a medium containing one or more substances that inhibit the growth or survival of the unfused parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT), the culture medium for the hybridomas will typically contain hypoxanthine, aminopterin, and thymidine (HAT medium), which substances inhibit the growth of HGPRT-deficient cells. Preferably, a serum-free hybridoma cell culture method is used to reduce the use of animal-derived serum, such as fetal bovine serum, as described, for example, in Even et al., Trends in Biotechnology, Vol. 24, No. 3, pp. 105-108 (2006).

[0177] Oligopeptides as tools to improve the productivity of hybridoma cell cultures are described by Franek in Trends in Monoclonal Antibody Research, pp. 111-122 (2005). Specifically, standard culture media are enriched with certain amino acids (alanine, serine, asparagine, proline) or protein hydrolyzate fractions, and apoptosis can be significantly inhibited by synthetic oligopeptides consisting of 3-6 amino acid residues. These peptides are present at millimolar or higher concentrations.

[0178] The culture medium in which the hybridoma cells grow can be assayed for production of monoclonal antibodies that bind to the antibodies of the present disclosure. The binding specificity of the monoclonal antibodies produced by the hybridoma cells can be determined by immunoprecipitation or in vitro binding assays, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). The binding affinity of the monoclonal antibodies can be determined, for example, by Scatchard analysis. See, e.g., Munson et al., Anal. Biochem. 107:220 (1980).

[0179] After hybridoma cells producing antibodies with the desired specificity, affinity, and / or activity are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. See, e.g., Goding, supra. Suitable culture media for this purpose include, e.g., D-MEM medium or RPMI-1640 medium. In addition, the hybridoma cells can be grown in vivo as ascites tumors in animals. The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures, such as, e.g., protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. One procedure for isolation of proteins from hybridoma cells is described in U.S. Patent Application Publication No. US2005 / 176122 and U.S. Patent No. 6,919,436. The method involves the use of minimal salts, such as lyotropic salts, in the binding process and preferably also involves the use of small amounts of organic solvents in the elution process.

[0180] (iii) Library-derived antibodies Antibodies of the present disclosure can be isolated by screening combinatorial libraries for antibodies with the desired activity(ies). Various methods are known in the art for generating phage display libraries, such as, for example, the methods described in Example 3, and screening such libraries for antibodies with the desired binding characteristics. Further methods are identified, for example, in Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al., eds., Human Press, Totowa, NJ, 2001), and in, for example, McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352:624-628 (1991); Marks et al., J. Mol. Biol. 222:581-597 (1992); Marks and Bradbury, Methods in Molecular Biology 248:161-175 (Lo, eds., Human Press, Totowa, NJ, 2001). Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol. 338, No. 2: 299-310 (2004); Lee et al., J. Mol. Biol. 340, No. 5: 1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101, No. 34: 12467-12472 (2004); and Lee et al., J. Immunol. Methods 284, No. 1-2: 119-132 (2004).

[0181] In certain phage display methods, repertoires of VH and VL genes can be cloned separately by polymerase chain reaction (PCR), randomly recombined in phage libraries, and then screened for antigen-binding phage as described by Winter et al., Ann. Rev. Immunol. 12:433-455 (1994). Phages typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high affinity antibodies to immunogens without the need to construct hybridomas. Alternatively, naive repertoires can be cloned (e.g., from humans) as described by Griffiths et al., EMBO J 12:725-734 (1993) to provide a single source of antibodies against a wide range of non-self and self antigens without any immunization. Finally, natural libraries can also be generated synthetically by cloning unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode the hypervariable CDR3 regions and perform rearrangement in vitro, as described in Hoogenboom and Winter, J. Mol. Biol. 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example, U.S. Pat. No. 5,750,373, and U.S. Patent Application Publication Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936, and 2009 / 0002360.

[0182] Antibodies or antibody fragments isolated from a human antibody library are considered to be human antibodies or human antibody fragments herein.

[0183] (iv) Chimeric, humanized, and human antibodies In certain embodiments, the antibody provided herein is a chimeric antibody. Certain chimeric antibodies are disclosed, for example, in U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, vol. 81, pp. 6851-6855 (1984). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a non-human primate, such as a mouse, rat, hamster, rabbit, or monkey) and a human constant region. In a further example, a chimeric antibody is a "class-switched" antibody whose class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0184] In certain embodiments, the chimeric antibody is a humanized antibody. Typically, humanization of a non-human antibody reduces its immunogenicity to humans, but maintains the specificity and affinity of the parent non-human antibody. Usually, a humanized antibody comprises one or more variable domains in which the HVRs, e.g., CDRs (or portions thereof), are derived from a non-human antibody, and the FRs (or portions thereof) are derived from a human antibody sequence. The humanized antibody optionally also comprises at least a portion of a human constant region. In some embodiments, some FR residues of the humanized antibody are replaced with corresponding residues from a non-human antibody (e.g., an antibody derived from HVR residues), e.g., to restore or improve antibody specificity or affinity.

[0185] Humanized antibodies and methods for making them are found, for example, in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further see, for example, Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S. Patent Nos. 5,821,337; 7,527,791; 6,982,321; and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (for a description of SDR (a-CDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing "surface reconstruction"); Dall'Acqua et al., Methods 36:43-60 (2005) (describing "FR reconstruction"); and Osbourn et al., Methods 36:61-68 (2005), and Klimka et al., Br. J. Cancer 83:252-260 (2000) (describing the "guided selection" approach for FR construction).

[0186] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (see, e.g., Sims et al., J. Immunol. 151:2296 (1993)); framework regions derived from human antibody consensus sequences of particular subtypes of heavy or light chain variable regions (see, e.g., Carter et al., Proc. Natl. Acad. Sci. USA 89:4285 (1992); and Presta et al., J. Immunol. 151:2623 (1993)). (1993); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and framework regions derived from screening of FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)).

[0187] In certain embodiments, the antibodies provided herein are human antibodies. Human antibodies can be produced using a variety of techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).

[0188] Human antibodies may be prepared by administering an immunogen to an intact human antibody or a transgenic animal that has been engineered to produce intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or part of a human immunoglobulin locus that replaces the endogenous immunoglobulin locus or is present extrachromosomally or randomly introduced into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin locus is usually inactive. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584, which describe XENOMOUSE™ technology; U.S. Patent No. 5,770,429, which describes HuMab® technology; U.S. Patent No. 7,041,870, which describes KM MOUSE® technology; and U.S. Patent Application Publication No. 2007 / 0061900, which describes VelociMouse® technology. The human variable regions from intact antibodies produced by such animals can be further modified, for example, by combining with a different human constant region.

[0189] Human antibodies can also be produced by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor, J. Immunol. 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol. 147:86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA 103:3557-3562 (2006). Further methods include, for example, U.S. Patent No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, Vol. 26, No. 4, pp. 265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, Vol. 20, No. 3: pp. 927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, Vol. 27, No. 3: pp. 185-91 (2005).

[0190] Human antibodies can also be generated by isolating Fv clone variable domain sequences selected from a human-derived phage display library. Such variable domain sequences can then be combined with the desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below.

[0191] (v)Antibody fragment Antibody fragments can be produced by traditional means such as enzymatic digestion or by recombinant techniques. Under certain circumstances, there are advantages to using antibody fragments rather than whole antibodies. The smaller size of the fragments allows for rapid clearance and may provide improved access to solid tumors. For a review of specific antibody fragments, see Hudson et al. (2003) Nat Med. 9:129-134.

[0192] Various techniques have been developed to produce antibody fragments. Traditionally, these fragments were obtained by proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)). However, these fragments can now be produced directly from recombinant host cells. Fab, Fv, and ScFv antibody fragments can all be expressed in and secreted from E. coli, allowing for the facile production of large amounts of these fragments. Antibody fragments can be isolated from the antibody phage libraries described above. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to produce F(ab') 2 (Carter et al., Bio / Technology 10:163-167 (1992)). According to another approach, F(ab') 2 Fragments can be directly isolated from recombinant host cell culture. Fab and F(ab') fragments with increased in vivo half-lives that contain salvage receptor binding epitope residues. 2Fragments are described in U.S. Pat. No. 5,869,046. Other techniques for producing antibody fragments will be apparent to those skilled in the art. In certain embodiments, the antibody is a single chain Fv fragment (scFv). See WO 93 / 16185; U.S. Pat. No. 5,571,894; and U.S. Pat. No. 5,587,458. Fv and scFv are the only species with intact binding sites that lack constant regions and may therefore be suitable for reducing non-specific binding during in vivo use. scFv fusion proteins can be constructed to provide fusion of an effector protein at either the amino or carboxy terminus of the scFv. See "Antibody Engineering," edited by Borrebaeck, supra. The antibody fragment may also be a "linear antibody," as described, for example, in U.S. Pat. No. 5,641,870. Such linear antibodies may be monospecific or bispecific.

[0193] (vi) Multispecific antibodies Multispecific antibodies have binding specificities for at least two different epitopes, which usually originate from different antigens. While such molecules usually bind only two different epitopes (i.e., bispecific antibodies, BsAbs), antibodies with additional specificities, such as trispecific antibodies, are encompassed by the term as used herein. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g., F(ab') 2 bispecific antibodies).

[0194] Methods for producing bispecific antibodies are known in the art. Traditional production of full-length bispecific antibodies is based on the co-expression of two immunoglobulin heavy-light chain pairs, where these two chains have different specificities (Millstein et al., Nature 305:537-539 (1983)). Due to the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) can produce a mixture with 10 different antibody molecules, only one of which has the correct bispecific structure. Purification of this correct molecule, usually done by affinity chromatography steps, is somewhat cumbersome and the product yield is low. Similar procedures are disclosed in WO 93 / 08829 and Traunecker et al., EMBO J. 10:3655-3659 (1991).

[0195] One approach to making bispecific antibodies known in the art is the "knobs-into-holes" or "protuberance-into-cavity" approach (see, e.g., U.S. Pat. No. 5,731,168). In this approach, two immunoglobulin polypeptides (e.g., heavy chain polypeptides) each contain an interface. An interface of one immunoglobulin polypeptide interacts with a corresponding interface of the other immunoglobulin polypeptide, thereby allowing the association of the two immunoglobulin polypeptides. These interfaces can be engineered such that a "knob" or "protuberance" (these terms may be used interchangeably herein) located at the interface of one immunoglobulin polypeptide corresponds to a "hole" or "cavity" (these terms may be used interchangeably herein) located at the interface of the other immunoglobulin polypeptide. In some embodiments, the holes are of the same or similar size as the knobs and are suitably positioned such that when the two interfaces interact, the knobs of one interface are positionable within the corresponding holes of the other interface. Without wishing to be bound by theory, it is believed that this stabilizes the heteromultimers and favors the formation of heteromultimers over other species, e.g., homomultimers. In some embodiments, this approach can be used to promote heteromultimerization of two different immunoglobulin polypeptides to generate bispecific antibodies that include two immunoglobulin polypeptides with binding specificities for different epitopes.

[0196] In some embodiments, knobs may be constructed by replacing small amino acid side chains with larger side chains. In some embodiments, holes may be constructed by replacing large amino acid side chains with smaller side chains. The knobs or holes may be present in the original interface or may be synthetically introduced. For example, knobs or holes may be synthetically introduced by modifying a nucleic acid sequence encoding the interface to replace at least one "original" amino acid residue with at least one "import" amino acid residue. Methods for modifying nucleic acid sequences may include standard molecular biology techniques well known in the art. The side chain volumes of various amino acid residues are shown in Table 1 below. In some embodiments, the original residues have small side chain volumes (e.g., alanine, asparagine, aspartic acid, glycine, serine, threonine, or valine) and the imported residues to form the knobs are naturally occurring amino acids and may include arginine, phenylalanine, tyrosine, and tryptophan. In some embodiments, the original residue has a large side chain volume (e.g., arginine, phenylalanine, tyrosine, and tryptophan) and the imported residue to form the hole is a naturally occurring amino acid, which may include alanine, serine, threonine, and valine. TIFF2024161372000004.tif167170 a The molecular weights of amino acids are minus the molecular weight of water. Values ​​are from "Handbook of Chemistry and Physics," 43rd ed., Cleveland, Chemical Rubber Publishing Co. (1961). b Values ​​from AAZamyatnin, Prog. Biophys. Mol. Biol., vol. 24, pp. 107-123 (1972). c Values ​​are from C. Chothia, J. Mol. Biol. 105, 1-14 (1975). Accessible surface area is defined in Figures 6-20 of that reference.

[0197] In some embodiments, the original residues for forming the knob or hole are identified based on the three-dimensional structure of the heteromultimer. Techniques for obtaining the three-dimensional structure known in the art may include X-ray crystallography and NMR. In some embodiments, the interface is the CH3 domain of an immunoglobulin constant domain. In these embodiments, the interface is the CH3 domain of a human IgG 1 The CH3 / CH3 interface of comprises 16 residues on each domain located on four anti-parallel β-strands. Without wishing to be bound by theory, the mutated residues are preferably located on these two central anti-parallel β-strands to minimize the risk that the knobs may be accommodated by the surrounding solvent rather than by a compensatory hole in the partner CH3 domain. In some embodiments, the mutations that form corresponding knobs and holes in the two immunoglobulin polypeptides correspond to one or more pairs provided in Table 2 below. TIFF2024161372000005.tif73170* Mutations are shown by the original residue, followed by its position using the Kabat numbering system, then the imported residue (all residues are shown in single letter amino acid code). Multiple mutations are separated by colons.

[0198] In some embodiments, the immunoglobulin polypeptide comprises a CH3 domain that comprises one or more amino acid substitutions listed in Table 2 above. In some embodiments, the bispecific antibody comprises a first immunoglobulin polypeptide that comprises a CH3 domain that comprises one or more amino acid substitutions listed in the left column of Table 2, and a second immunoglobulin polypeptide that comprises a CH3 domain that comprises one or more corresponding amino acid substitutions listed in the right column of Table 2.

[0199] After mutating the DNA as described above, polynucleotides encoding modified immunoglobulin polypeptides having one or more corresponding knob- or hole-forming mutations can be expressed and purified using standard recombinant techniques and cell systems known in the art. See, for example, U.S. Patent Nos. 5,731,168; 5,807,706; 5,821,333; 7,642,228; 7,695,936; 8,216,805; U.S. Patent Application Publication No. 2013 / 0089553; and Spiess et al., Nature Biotechnology, vol. 31, pp. 753-758 (2013). Modified immunoglobulin polypeptides can be produced using prokaryotic host cells such as E. coli or eukaryotic host cells such as CHO cells. Immunoglobulin polypeptides with corresponding knobs and holes can be expressed in host cells in co-culture and purified together as heteromultimers, or expressed in monoculture and purified separately and assembled in vitro. In some embodiments, two strains of bacterial host cells (one expressing an immunoglobulin polypeptide with knobs and the other expressing an immunoglobulin polypeptide with holes) are co-cultured using standard bacterial culture techniques known in the art. In some embodiments, the two strains can be mixed in a specific ratio, for example, to achieve equal expression levels in culture. In some embodiments, the two strains can be mixed in a ratio of 50:50, 60:40, or 70:30. After the polypeptides are expressed, the cells can be lysed together and the proteins can be extracted. Standard techniques known in the art that allow for the measurement of the abundance of homomultimeric versus heteromultimeric species can include size exclusion chromatography. In some embodiments, each modified immunoglobulin polypeptide is expressed separately using standard recombinant techniques and they can be assembled together in vitro. Assembly can be accomplished, for example, by purifying each modified immunoglobulin polypeptide, mixing and incubating them together in equal masses, reducing disulfides (e.g., by treatment with dithiothreitol), concentrating, and reoxidizing the polypeptides.The bispecific antibodies formed can be purified using standard techniques such as cation exchange chromatography and measured using standard techniques such as size exclusion chromatography. For further details of these methods, see Speiss et al., Nat Biotechnol 31:753-8 (2013). In some embodiments, modified immunoglobulin polypeptides can be separately expressed in CHO cells and constructed in vitro using the methods described above.

[0200] According to a different approach, antibody variable domains with the desired binding specificity (antibody-antigen binding sites) are fused to immunoglobulin constant domain sequences. The fusion is preferably with an immunoglobulin heavy chain constant domain, including at least a part of the hinge, CH2 and CH3 regions. It is typical to have the first heavy chain constant region (CH1), containing the site necessary for light chain binding, present in at least one of these fusions. DNAs encoding the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors and co-transfected into a suitable host organism. This provides great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments where unequal ratios of the three polypeptide chains used in the construction provide optimal yields. However, it is possible to insert sequences encoding two or all three polypeptide chains into one expression vector when expression of at least two polypeptide chains in equal ratios results in high yields or when their ratio is not particularly important.

[0201] In one embodiment of this approach, the bispecific antibody is composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm. It has been found that this asymmetric structure facilitates separation of the desired bispecific compound from undesired immunoglobulin chain combinations, since the presence of an immunoglobulin light chain in only one half of the bispecific molecule provides an easy method of separation. This approach is disclosed in International Publication No. WO 94 / 04690. For further details of the generation of bispecific antibodies, see, for example, Suresh et al., Methods in Enzymology 121:210 (1986).

[0202] According to another approach described in International Publication No. WO 96 / 27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. One interface is the C H The method comprises at least a portion of the three domains. In this method, one or more small amino acid side chains from the interface of a first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of a second antibody molecule by replacing the large amino acid side chain with a smaller one (e.g., alanine or threonine). This provides a mechanism for increasing the yield of heterodimers over other unwanted end-products such as homodimers.

[0203] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin and the other to biotin. Such antibodies have been proposed, for example, to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980) and to treat HIV infection (International Publication Nos. WO 91 / 00360, WO 92 / 200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking method. Suitable cross-linking agents are well known in the art and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

[0204] Techniques for generating bispecific antibodies from antibody fragments are also described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe the proteolytic cleavage of intact antibodies to generate F(ab') fragments. 2 A procedure is described to generate Fab' fragments that are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The generated Fab' fragments are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibody produced can be used as an agent for the selective immobilization of enzymes.

[0205] Recent advances have facilitated the direct recovery from E. coli of Fab'-SH fragments, which can be chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992), describe the production of a fully humanized bispecific antibody F(ab') 2The production of the molecule has been described. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody.

[0206] Various techniques have also been described for producing and isolating bispecific antibody fragments directly from recombinant cell culture. For example, bispecific antibodies have been produced using leucine zippers (Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). Leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then reoxidized to form the antibody heterodimers. This method can also be used to produce antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90(6444-6448, 1993) provides an alternative mechanism for making bispecific antibody fragments. These fragments consist of a light chain variable domain (V) connected to a light chain variable domain (V) by a linker that is too short to allow pairing between the two domains on the same chain. L ) connected to a heavy chain variable domain (V H ) in a given fragment. H Domain and V L Domain complementary to another fragment V L Domain and V H The domains are paired together to form two antigen-binding sites. Another strategy for making bispecific antibody fragments by using single-chain Fv (sFv) dimers has also been reported. See Gruber et al., J. Immunol 152:5368 (1994).

[0207] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tuft et al., J. Immunol. 147:60 (1991).

[0208] (vii) single domain antibody In some embodiments, the antibodies of the present disclosure are single domain antibodies. Single domain antibodies are single polypeptide chains that contain all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, single domain antibodies are human single domain antibodies (Domantis, Inc., Waltham, Massachusetts; see, e.g., U.S. Pat. No. 6,248,516 B1). In one embodiment, a single domain antibody consists of all or a portion of the heavy chain variable domain of an antibody.

[0209] (viii) antibody variants In some embodiments, amino acid sequence modification(s) of the antibodies described herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the antibodies can be prepared by introducing appropriate changes into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletion, and / or insertion, and / or substitution of residues within the amino acid sequence of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired properties. Amino acid alterations may be introduced into the amino acid sequence of the subject antibodies as that sequence is made.

[0210] (ix) Substitution, insertion, and deletion variants In certain embodiments, antibody variants with one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include HVRs and FRs. Conservative substitutions are shown in Table 3. More substantial changes are provided in Table 1 under the heading of "exemplary substitutions" and as further described below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into the antibody of interest and the products screened for the desired activity, for example, retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC. TIFF2024161372000006.tif150170

[0211] Amino acids may be grouped according to common side chain properties. a. Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; b. Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; c. Acidic: Asp, Glu; d. Basic: His, Lys, Arg; e. Affected residues Chain orientation: Gly, Pro; f. Aromatics: Trp, Tyr, Phe.

[0212] Non-conservative substitutions will involve exchanging a member of one of these classes for another class.

[0213] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant that is selected for further study will have a modification (e.g., improvement) in a certain biological property (e.g., increased affinity, reduced immunogenicity) compared to the parent antibody and / or will have a certain biological property of the parent antibody substantially retained. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated using, for example, phage display-based affinity maturation techniques as described herein. Briefly, one or more HVR residues are mutated and the variant antibodies are displayed on phage and screened for a particular biological activity (e.g., binding affinity).

[0214] Modifications (e.g., substitutions) may be made in the HVRs, for example, to improve antibody affinity. Such modifications may be made in "hot spots" of the HVRs, i.e., residues encoded by codons where mutations occur frequently during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and / or in the SDRs (a-CDRs), and the resulting variant VH or VL are tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries is described, for example, in Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al., eds., Human Press, Totowa, NJ (2001)). In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. This library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity includes an HVR-directed approach, randomizing several HVR residues (e.g., 4-6 residues at a time). HVR residues involved in antigen binding may be specifically identified, for example, using alanine scanning mutagenesis or modeling. In particular, CDR-H3 and CDR-L3 are often targeted.

[0215] In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs, so long as such modifications do not substantially reduce the ability of the antibody to bind to the antigen. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in the HVRs. Such modifications may be outside the HVR "hot spots" or SDRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR is either unaltered or contains no more than one, two, or three amino acid substitutions.

[0216] A useful method for identification of antibody residues or regions that may be targeted for mutation is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989), Science 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) are identified and replaced by neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Further substitutions may be introduced at amino acid positions that show functional sensitivity to the initial substitution. Alternatively, or in addition, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and the antigen. Such contact and adjacent residues may be targeted as candidates for substitution or removed. The variants may be screened to determine whether they contain the desired properties.

[0217] Amino acid sequence insertions include amino- and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of one or more amino acid residues. An example of a terminal insertion is an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme or polypeptide which increases the serum half-life of the antibody (e.g., for ADEPT).

[0218] (x) Glycosylation variants In certain embodiments, the antibodies provided herein are altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody can be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites are created or removed.

[0219] If the antibody comprises an Fc region, the carbohydrate attached thereto may be modified. Natural antibodies produced by mammalian cells typically contain branched, biantennary oligosaccharides that are generally attached to Asn297 of the CH2 domain of the Fc region by an N-linkage. See, for example, Wright et al., TIBTECH vol. 15, pp. 26-32 (1997). The oligosaccharides may include various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to the GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharides in the antibodies of the present disclosure may be made to generate antibody variants with improved certain properties.

[0220] In one embodiment, antibody variants are provided that include an Fc region, where the carbohydrate structure attached to the Fc region has reduced fucose or lacks fucose, which may improve ADCC function. Specifically, antibodies are contemplated herein that have reduced fucose compared to the amount of fucose of the same antibody produced in wild-type CHO cells. That is, they are characterized as having an amount of fucose that is less than they would otherwise have if produced by a native CHO cell (e.g., a CHO cell that produces a native glycosylation pattern, such as a CHO cell containing a native FUT8 gene). In certain embodiments, the antibody is one in which less than about 50%, 40%, 30%, 20%, 10%, or 5% of its N-linked glycans comprise fucose. For example, the amount of fucose in such antibodies may be between 1% and 80%, between 1% and 65%, between 5% and 65%, or between 20% and 40%. In certain embodiments, the antibody is an antibody in which none of its N-linked glycans contain fucose, i.e., the antibody has no fucose at all, no fucose, or is afucosylated. The amount of fucose is determined by calculating the average amount of fucose in the glycan at Asn297 relative to the sum of all glycostructures (e.g., complex, hybrid, and high mannose structures) attached to Asn297, as measured, for example, by MALDI-TOF mass spectrometry as described in International Publication No. WO2008 / 077546. Asn297 refers to an asparagine residue located at about position 297 (EU numbering of Fc region residues) in the Fc region. However, Asn297 may also be located about ±3 amino acids upstream or downstream from position 297, i.e., between positions 294-300, due to minor sequence variations in the antibody. Such fucosylation variants may have improved ADCC function. See, for example, U.S. Patent Application Publication Nos. US 2003 / 0157108 (Presta, L.); 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd.).Examples of publications relating to "defucosylated" or "fucose-deficient" antibody variants include U.S. Patent Application Publication No. 2003 / 0157108; WO 2000 / 61739; WO 2001 / 29246; U.S. Patent Application Publication No. 2003 / 0115614; WO 2002 / 0164328; WO 2004 / 0093621; WO 2004 / 0132140; WO 2004 / 0110704; WO 2004 / 0110282; WO 2004 / 01 09865; WO 2003 / 085119; WO 2003 / 084570; WO 2005 / 035586; WO 2005 / 035778; WO 2005 / 053742; WO 2002 / 031140; Okazaki et al., J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al., Biotech. Bioeng. 87:614 (2004). An example of a cell line capable of producing defucosylated antibodies is Lec13, which is deficient in protein fucosylation. CHO cells (Ripka et al., Arch. Biochem. Biophys. 249:533-545 (1986); U.S. Patent Application Publication No. 2003 / 0157108A1, Presta, L; and WO 2004 / 056312A1, Adams et al., especially in Example 11), and knockout cell lines such as α-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al., Biotech. Bioeng. 87:614 (2004); Kanda, Y. et al., Biotechnol. Bioeng. 94:4:680-688 (2006); and WO 2003 / 085107).

[0221] Further provided are antibody variants having bisected oligosaccharides, for example, biantennary oligosaccharides attached to the Fc region of the antibody are bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in International Publication No. WO2003 / 011878 (Jean-Mairet et al.); U.S. Patent No. 6,602,684 (Umana et al.); U.S. Patent Application Publication No. US2005 / 0123546 (Umana et al.), and Ferrara et al., Biotechnology and Bioengineering, Vol. 93, No. 5, pp. 851-861 (2006). Also provided are antibody variants having at least one galactose residue in the oligosaccharide attached to the Fc region. Such antibody variants may have improved CDC function. Such antibody variants are described, for example, in WO 1997 / 30087 (Patel et al.), WO 1998 / 58964 (Raju, S.), and WO 1999 / 22764 (Raju, S.).

[0222] In certain embodiments, antibody variants having an Fc region described herein are capable of binding to FcγRIII. In certain embodiments, antibody variants comprising an Fc region described herein have ADCC activity in the presence of human effector cells or have increased ADCC activity in the presence of human effector cells compared to the same antibody but having a human wild-type IgG1 Fc region.

[0223] (xi) Fc domain variants In certain embodiments, one or more amino acid modifications can be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant can comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) that contains an amino acid modification (e.g., a substitution) at one or more amino acid positions.

[0224] In certain embodiments, the present disclosure contemplates antibody variants that possess some, but not all, effector functions, making them desirable candidates for applications in which antibody half-life in vivo is important, but certain effector functions (such as complement and ADCC) are unnecessary or deleterious. In vitro and / or in vivo cytotoxicity assays may be performed to confirm reduced / lack of CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks FcγR binding (and thus likely lacks ADCC activity) but retains FcRn binding ability. NK cells, the primary cells for mediating ADCC, express only Fc(RIII, whereas monocytes express Fc(RI, Fc(RII, and Fc(RIII. FcR expression in hematopoietic cells is summarized in Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991) at p. 464, Table 3. Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest include those described in U.S. Pat. No. 5,500,362 (see, e.g., Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)), and Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)). Acad. Sci. USA, vol. 82:1499-1502 (1985); U.S. Patent No. 5,821,337 (see Bruggemann, M. et al., J. Exp. Med., vol. 166:1351-1361 (1987)). Alternatively, non-radioactive assay methods may be used (see, for example, ACTI™ Non-Radioactive Cytotoxicity Assay for Flow Cytometry (CellTechnology, Inc. Mountain View, Calif.), and CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, Wis.)). Effector cells useful for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells.Alternatively, or in addition, ADCC activity of the molecule of interest can be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al., Proc. Nat'l Acad. Sci. USA, 95:652-656 (1998). A C1q binding assay may be performed to confirm that the antibody is unable to bind C1q and therefore lacks CDC activity. See, e.g., C1q and C3c binding ELISAs in WO2006 / 029879 and WO2005 / 100402. To assess complement activation, CDC assays may be performed (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods, 202:163 (1996); Cragg, MS et al., Blood, 101:1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood, 103:2738-2743 (2004)). FcRn binding and in vivo clearance / half-life determinations may also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int'l. Immunol., 18:12:1759-1769 (2006)).

[0225] Antibodies with reduced effector function include those with substitutions at one or more of residues 238, 265, 269, 270, 297, 327, and 329 in the Fc region (U.S. Patent No. 6,737,056). Such Fc variants include Fc variants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc variant in which residues 265 and 297 have been substituted with alanine (U.S. Patent No. 7,332,581).

[0226] Certain antibody variants have been described with improved or diminished binding to FcRs (see, e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312, and Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001)).

[0227] In certain embodiments, the antibody variant comprises an Fc region with one or more amino acid substitutions that improve ADCC, e.g., substitutions at Fc region positions 298, 333, and / or 334 (EU numbering of residues). In an exemplary embodiment, the antibody comprises the following amino acid substitutions in its Fc region: S298A, E333A, and K334A.

[0228] In some embodiments, modifications are made in the Fc region that result in altered (i.e., either improved or decreased) C1q binding and / or complement dependent cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99 / 51642, and Idusogie et al., J. Immunol. 164:4178-4184 (2000).

[0229] Antibodies with increased half-lives and improved binding to fetal Fc receptors (FcRn), which play a role in transferring maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)), have been described in U.S. Patent Application Publication No. 2005 / 0014934A1 (Hinton et al.). These antibodies comprise an Fc region with one or more substituents that improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424, or 434, such as those with substitutions at Fc region residue 434 (U.S. Patent No. 7,371,826). See also Duncan and Winter, Nature 322:738-40 (1988); U.S. Patent Nos. 5,648,260; 5,624,821; and WO 94 / 29351 for other examples of Fc region variants.

[0230] VII. Pharmaceutical Compositions and Formulations Also provided herein are pharmaceutical compositions and formulations, e.g., for the treatment of lung cancer (e.g., stage IV non-squamous non-small cell lung cancer, such as non-small cell lung cancer), comprising a PD-1 axis binding antagonist (e.g., atezolizumab), a platinum agent (e.g., carboplatin or cisplatin), and an antimetabolite (e.g., pemetrexed). In some embodiments, the pharmaceutical compositions and formulations further comprise a pharma- ceutical acceptable carrier.

[0231] In some embodiments, the anti-PDL1 antibody described herein (such as atezolizumab) is present in a formulation comprising an antibody in an amount of about 60 mg / mL, histidine acetate in a concentration of about 20 mM, sucrose in a concentration of about 120 mM, and polysorbate (e.g., polysorbate 20) in a concentration of 0.04% (w / v), the formulation having a pH of about 5.8. In some embodiments, the anti-PDL1 antibody described herein (such as atezolizumab) is present in a formulation comprising an antibody in an amount of about 125 mg / mL, histidine acetate in a concentration of about 20 mM, sucrose in a concentration of about 240 mM, and polysorbate (e.g., polysorbate 20) in a concentration of 0.02% (w / v), the formulation having a pH of about 5.5.

[0232] After preparation of the antibody of interest (e.g., techniques for producing antibodies that can be formulated as disclosed herein are detailed herein and known in the art), a pharmaceutical formulation containing the same is prepared. In certain embodiments, the antibody to be formulated has not been subjected to prior lyophilization, and the formulation of interest herein is an aqueous formulation. In certain embodiments, the antibody is a full-length antibody. In one embodiment, the antibody in the formulation is an F(ab') 2and the like, which may have to deal with issues not encountered with full-length antibodies, such as clipping of the antibody to Fab. The therapeutically effective amount of antibody present in the formulation is determined, for example, by considering the desired dose volume and mode(s) of administration. Exemplary antibody concentrations in the formulations are about 25 mg / mL to about 150 mg / mL, or about 30 mg / mL to about 140 mg / mL, or about 35 mg / mL to about 130 mg / mL, or about 40 mg / mL to about 120 mg / mL, or about 50 mg / mL to about 130 mg / mL, or about 50 mg / mL to about 125 mg / mL, or about 50 mg / mL to about 120 mg / mL, or about 50 mg / mL to about 110 mg / mL, or about 50 mg / mL to about 100 mg / mL, or about 50 mg / mL to about 90 mg / mL, or about 50 mg / mL to about 80 mg / mL, or about 54 mg / mL to about 66 mg / mL.

[0233] An aqueous formulation is prepared comprising an antibody in a pH buffer solution, hi some embodiments, the buffer of the present disclosure has a pH in the range of about 5.0 to about 7.0. In certain embodiments, the pH is in the range of about 5.0 to about 6.5, about 5.0 to about 6.4, about 5.0 to about 6.3, about 5.0 to about 6.2, about 5.0 to about 6.1, about 5.5 to about 6.1, about 5.0 to about 6.0, about 5.0 to about 5.9, about 5.0 to about 5.8, about 5.1 to about 6.0, about 5.2 to about 6.0, about 5.3 to about 6.0, about 5.4 to about 6.0, about 5.5 to about 6.0, about 5.6 to about 6.0, about 5.7 to about 6.0, or about 5.8 to about 6.0. In some embodiments, the formulation is at or about pH 6.0. In some embodiments, the formulation is at or about pH 5.9. In some embodiments, the formulation is at or about pH 5.8. In some embodiments, the formulation is at or about pH 5.7. In some embodiments, the formulation is at or about pH 5.6. In some embodiments, the formulation is at or about pH 5.5. In some embodiments, the formulation is at or about pH 5.4. In some embodiments, the formulation is at or about pH 5.3. In some embodiments, the formulation is at or about pH 5.2. Examples of buffers that control the pH within this range include histidine (such as L-histidine) or sodium acetate. In certain embodiments, the buffer contains histidine acetate or sodium acetate at a concentration of about 15 mM to about 25 mM. In some embodiments, the buffer contains histidine acetate or sodium acetate at a concentration of about 15 mM to about 25 mM, about 16 mM to about 25 mM, about 17 mM to about 25 mM, about 18 mM to about 25 mM, about 19 mM to about 25 mM, about 20 mM to about 25 mM, about 21 mM to about 25 mM, about 22 mM to about 25 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, or about 25 mM.In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.0 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.1 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.2 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.3 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.4 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.5 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.6 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.7 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.8 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.9 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 6.0 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 6.1 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 6.2 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 6.3 in an amount of about 20 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.2 in an amount of about 25 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.3 in an amount of about 25 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.4 in an amount of about 25 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.5 in an amount of about 25 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.6 in an amount of about 25 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.7 in an amount of about 25 mM.In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.8 in an amount of about 25 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 5.9 in an amount of about 25 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 6.0 in an amount of about 25 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 6.1 in an amount of about 25 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 6.2 in an amount of about 25 mM. In one embodiment, the buffer is histidine acetate or sodium acetate at pH 6.3 in an amount of about 25 mM.

[0234] In some embodiments, the formulation further comprises sucrose in an amount of about 60 mM to about 240 mM. In some embodiments, the sucrose in the formulation is about 60 mM to about 230 mM, about 60 mM to about 220 mM, about 60 mM to about 210 mM, about 60 mM to about 200 mM, about 60 mM to about 190 mM, about 60 mM to about 180 mM, about 60 mM to about 170 mM, about 60 mM to about 160 mM, about 60 mM to about 150 mM, about 60 mM to about 140 mM, about 80 mM to about 240 mM, about 90 mM to about 240 mM, about 100 mM to about 240 mM, or the like. 0 mM, about 110 mM to about 240 mM, about 120 mM to about 240 mM, about 130 mM to about 240 mM, about 140 mM to about 240 mM, about 150 mM to about 240 mM, about 160 mM to about 240 mM, about 170 mM to about 240 mM, about 180 mM to about 240 mM, about 190 mM to about 240 mM, about 200 mM to about 240 mM, about 80 mM to about 160 mM, about 100 mM to about 140 mM, or about 110 mM to about 130 mM. In some embodiments, the sucrose in the formulation is about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, or about 240 mM.

[0235] In some embodiments, the antibody concentration in the formulation is about 40 mg / mL to about 125 mg / mL. In some embodiments, the antibody concentration in the formulation is about 40 mg / mL to about 120 mg / mL, about 40 mg / mL to about 110 mg / mL, about 40 mg / mL to about 100 mg / mL, about 40 mg / mL to about 90 mg / mL, about 40 mg / mL to about 80 mg / mL, about 40 mg / mL to about 70 mg / mL, about 50 mg / mL to about 120 mg / mL, about 60 mg / mL to about 120 mg / mL, about 70 mg / mL to about 120 mg / mL, about 80 mg / mL to about 120 mg / mL, about 90 mg / mL to about 120 mg / mL, or about 100 mg / mL to about 120 mg / mL. In some embodiments, the antibody concentration in the formulation is about 60 mg / mL. In some embodiments, the antibody concentration in the formulation is about 65 mg / mL. In some embodiments, the antibody concentration in the formulation is about 70 mg / mL. In some embodiments, the antibody concentration in the formulation is about 75 mg / mL. In some embodiments, the antibody concentration in the formulation is about 80 mg / mL. In some embodiments, the antibody concentration in the formulation is about 85 mg / mL. In some embodiments, the antibody concentration in the formulation is about 90 mg / mL. In some embodiments, the antibody concentration in the formulation is about 95 mg / mL. In some embodiments, the antibody concentration in the formulation is about 100 mg / mL. In some embodiments, the antibody concentration in the formulation is about 110 mg / mL. In some embodiments, the antibody concentration in the formulation is about 125 mg / mL.

[0236] In some embodiments, a surfactant is added to the antibody formulation. Exemplary surfactants include non-ionic surfactants such as polysorbates (e.g., polysorbate 20, 80) or poloxamers (e.g., poloxamer 188, etc.). The amount of surfactant added is such that the surfactant reduces aggregation of the formulated antibody and / or minimizes particle formation in the formulation and / or reduces adsorption. For example, the surfactant may be present in the formulation in an amount of about 0.001 to about 0.5% (w / v). In some embodiments, the surfactant (e.g., polysorbate 20) is about 0.005% to about 0.2%, about 0.005% to about 0.1%, about 0.005% to about 0.09%, about 0.005% to about 0.08%, about 0.005% to about 0.07%, about 0.005% to about 0.06%, about 0.005% to about 0.05%, about 0.005% to about 0.04%, about 0.008% to about 0.06%, about 0.01% to about 0.06%, about 0.02% to about 0.06%, about 0.01% to about 0.05%, or about 0.02% to about 0.04%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.005% or about 0.005%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.006% or about 0.006%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.007% or about 0.007%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.008% or about 0.008%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.009% or about 0.009%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.01% or about 0.01%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.02% or about 0.02%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.03% or about 0.03%.In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.04% or about 0.04%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.05% or about 0.05%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.06% or about 0.06%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.07% or about 0.07%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.08% or about 0.08%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.1% or about 0.1%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.2% or about 0.2%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.3% or about 0.3%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.4% or about 0.4%. In certain embodiments, the surfactant (e.g., polysorbate 20) is present in the formulation in an amount of 0.5% or about 0.5%.

[0237] In one embodiment, the formulation comprises an agent as defined above (e.g., an antibody, a buffer, sucrose, and / or a surfactant) and is essentially free of one or more preservatives, such as benzyl alcohol, phenol, m-cresol, chlorobutanol, and benzethonium Cl. In another embodiment, a preservative may be included in the formulation, specifically, the formulation is a multi-dose formulation. The concentration of the preservative may range from about 0.1% to about 2%, preferably from about 0.5% to about 1%. One or more other pharma- ceutically acceptable carriers, excipients, or stabilizers, such as those described in "Remington's Pharmaceutical Sciences", 16th Edition (Osol, A., Ed. (1980)), may be included in the formulation, provided that they do not adversely affect the desired properties of the formulation. Acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed, and include additional buffering agents; co-solvents; antioxidants, including ascorbic acid and methionine; chelating agents, such as EDTA; metal complexes (e.g., Zn-protein complexes); biodegradable polymers, such as polyesters; and / or salt-forming counterions. Exemplary pharma- ceutical acceptable carriers herein further include intermediate drug dispersing agents, such as soluble neutral active hyaluronidase glycoproteins (sHASEGPs), e.g., human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Application Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one embodiment, the sHASEGP is combined with one or more additional glycosaminoglycanases (eg, chondroitinases).

[0238] The formulation herein may optionally contain more than one protein for the particular indication being treated, preferably one with complementary activity that does not adversely affect the other protein. For example, if the antibody is anti-PDL1 (e.g., atezolizumab), the antibody may be combined with another agent (e.g., a chemotherapeutic agent and an antitumor agent).

[0239] The pharmaceutical compositions and formulations described herein may be prepared in the form of a lyophilized formulation or an aqueous solution by mixing the active ingredient (e.g., an antibody or polypeptide) having the desired purity with one or more pharma- ceutically acceptable carriers (Remington's Pharmaceutical Sciences, 16th ed., Osol, A., ed. (1980)). Pharmaceutically acceptable carriers are generally non-toxic to recipients at the dosages and concentrations employed, and may include buffers such as phosphates, citrates, and other organic acids, antioxidants including ascorbic acid and methionine, preservatives (such as octadecyldimethylbenzylammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl, or benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol), low molecular weight (less than about 10 residues) polypeptides, serum, and the like. Examples of suitable pharmacopoeitic carriers include, but are not limited to, proteins such as albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine, monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins, chelating agents such as EDTA, sugars such as sucrose, mannitol, trehalose, or sorbitol, salt-forming counterions such as sodium, metal complexes (e.g., Zn-protein complexes), and / or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmacopoeitic carriers herein further include intermediate drug dispersing agents, such as soluble neutral active hyaluronidase glycoproteins (sHASEGPs), e.g., human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Application Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one embodiment, the sHASEGP is combined with one or more additional glycosaminoglycanases (eg, chondroitinases).

[0240] Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6,267,958. Aqueous antibody formulations include those described in U.S. Patent No. 6,171,586 and International Publication No. WO2006 / 044908, the latter formulations including histidine acetate buffers.

[0241] The compositions and formulations herein may contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.

[0242] The active ingredient may be encapsulated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (e.g., hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively), in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions. Such techniques are disclosed in "Remington's Pharmaceutical Sciences", 16th Edition, edited by Osol, A. (1980).

[0243] Sustained release preparations may be prepared.Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, such as films or microcapsules.Preparations used for in vivo administration are generally sterilized.Sterility can be easily achieved, for example, by filtering through a sterile filtration membrane.

[0244] Pharmaceutical formulations of carboplatin, cisplatin, and / or pemetrexed are commercially available. For example, carboplatin is known under various trade names, including PARAPLATIN® (described elsewhere herein). Cisplatin is known under various trade names, including PLATINOL® (described elsewhere herein). Pemetrexed is known under various trade names, including ALIMTA®, GIOPEM, PEXATE, and CIAMBRA (described elsewhere herein). In some embodiments, carboplatin and / or pemetrexed are provided in separate containers. In some embodiments, cisplatin and / or pemetrexed are provided in separate containers. In some embodiments, carboplatin and / or pemetrexed are each used and / or prepared for administration to an individual as described in the prescribing information available with the commercially available product. In some embodiments, cisplatin and / or pemetrexed are each used and / or prepared for administration to an individual as described in the prescribing information available for the commercial product.

[0245] VIII. Treatment method Provided herein are methods for treating or delaying progression of cancer in an individual, including administering to the individual effective amounts of a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody), an antimetabolite (e.g., pemetrexed), and a platinum agent (e.g., carboplatin or cisplatin). In some embodiments, the treatment results in a durable response in the individual after cessation of treatment. In some embodiments, the treatment extends the progression-free survival (PFS) of the individual. In some embodiments, the treatment increases the progression-free survival (PFS) of the individual by at least any one of about 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 months (including any ranges between these values). In some embodiments, the treatment increases the progression-free survival (PFS) of the individual by at least about 7.6 months. In some embodiments, administration increases the overall survival (OS) of the individual. In some embodiments, treatment increases the OS of the individual by at least any one of about 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 months (including any ranges between these values). In some embodiments, treatment increases the OS of the individual by at least about 18.1 months.

[0246] The methods described herein may find use in the treatment of conditions in which enhanced immunogenicity is desired, such as increasing tumor immunogenicity for the treatment of cancer. Also provided herein is a method of improving immune function in an individual having lung cancer (e.g., non-small cell lung cancer, such as stage IV non-squamous non-small cell lung cancer), comprising administering to the individual effective amounts of a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody), an antimetabolite (e.g., pemetrexed), and a platinum agent (e.g., carboplatin or cisplatin).

[0247] In some embodiments, the lung cancer is non-small cell lung cancer (NSCLC). In some embodiments, the NSCLC is stage IV NSCLC. In some embodiments, the stage IV NSCLC is non-squamous NSCLC. In some embodiments, the NSCLC is histologically or cytologically confirmed to be stage IV non-squamous NSCLC according to or as defined by the Union Internationale contre le Cancer / American Joint Committee on Cancer staging system, 7th edition (see, e.g., Detterbeck et al., (2009) Chest 136:260-71). In some embodiments, stage IV NSCLC has mixed non-small cell histology (e.g., squamous and non-squamous), with the predominant histological component being or appearing to be non-squamous. In some embodiments, NSCLC is classified as stage IV when the tumor is growing into nearby structures. In some embodiments, NSCLC is classified as stage IV if the tumor has grown into nearby structures and / or reached proximal lymph nodes. In some embodiments, NSCLC is classified as stage IV if the cancer has spread from the first affected lung to the other lung. In some embodiments, NSCLC is classified as stage IV if cancer cells are found in the fluid around the lung (i.e., malignant pleural effusion). In some embodiments, NSCLC is classified as stage IV if cancer cells are found in the fluid around the heart (i.e., malignant pericardial infusion). In some embodiments, NSCLC is classified as stage IV if the cancer has spread as a single tumor outside the chest, such as to distant lymph nodes, liver, bone, and / or brain. In some embodiments, NSCLC is classified as stage IV if the cancer has spread as multiple tumors outside the chest, such as to distant lymph nodes, liver, bone, and / or brain. In some embodiments, stage IV NSCLC is difficult to treat.Further details regarding staging of NSCLC can be found in the American Joint Committee on Cancer. Lung. In: AJCC Cancer Staging Manual. 8th ed., New York, NY, Springer (2017) pp. 431-456.

[0248] In some embodiments, the individual has a poor prognosis. In some embodiments, the individual is a treatment-naïve individual. In some embodiments, the treatment-naïve individual is an individual who has not been previously treated, for example, for cancer, NSCLC, or stage IV non-squamous NSCLC. In some embodiments, the treatment-naïve individual is an individual who has not been previously treated, for example, for stage IV non-squamous NSCLC. In some embodiments, the individual is, for example, chemotherapy-naïve, for example, an individual who has not previously received chemotherapy for the treatment of cancer, NSCLC, and / or stage IV non-squamous NSCLC. In some embodiments, the individual is treatment-naïve for stage IV non-squamous NSCLC. In some embodiments, the individual is treatment-naïve for stage IV non-squamous NSCLC. In some embodiments, the individual is treatment-naïve for stage IV non-squamous NSCLC.

[0249] In some embodiments, the individual is Asian. In some embodiments, the individual is of Asian descent. In some embodiments, the individual is at least 65 years old. In some embodiments, the individual is a non-smoker. In some embodiments, a non-smoker is an adult who has never smoked or has smoked fewer than 100 cigarettes in their lifetime. In some embodiments, the individual does not have liver metastases.

[0250] In some embodiments, an individual is "PD-L1 high." In some embodiments, a patient is "PD-L1 high" if tumor cells expressing PD-L1 in a pre-treatment sample from the patient total more than 50% of all tumor cells in the sample. In some embodiments, PD-L1 expression on more than 50% of tumor cells in the pre-treatment sample is defined / scored as "TC3." In some embodiments, a patient is "PD-L1 high" if tumor infiltrating immune cells expressing PD-L1 in a pre-treatment sample from the patient total more than 10% of all tumor filtered immune cells in the sample. In some embodiments, PD-L1 expression on more than 10% of tumor infiltrating immune cells in the pre-treatment sample is defined / scored as "IC3." In some embodiments, the pre-treatment sample is a fresh tumor sample. In some embodiments, the pre-treatment sample is a formalin-fixed paraffin-embedded (FFPE) tumor sample. In some embodiments, the level of PD-L1 expression on tumor cells and / or tumor infiltrating immune cells in the pre-treatment sample is determined by an immunohistochemical assay, hi some embodiments, the immunohistochemical assay is the VENTANA SP142 assay.

[0251] In some embodiments, a patient is "PD-L1 low" if tumor cells expressing PD-L1 in a pre-treatment sample from the patient total less than 1%-5% of all tumor cells in the sample. In some embodiments, PD-L1 expression on less than 1%-5% of tumor cells in the pre-treatment sample is defined / scored as "TC1". In some embodiments, a patient is "PD-L1 low" if tumor cells expressing PD-L1 in a pre-treatment sample from the patient total less than 5%-50% of all tumor cells in the sample. In some embodiments, PD-L1 expression on less than 5%-50% of tumor cells in the pre-treatment sample is defined / scored as "TC2". In some embodiments, a patient is "PD-L1 low" if tumor infiltrating immune cells expressing PD-L1 in a pre-treatment sample from the patient total less than 1%-5% of all tumor filtered immune cells in the sample. In some embodiments, PD-L1 expression on less than 1%-5% of tumor infiltrating immune cells in the pre-treatment sample is defined / scored as "IC1". In some embodiments, a patient is "PD-L1 low" if tumor infiltrating immune cells expressing PD-L1 in a pre-treatment sample from the patient total less than 5%-10% of all tumor-filtrated immune cells in the sample. In some embodiments, PD-L1 expression in less than 5%-10% of tumor infiltrating immune cells in the pre-treatment sample is defined / scored as "IC2". In some embodiments, the pre-treatment sample is a fresh tumor sample. In some embodiments, the pre-treatment sample is a formalin-fixed paraffin-embedded (FFPE) tumor sample. In some embodiments, PD-L1 expression levels in tumor cells and / or tumor infiltrating immune cells in the pre-treatment sample are determined by an immunohistochemical assay. In some embodiments, the immunohistochemical assay is a VENTANA SP142 assay.

[0252] In some embodiments, an individual is "PD-L1 negative". In some embodiments, a patient is "PD-L1 negative" when tumor cells expressing PD-L1 in a pre-treatment sample from the patient total less than 1% of all tumor cells in the sample. In some embodiments, PD-L1 expression in less than 1% of tumor cells in the pre-treatment sample is defined as "TC0". In some embodiments, a patient is "PD-L1 negative" when tumor infiltrating immune cells expressing PD-L1 in a pre-treatment sample from the patient total less than 1% of all tumor filtered immune cells in the sample. In some embodiments, PD-L1 expression in less than 1% of tumor infiltrating immune cells in the pre-treatment sample is defined as "IC0". In some embodiments, the pre-treatment sample is a fresh tumor sample. In some embodiments, the pre-treatment sample is a formalin-fixed paraffin-embedded (FFPE) tumor sample. In some embodiments, PD-L1 expression levels in tumor cells and / or tumor infiltrating immune cells in the pre-treatment sample are determined by immunohistochemical assay. In some embodiments, the immunohistochemical assay is the VENTANA SP142 assay, which is described in more detail elsewhere herein.

[0253] In some embodiments, TC0, TC1, TC2, TC3, IC0, IC1, IC2, and IC3 are defined / scored as outlined in the table below: Exemplary tumor cell (TC) and tumor-infiltrating immune cell (IC) scoring definitions* TIFF2024161372000007.tif31170*Score TC first, followed by IC in a stepwise approach *See "The Assessment Guide for the VENTANA PD-L1(SP142)IHC Assay:Staining of Non-Small Cell Lung Cancer Universal Training." (See www(dot)rocheplus(dot)es / content / dam / hcp-portals / spain / documents / formaci%C3%B3n / uropath / PD-L1%20SP142%20Assessment%20%20v2.5(dot)pdf)

[0254] In some embodiments, the individual has histologically or cytologically confirmed stage IV non-squamous NSCLC (as described in Detterbeck et al. (2009) "The new lung cancer staging system.", Chest. vol. 136, pp. 260-71, by criteria outlined by the Union Internationale contre le Cancer / American Joint Committee on Cancer staging system, 7th edition). In some embodiments, the individual has NSCLC with mixed non-small cell histology (i.e., squamous and non-squamous) and is considered to have non-squamous NSCLC if the predominant histological component is or appears to be non-squamous. In some embodiments, the individual does not have a sensitizing mutation in the EGFR gene. In some embodiments, the individual does not have an ALK fusion oncogene. In some embodiments, the individual's EGFR and ALK status is screened prior to treatment.

[0255] In some embodiments, the individual has previously received neoadjuvant chemotherapy, adjuvant chemotherapy, or chemoradiotherapy with curative intent for non-metastatic disease, and has had at least 6 months of treatment-free time since the most recent dose of chemotherapy and / or radiation therapy prior to initiating treatment. In some embodiments, the individual does not have active or untreated central nervous system (CNS) metastases. In some embodiments, the individual has been treated for asymptomatic supratentorial or cerebellar CNS metastases. In some embodiments, the individual does not have metastases to the midbrain, pons, medulla, or spinal cord. In some embodiments, the individual has CNS disease and does not require corticosteroid treatment for the CNS disease. In some embodiments, the individual has new asymptomatic metastases and has undergone radiation therapy and / or surgery for the CNS metastases. In some embodiments, the individual with CNS metastases has not undergone stereotactic radiation within 7 days of initiating treatment. In some embodiments, the individual with CNS metastases has not undergone whole brain radiation within 14 days of initiating treatment. In some embodiments, the individual does not have leptomeningeal disease. In some embodiments, the individual does not have uncontrolled tumor pain. In some embodiments, the individual does not have uncontrolled pleural effusion. In some embodiments, the individual does not have uncontrolled pericardial effusion. In some embodiments, the individual does not have a malignancy other than NSCLC within 5 years prior to the start of treatment.

[0256] In some embodiments, the individual has measurable NSCLC (e.g., stage IV non-squamous NSCLC) as defined according to / by RECIST version 1.1 criteria (see, e.g., Eisenhauer et al. (2009) "New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)," Eur. J. Cancer. 45:228-247). In some embodiments, the individual has not been previously treated with a CD137 agonist or immune checkpoint inhibitor therapy, including, but not limited to, an anti-PD-1 antibody or an anti-PD-L1 antibody. In some embodiments, the patient has been previously treated with anti-cytotoxic T-lymphocyte-associated antigen 4 (CLTA-4), where the treatment was administered at least 6 weeks prior to the initiation of the treatment described herein.

[0257] Any of the PD-1 axis binding antagonists, antimetabolites, and platinum agents known in the art or described herein may be used in the methods, hi some embodiments, the PD-1 axis binding antagonist is atezolizumab, the antimetabolite is pemetrexed, and / or the platinum agent is carboplatin or cisplatin.

[0258] In some embodiments, the atezolizumab is administered at a dose of 1200 mg, the carboplatin is administered at a dose sufficient to achieve an AUC=6 mg / mL / min, and the pemetrexed is administered at a dose of 500 mg / m 2 is administered at a dose of

[0259] In some embodiments, the atezolizumab is administered at a dose of 1200 mg and the cisplatin is 75 mg / m 2 and the pemetrexed is administered at a dose of 500 mg / m 2 is administered at a dose of

[0260] In some embodiments, the treatment includes an induction phase and a maintenance phase (or "maintenance therapy"). In some embodiments, the induction phase includes a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab) administered at a dose of 1200 mg on day 1 and an antimetabolite (e.g., pemetrexed) administered at a dose of 500 mg / m on day 1. 2 and a platinum agent (e.g., carboplatin) at a dose sufficient to achieve an initial area under the curve (AUC) target of 6 mg / mL / min on day 1 of each 21-day cycle for cycles 1 through 4. In some embodiments, the maintenance phase includes a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab) at a dose of 1200 mg on day 1 and an antimetabolite (e.g., pemetrexed) at a dose of 500 mg / m on day 1 of each 21-day cycle after cycle 4. 2 and administering at a dose of

[0261] In some embodiments, the induction phase consists of a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab) administered at a dose of 1200 mg on day 1 and an antimetabolite (e.g., pemetrexed) administered at 500 mg / m on day 1. 2 and a platinum agent (e.g., cisplatin) at a dose of 75 mg / m on day 1 of each 21-day cycle for cycles 1-4. 2 In some embodiments, the maintenance phase includes administering a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab) at a dose of 1200 mg on day 1 and an antimetabolite (e.g., pemetrexed) at a dose of 500 mg / m on day 1 of each 21-day cycle after cycle 4. 2 and administering at a dose of

[0262] In some embodiments, the induction phase consists of a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab) administered at a dose of 1200 mg on day 1 and an antimetabolite (e.g., pemetrexed) administered at 500 mg / m on day 1. 2 and a platinum agent (e.g., carboplatin) at a dose sufficient to achieve an initial area under the curve (AUC) target of 6 mg / mL / min on day 1 of each 21-day cycle for cycles 1 through 6. In some embodiments, the maintenance phase includes a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab) at a dose of 1200 mg on day 1 and an antimetabolite (e.g., pemetrexed) at a dose of 500 mg / m on day 1 of each 21-day cycle after cycle 6. 2 and administering at a dose of

[0263] In some embodiments, the induction phase consists of a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab) administered at a dose of 1200 mg on day 1 and an antimetabolite (e.g., pemetrexed) administered at 500 mg / m on day 1. 2 and a platinum agent (e.g., cisplatin) at a dose of 75 mg / m on day 1 of each 21-day cycle for cycles 1 through 6. 2 In some embodiments, the maintenance phase includes administering a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody such as atezolizumab) at a dose of 1200 mg on day 1 and an antimetabolite (e.g., pemetrexed) at a dose of 500 mg / m on day 1 of each 21-day cycle after cycle 6. 2 and administering at a dose of

[0264] Exemplary dosing and administration schedules, including induction and maintenance cycles, are provided below in Tables 4A and 4B: TIFF2024161372000008.tif82170TIFF2024161372000009.tif83170

[0265] In some embodiments, a 1200 mg dose of atezolizumab is equivalent to a mean weight-based dose of 15 mg / kg. In some embodiments, the dose of carboplatin required to achieve an AUC of 6 mg / mL / min is calculated according to the Calvert formula (see, e.g., Calvert et al. (1989) "Carboplatin dosage: prospective evaluation of a simple formula based on renal function.", J. Clin Oncol. 7:1748-56; van Warmerdam et al. (1995) "J. Cancer Res. Clin. Oncol. 121:8:478-486"). For further details, see Example 1 below.

[0266] In some embodiments, the progression-free survival (PFS) of an individual can be measured according to RECIST version 1.1 criteria as described in Eisenhauer et al. (2009) "New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)," Eur. J. Cancer., vol. 45, pp. 228-47. In some embodiments, PFS is measured as the time from the start of treatment to the first occurrence of disease progression as determined by RECIST version 1.1 criteria. In some embodiments, PFS is measured as the time from the start of treatment to the time of death. In some embodiments, the treatment increases the progression-free survival (PFS) of an individual by at least any one of about 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 months (including any range between these values). In some embodiments, the treatment increases the progression-free survival (PFS) of an individual by at least about 7.6 months. In some embodiments, the treatment increases the individual's PFS by at least one of about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 months (including any ranges between these values) compared to an individual with lung cancer (non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer) who has been treated with an antimetabolite (e.g., pemetrexed) and a platinum agent (e.g., carboplatin or cisplatin).

[0267] In some embodiments, overall survival (OS) is measured as the time from the start of treatment to death. In some embodiments, the treatment increases the OS of an individual by at least any one of about 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 months (including any range between these values). In some embodiments, the treatment increases the OS of an individual by at least about 18.1 months. In some embodiments, the treatment increases the OS of the individual by at least any one of about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, or 7 months (including any ranges between these values) compared to an individual with lung cancer (non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer) who has been treated with an antimetabolite (e.g., pemetrexed) and a platinum agent (e.g., carboplatin or cisplatin).

[0268] In some embodiments, the individual is a human.

[0269] In some embodiments, the individual has a cancer that is resistant (demonstrated to be resistant) to one or more PD-1 axis antagonists. In some embodiments, resistance to a PD-1 axis antagonist includes recurrence of the cancer or a refractory cancer. Recurrence may refer to the reappearance of the cancer at the original site or at a new site after treatment. In some embodiments, resistance to a PD-1 axis antagonist includes progression of the cancer during treatment with a PD-1 axis antagonist. In some embodiments, resistance to a PD-1 axis antagonist includes a cancer that does not respond to treatment. The cancer may be resistant at the start of treatment or may become resistant during treatment. In some embodiments, the cancer is in an early or late stage.

[0270] In another aspect, the individual has a cancer that expresses (e.g., has been shown to express in a diagnostic test) the PD-L1 biomarker. In some embodiments, the patient's cancer expresses a low PD-L1 biomarker. In some embodiments, the patient's cancer expresses a high PD-L1 biomarker. In some embodiments of any of these methods, assays, and / or kits, the PD-L1 biomarker is absent in the sample if it is present in 0% of samples.

[0271] In some embodiments of any of these methods, assays, and / or kits, the PD-L1 biomarker is present in a sample when it is present in greater than 0% of the samples. In some embodiments, the PD-L1 biomarker is present in at least 1% of the samples. In some embodiments, the PD-L1 biomarker is present in at least 5% of the samples. In some embodiments, the PD-L1 biomarker is present in at least 10% of the samples.

[0272] In some embodiments of any of these methods, assays, and / or kits, the PD-L1 biomarker is detected in the sample using a method selected from the group consisting of FACS, Western blot, ELISA, immunoprecipitation, immunohistochemistry, immunofluorescence, radioimmunoassay, dot blot, immunodetection methods, HPLC, surface plasmon resonance, optical spectroscopy, mass spectroscopy, HPLC, qPCR, RT-qPCR, multiplex qPCR or RT-qPCR, RNA-seq, microarray analysis, SAGE, MassARRAY technology, and FISH, and combinations thereof.

[0273] In some embodiments of any of these methods, assays, and / or kits, the PD-L1 biomarker is detected in the sample by protein expression. In some embodiments, protein expression is determined by immunohistochemistry (IHC). In some embodiments, the PD-L1 biomarker is detected using an anti-PD-L1 antibody. In some embodiments, the PD-L1 biomarker is detected as weak staining intensity by IHC. In some embodiments, the PD-L1 biomarker is detected as moderate staining intensity by IHC. In some embodiments, the PD-L1 biomarker is detected as strong staining intensity by IHC. In some embodiments, the PD-L1 biomarker is detected in tumor cells, tumor-infiltrating immune cells, stromal cells, and any combination thereof. In some embodiments, the staining is membranous staining, cytoplasmic staining, or a combination thereof.

[0274] In some embodiments, the PD-L1 biomarker is detected using an anti-PD-L1 rabbit monoclonal primary antibody. In some embodiments, PD-L1 is detected in formalin-fixed paraffin-embedded samples. In some embodiments, the anti-PD-L1 rabbit monoclonal primary antibody is detected with a secondary antibody that comprises a detectable label. In some embodiments, the assay used to detect PD-L1 is the VENTANA PD-L1 (SP142) assay (commercially available from VENTANA®), which is described in more detail in the Examples.

[0275] In some embodiments of any of these methods, assays, and / or kits, the absence of the PD-L1 biomarker is detected as an absence or no staining in the sample. In some embodiments of any of these methods, assays, and / or kits, the presence of the PD-L1 biomarker is detected as any staining in the sample.

[0276] The PD-1 axis binding antagonist (such as atezolizumab), the antimetabolite (such as pemetrexed), and the platinum drug (such as carboplatin or cisplatin) can be administered in any order. For example, the PD-1 axis binding antagonist (such as atezolizumab), the antimetabolite (such as pemetrexed), and the platinum drug (such as carboplatin or cisplatin) can be administered sequentially (at different times) or simultaneously (at the same time). In some embodiments, the PD-1 axis binding antagonist (such as atezolizumab), the antimetabolite (such as pemetrexed), and the platinum drug (such as carboplatin or cisplatin) are in separate compositions. In some embodiments, one or more (or all three) of the PD-1 axis binding antagonist (such as atezolizumab), the antimetabolite (such as pemetrexed), and the platinum agent (such as carboplatin or cisplatin) are in the same composition.

[0277] The PD-1 axis binding antagonist (such as atezolizumab), the antimetabolite (such as pemetrexed), and the platinum agent (such as carboplatin or cisplatin) may be administered by the same route of administration or by different routes of administration. In some embodiments, the PD-1 axis binding antagonist is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, implanted, inhaled, intrathecally, intraventricularly, or intranasally. In some embodiments, the antimetabolite (such as pemetrexed) is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, implanted, inhaled, intrathecally, intraventricularly, or intranasally. In some embodiments, the platinum agent (such as carboplatin or cisplatin) is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, implanted, inhaled, intrathecally, intraventricularly, or intranasally. In some embodiments, the PD-1 axis binding antagonist (such as atezolizumab), the antimetabolite (such as pemetrexed), and the platinum agent (such as carboplatin or cisplatin) are administered by intravenous infusion. Effective amounts of the PD-1 axis binding antagonist (such as atezolizumab), the antimetabolite (such as pemetrexed), and the platinum agent (such as carboplatin or cisplatin) may be administered to prevent or treat a disease.

[0278] In some embodiments, a method of treating lung cancer, e.g., stage IV non-squamous non-small cell lung cancer (NSCLC), in an individual (e.g., an individual who has previously untreated stage IV non-squamous non-small cell lung cancer (NSCLC)) comprising administering to the individual effective amounts of atezolizumab, pemetrexed, and carboplatin, wherein the administration includes an induction phase and a maintenance phase, the induction phase comprising administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1. 2 and carboplatin at a dose sufficient to achieve an initial target area under the curve (AUC) of 6 mg / mL / min for each 21-day cycle for cycles 1 through 4. In some embodiments, the maintenance phase comprises administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at 500 mg / m on day 1 of each 21-day cycle after cycle 4. 2 and administering at a dose of

[0279] In some embodiments, a method of treating lung cancer, e.g., stage IV non-squamous non-small cell lung cancer (NSCLC), in an individual (e.g., an individual who has previously untreated stage IV non-squamous non-small cell lung cancer (NSCLC)) comprising administering to the individual effective amounts of atezolizumab, pemetrexed, and cisplatin, wherein the administration includes an induction phase and a maintenance phase, the induction phase comprising administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1. 2 and cisplatin at 75 mg / m on day 1 of each 21-day cycle for cycles 1 to 4. 2 In some embodiments, the maintenance phase comprises administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1 of each 21-day cycle after cycle 4. 2 and administering at a dose of

[0280] In some embodiments, a method of treating lung cancer, e.g., stage IV non-squamous non-small cell lung cancer (NSCLC), in an individual (e.g., an individual who has previously untreated stage IV non-squamous non-small cell lung cancer (NSCLC)) comprising administering to the individual effective amounts of atezolizumab, pemetrexed, and carboplatin, wherein the administration includes an induction phase and a maintenance phase, the induction phase comprising administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1. 2 and carboplatin at a dose sufficient to achieve an initial target area under the curve (AUC) of 6 mg / mL / min on day 1 of each 21-day cycle for cycles 1 through 6. In some embodiments, the maintenance phase comprises administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1 of each 21-day cycle after cycle 6. 2 and administering at a dose of

[0281] In some embodiments, a method of treating lung cancer, e.g., stage IV non-squamous non-small cell lung cancer (NSCLC), in an individual (e.g., an individual who has previously untreated stage IV non-squamous non-small cell lung cancer (NSCLC)) comprising administering to the individual effective amounts of atezolizumab, pemetrexed, and cisplatin, wherein the administration includes an induction phase and a maintenance phase, the induction phase comprising administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1. 2 and cisplatin at 75 mg / m on day 1 of each 21-day cycle for cycles 1 to 6. 2 In some embodiments, the maintenance phase comprises administering atezolizumab at a dose of 1200 mg on day 1 and pemetrexed at a dose of 500 mg / m on day 1 of each 21-day cycle after cycle 6. 2 and administering at a dose of

[0282] In some embodiments, the method increases the individual's PFS (e.g., by at least one of about 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 months (including any ranges between these values)) and / or the individual's OS (e.g., by at least one of about 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, or 20 months (including any ranges between these values)). In some embodiments, the treatment increases the individual's progression-free survival (PFS) by at least about 7.6 months and / or increases the individual's OS by at least about 18.1 months. In some embodiments, the method increases the individual's PFS (e.g., by at least one of 0.5, 1, 1.5, 2, 2.5, 3, 3.5, or 4 months (including any ranges between these values)) and / or the individual's OS (e.g., by at least one of 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, or 7 months (including any ranges between these values)) compared to an individual with lung cancer (non-small cell lung cancer, e.g., stage IV non-squamous non-small cell lung cancer) who has been treated with a platinum agent (e.g., carboplatin or cisplatin) and an antimetabolite (e.g., pemetrexed).

[0283] In some embodiments, atezolizumab is administered followed by pemetrexed and pemetrexed is administered followed by carboplatin or cisplatin on day 1 of each 21-day cycle for cycles 1-4, e.g., as shown in Table 4A above. In some embodiments, atezolizumab is administered followed by pemetrexed and pemetrexed is administered followed by carboplatin or cisplatin on day 1 of each 21-day cycle for cycles 1-6, e.g., as shown in Table 4B above.

[0284] In some embodiments, for each 21-day cycle in Cycles 1-4, atezolizumab is administered intravenously over 60 (± 15 minutes), pemetrexed is administered intravenously over about 10 minutes, and carboplatin is administered intravenously over about 30-60 minutes on day 1. In some embodiments, for Cycle 1, atezolizumab is administered intravenously over 60 (± 15 minutes), pemetrexed is administered intravenously over about 10 minutes, and carboplatin is administered intravenously over about 30-60 minutes on day 1, and on day 1 of Cycles 2-4, atezolizumab is administered intravenously over 30 (± 10 minutes), pemetrexed is administered intravenously over about 10 minutes, and carboplatin is administered intravenously over about 30-60 minutes. In some embodiments, atezolizumab is administered intravenously over 60 (± 15 minutes) and pemetrexed is administered intravenously over approximately 10 minutes on day 1 of each 21-day cycle after cycle 4. In some embodiments, atezolizumab is administered intravenously over 30 (± 10 minutes) and pemetrexed is administered intravenously over approximately 10 minutes on day 1 of each 21-day cycle after cycle 4.

[0285] In some embodiments, for each 21-day cycle in cycles 1-4, atezolizumab is administered intravenously over 60 (± 15 minutes) on day 1, pemetrexed is administered intravenously over about 10 minutes on day 1, and cisplatin is administered intravenously over about 1-2 hours on day 1. In some embodiments, for cycle 1, atezolizumab is administered intravenously over 60 (± 15 minutes) on day 1, pemetrexed is administered intravenously over about 10 minutes on day 1, and cisplatin is administered intravenously over about 1-2 hours on day 1, and for cycles 2-4, atezolizumab is administered intravenously over 30 (± 10 minutes) on day 1, pemetrexed is administered intravenously over about 10 minutes on day 1, and cisplatin is administered intravenously over about 30-60 minutes on day 1. In some embodiments, atezolizumab is administered intravenously over 60 (± 15 minutes) on day 1 of each 21-day cycle after cycle 4, and pemetrexed is administered intravenously over approximately 10 minutes on day 1. In some embodiments, atezolizumab is administered intravenously over 30 (± 10 minutes) on day 1 of each 21-day cycle after cycle 4, and pemetrexed is administered intravenously over approximately 10 minutes on day 1.

[0286] In some embodiments, for each 21-day cycle in cycles 1-6, atezolizumab is administered intravenously over 60 (± 15 minutes) on day 1, pemetrexed is administered intravenously over about 10 minutes on day 1, and carboplatin is administered intravenously over about 30-60 minutes on day 1. In some embodiments, for cycle 1, atezolizumab is administered intravenously over 60 (± 15 minutes) on day 1, pemetrexed is administered intravenously over about 10 minutes on day 1, and carboplatin is administered intravenously over about 30-60 minutes on day 1, and for cycles 2-6, atezolizumab is administered intravenously over 30 (± 10 minutes) on day 1, pemetrexed is administered intravenously over about 10 minutes on day 1, and carboplatin is administered intravenously over about 30-60 minutes on day 1. In some embodiments, atezolizumab is administered intravenously over 60 (± 15 minutes) on day 1 of each 21-day cycle after cycle 6, and pemetrexed is administered intravenously over approximately 10 minutes on day 1. In some embodiments, atezolizumab is administered intravenously over 30 (± 10 minutes) on day 1 of each 21-day cycle after cycle 6, and pemetrexed is administered intravenously over approximately 10 minutes on day 1.

[0287] In some embodiments, for each 21-day cycle in cycles 1-6, atezolizumab is administered intravenously over 60 (± 15 minutes) on day 1, pemetrexed is administered intravenously over about 10 minutes on day 1, and cisplatin is administered intravenously over about 1-2 hours on day 1. In some embodiments, for cycle 1, atezolizumab is administered intravenously over 60 (± 15 minutes) on day 1, pemetrexed is administered intravenously over about 10 minutes on day 1, and cisplatin is administered intravenously over about 1-2 hours on day 1, and for cycles 2-6, atezolizumab is administered intravenously over 30 (± 10 minutes) on day 1, pemetrexed is administered intravenously over about 10 minutes on day 1, and cisplatin is administered intravenously over about 30-60 minutes on day 1. In some embodiments, atezolizumab is administered intravenously over 60 (± 15 minutes) on day 1 of each 21-day cycle after cycle 6, and pemetrexed is administered intravenously over approximately 10 minutes on day 1. In some embodiments, atezolizumab is administered intravenously over 30 (± 10 minutes) on day 1 of each 21-day cycle after cycle 6, and pemetrexed is administered intravenously over approximately 10 minutes on day 1.

[0288] As a general proposition, a therapeutically effective amount of an antibody administered to a human, whether by one or more administrations, would be in the range of about 0.01 to about 50 mg / kg of patient body weight. In some embodiments, the antibody is used at about 0.01 to about 45 mg / kg, about 0.01 to about 40 mg / kg, about 0.01 to about 35 mg / kg, about 0.01 to about 30 mg / kg, about 0.01 to about 25 mg / kg, about 0.01 to about 20 mg / kg, about 0.01 to about 15 mg / kg, about 0.01 to about 10 mg / kg, about 0.01 to about 5 mg / kg, or about 0.01 to about 1 mg / kg, for example, administered daily. In some embodiments, the antibody is administered at 15 mg / kg. However, other dosing regimens may be useful. In one embodiment, the anti-PDL1 antibody described herein is administered to a human at a dose of about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, or about 1400 mg on the first day of a 21-day cycle. The dose may be administered in a single dose, such as an infusion, or in multiple doses (e.g., two or three doses). The dose of the antibody administered in combination therapy may be reduced compared to monotherapy. The progress of this therapy is easily monitored by conventional techniques.

[0289] In some embodiments, these methods may further comprise an additional therapy. The additional therapy may be radiation therapy, surgery (e.g., lumpectomy and mastectomy), chemotherapy, gene therapy, DNA therapy, viral therapy, RNA therapy, immunotherapy, bone marrow transplant, nanotherapy, monoclonal antibody therapy, or a combination thereof. The additional therapy may be in the form of adjuvant therapy or neoadjuvant therapy. In some embodiments, the additional therapy is administration of a small molecule enzyme inhibitor or an anti-metastatic drug. In some embodiments, the additional therapy is administration of a side effect limiting agent (e.g., an agent intended to reduce the occurrence and / or severity of side effects of the treatment, such as an antiemetic agent). In some embodiments, the additional therapy is radiation therapy. In some embodiments, the additional therapy is surgery. In some embodiments, the additional therapy is a combination of radiation therapy and surgery. In some embodiments, the additional therapy is gamma irradiation.

[0290] In some embodiments, the additional therapy comprises CT-011 (also known as pidilizumab or MDV9300; CAS Registry Number 1036730-42-3; CureTech / Medivation). CT-011, also known as hBAT or hBAT-1, is an antibody described in International Publication No. WO2009 / 101611. In some embodiments, the additional therapy comprises an antibody comprising heavy and light chain sequences, wherein: (a) the heavy chain has the amino acid sequence: QVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 19); and (b) the light chain comprises the amino acid sequence: EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTSYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 20).

[0291] In some embodiments, the further therapeutic antibody comprises six HVR sequences from SEQ ID NO: 19 and SEQ ID NO: 20 (e.g. three heavy chain HVRs from SEQ ID NO: 19 and three light chain HVRs from SEQ ID NO: 20). In some embodiments, the further therapeutic antibody comprises a heavy chain variable domain from SEQ ID NO: 19 and a light chain variable domain from SEQ ID NO: 20.

[0292] Other additional therapeutic antibodies contemplated for use herein include alemtuzumab (Campath), bevacizumab (AVASTIN®, Genentech); cetuximab (ERBITUX®, Imclone); panitumumab (VECTIBIX®, Amgen), rituximab (RITUXAN®, Genentech / Biogen Idec), pertuzumab (OMNITARG®, 2C4, Genentech), trastuzumab (HERCEPTIN®, Genentech), tositumomab (Bexxar, Corixia), the antibody drug conjugate gemtuzumab ozogamicin (MYLOTARG®, Wyeth), apolizumab, acelizumab, atlizumab, bapineuzumab, bivatuzumab mertansine,mertansine, cantuzumab mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab ozogamicin, inotuzumab ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizu mab, numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan These include, but are not limited to, tetraxetan, tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, tucotuzumab celmoleukin, tucusituzumab, umavizumab, urtoxazumab, ustekinumab, visilizumab, and anti-interleukin-12 (ABT-874 / J695, Wyeth Research and Abbott Laboratories).

[0293] In some embodiments, the additional therapy is a therapy targeting the PI3K / AKT / mTOR pathway, an HSP90 inhibitor, a tubulin inhibitor, an apoptosis inhibitor, and / or a chemopreventive agent. ... CTLA-4 (also known as CD152), e.g., a blocking antibody, ipilimumab (also known as MDX-010, MDX-101, or Yervoy®), tremelimumab (also known as ticilimumab or CP-675,206), an antagonist against B7-H3 (also known as CD276), e.g., a blocking antibody, MGA271, an antagonist against TGFβ, e.g., metelimumab (also known as CAT-192), fresolimumab (also known as GC1008), or LY2157299, a chimeric antigen receptor agonist (TAG) (also known as CYP2001), or a cytotoxic T cell receptor agonist (CYP2002), or a cytotoxic T cell receptor agonist (CYP2003), or a cytotoxic T cell receptor agonist (CYP2004), or a cytotoxic T cell receptor agonist (CYP2005), or a cytotoxic T cell receptor agonist (CYP2006), or a cytotoxic T cell receptor agonist (CYP2009), or a cytotoxic T cell receptor agonist (CYP2009), or a cytotoxic T cell receptor agonist (CYP2009), or a cytotoxic T cell receptor agonist (CYP2009), or a cyto treatments involving adoptive transfer of T cells expressing a dominant-negative TGFβ receptor (CAR) (e.g., cytotoxic T cells or CTLs), treatments involving adoptive transfer of T cells comprising a dominant-negative TGFβ receptor, e.g., a dominant-negative TGFβ type II receptor, treatments involving the HERCREEM protocol (e.g., ClinicalTrials.gov Identifier see NCT00889954), agonists against CD137 (also known as TNFRSF9, 4-1BB, or ILA), such as the activating antibody urelumab (also known as BMS-663513), agonists against CD40, such as the activating antibody CP-870893, agonists against OX40 (also known as CD134), such as activating antibodies, combined administration with a different anti-OX40 (e.g., AgonOX), agonists against CD27, such as the activating antibody CDX-1127, indoleamine-2,3-dioxygenase (IDO), 1-methyl-D-tryptophan (also known as 1-D-MT), antibody-drug conjugates (in some embodiments, mertansine or monomethyl auristatin E),E:MMAE), anti-NaPi2b antibody-MMAE conjugates (also known as DNIB0600A or RG7599), trastuzumab emtansine (also known as T-DM1, ado-trastuzumab emtansine, or KADCYLA® (Genentech)), DMUC5754A, antibody-drug conjugates targeting the endothelin B receptor (EDNBR), such as antibodies against EDNBR conjugated with MMAE, angiogenesis inhibitors, antibodies against VEGF, such as such as VEGF-A, bevacizumab (also known as AVASTIN® (Genentech)), antibody against angiopoietin 2 (also known as Ang2), MEDI3617, antineoplastic agents, antibody targeting CSF-1R (also known as M-CSFR or CD115), anti-CSF-1R (also known as IMC-CS4), interferons such as interferon alpha or interferon gamma, Roferon-A, GM-CSF (recombinant human granulocyte-macrophage colony-stimulating factor, rhu GM-CSF, also known as Sargramostim, or Leukine®), IL-2 (also known as Aldesleukin or Proleukin®), IL-12, antibody targeted to CD20 (in some embodiments, the antibody targeted to CD20 is obinutuzumab (also known as GA101 or Gazyva®) or rituximab), antibody targeted to GITR (in some embodiments, the antibody targeted to GITR is TRX518), combination with a cancer vaccine (in some embodiments, the cancer vaccine is a peptide cancer vaccine, in some embodiments, a personalized peptide vaccine; in some embodiments, the peptide cancer vaccine is a multivalent long peptide, multi-peptide, peptide cocktail, hybrid peptide, or peptide-pulsed dendritic cell vaccine (see, e.g., Yamada et al., Cancer Sci 104:14-21 (2013)), combination with an adjuvant, TLR agonist, such as poly-ICLC (also known as Hiltonol®), LPS, MPL, or CpGODN, tumor necrosis factor (TNF) alpha, IL-1, HMGB1, IL-10 antagonists, IL-4 antagonists, IL-13 antagonists, HVEM antagonists, ICOS agonists, such as ICOS-L or agonist antibodies against ICOS, CX3CL1 targeted therapy, CXCL10 targeted therapy, CCL5 targeted therapy, LFA-1 or ICAM1 agonists, selectin agonists, targeted therapy, inhibitors of B-Raf, vemurafenib (also known as Zelboraf®) ), dabrafenib (also known as Tafinlar®), erlotinib (also known as Tarceva®), inhibitors of MEK, such as MEK1 (also known as MAP2K1) or MEK2 (also known as MAP2K2), cobimetinib (also known as GDC-0973 or XL-518), trametinib (also known as Mekinist®), inhibitors of K-Ras, inhibitors of c-Met, onartuzumab (MetM Ab), inhibitors of Alk, AF802 (also known as CH5424802 or alectinib), inhibitors of phosphatidylinositol 3-kinase (PI3K), BKM120, idelalisib (also known as GS-1101 or CAL-101), perifosine (also known as KRX-0401), Akt, MK2206, GSK690693, GDC-0941, inhibitors of mTOR, sirolimus (also known as rapamycin), temsirolimus (CCI-779 or Tor isel®), everolimus (also known as RAD001), ridaforolimus (also known as AP-23573, MK-8669, or deforolimus), OSI-027, AZD8055, INK128, dual PI3K / mTOR inhibitor, XL765, GDC-0980, BEZ235 (also known as NVP-BEZ235), BGT226, GSK2126458, PF-04691502, PF-05212384 (also known as PKI-587). The additional therapy may be one or more of the chemotherapeutic agents described herein.

[0294] IX. Detection and Diagnostic Methods In some embodiments, the sample is obtained prior to treatment with a PD-1 axis binding antagonist (e.g., atezolizumab), a platinum agent (e.g., carboplatin or cisplatin), and an antimetabolite (e.g., pemetrexed). In some embodiments, the tissue sample is a formalin-fixed and paraffin-embedded sample, an archived sample, a fresh sample, or a frozen sample.

[0295] In some embodiments, the sample is whole blood, hi some embodiments, the whole blood comprises immune cells, circulating tumor cells, and any combination thereof.

[0296] The presence and / or expression level / amount of a biomarker (e.g., PD-L1) may be qualitatively and / or quantitatively determined based on any suitable criteria known in the art, including but not limited to DNA, mRNA, cDNA, protein, protein fragment, and / or gene copy number in an individual. In certain embodiments, the presence and / or expression level / amount of the biomarker in a first sample is increased or elevated compared to the presence / absence and / or expression level / amount in a second sample. In certain embodiments, the presence / absence and / or expression level / amount of the biomarker in a first sample is decreased or reduced compared to the presence and / or expression level / amount in a second sample. In certain embodiments, the second sample is a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue. Further disclosure for determining the presence / absence and / or expression level / amount of a gene is described herein.

[0297] In some embodiments of any of these methods, elevated expression refers to an overall increase of any of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more in the level of a biomarker (e.g., a protein or nucleic acid (e.g., a gene or mRNA)) as detected by standard art-known methods, such as those described herein, compared to a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue. In certain embodiments, elevated expression refers to an increase in the expression level / amount of a biomarker in a sample, which increase is at least about any of 1.5-fold, 1.75-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 25-fold, 50-fold, 75-fold, or 100-fold the expression level / amount of the respective biomarker in a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue. In some embodiments, elevated expression refers to an overall increase of more than about 1.5-fold, about 1.75-fold, about 2-fold, about 2.25-fold, about 2.5-fold, about 2.75-fold, about 3.0-fold, or about 3.25-fold compared to a reference sample, reference cell, reference tissue, control sample, control cell, control tissue, or an internal control (e.g., housekeeping gene).

[0298] In some embodiments of any of these methods, reduced expression refers to an overall reduction of any of about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more in the level of a biomarker (e.g., a protein or nucleic acid (e.g., a gene or mRNA)) as detected by standard art-known methods, such as those described herein, compared to a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue. In certain embodiments, reduced expression refers to a decrease in the expression level / amount of a biomarker in a sample, which decrease is at least about any of 0.9-fold, 0.8-fold, 0.7-fold, 0.6-fold, 0.5-fold, 0.4-fold, 0.3-fold, 0.2-fold, 0.1-fold, 0.05-fold, or 0.01-fold the expression level / amount of the respective biomarker in a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue.

[0299] The presence and / or expression levels / amounts of various biomarkers in a sample may be analyzed by a number of methodologies, many of which are known in the art and understood by those of skill in the art, including, but not limited to, immunohistochemistry ("IHC"), Western blot analysis, immunoprecipitation, molecular binding assays, ELISA, ELIFA, fluorescence activated cell sorting ("FACS"), MassARRAY, proteomics, quantitative blood-based assays (e.g., serum ELISA), biochemical enzyme activity assays, in situ hybridization, Southern analysis, Northern analysis, whole genome sequencing, polymerase chain reaction ("PCR"), such as quantitative real-time PCR ("qRT-PCR") and other amplification-based detection methods, e.g., branched DNA, SISBA, TMA, etc.), RNA-Seq, FISH, microarray analysis, gene expression profiling, and / or serial analysis of gene expression ("SAGE"), as well as any of a wide variety of assays that may be performed by protein, gene, and / or tissue array analysis. Exemplary protocols for assessing the status of genes and gene products are found, for example, in Parts 2 (Northern blotting), 4 (Southern blotting), 15 (immunoblotting), and 18 (PCR analysis) of Current Protocols In Molecular Biology, eds. Ausubel et al. (1995). Multiplexed immunoassays, such as those available from Rules Based Medicine or Meso Scale Discovery ("MSD"), can also be used.

[0300] In some embodiments, the presence and / or expression level / amount of biomarkers is determined using a method comprising: (a) performing gene expression profiling, PCR (such as rtPCR or qRT-PCR), RNA-seq, microarray analysis, SAGE, MassARRAY techniques, or FISH in a sample (such as a subject cancer sample); and b) determining the presence and / or expression level / amount of biomarkers in the sample. In some embodiments, the microarray method comprises the use of a microarray chip having one or more nucleic acid molecules capable of hybridizing under stringent conditions to a nucleic acid molecule encoding the above-mentioned genes, or having one or more polypeptides (such as peptides or antibodies) capable of binding to one or more of the proteins encoded by the above-mentioned genes. In one embodiment, the PCR method is qRT-PCR. In one embodiment, the PCR method is multiplex PCR. In some embodiments, gene expression is measured by microarray. In some embodiments, gene expression is measured by qRT-PCR. In some embodiments, expression is measured by multiplex PCR.

[0301] Methods for evaluating mRNA in cells are well known and include, for example, hybridization assays using complementary DNA probes (such as in situ hybridization, Northern blots, and related techniques using labeled riboprobes specific for one or more of the genes) and various nucleic acid amplification assays (such as RT-PCR using complementary primers specific for one or more of the genes, and other amplification-based detection methods such as branched DNA, SISBA, TMA, etc.).

[0302] A sample from a mammal can be conveniently assayed for mRNA using Northern blot, dot blot, or PCR analysis. In addition, such methods can include one or more steps that allow the level of target mRNA in a biological sample to be determined (e.g., by simultaneously testing the level of a control mRNA sequence of a "housekeeping" gene, such as an actin family member). Optionally, the sequence of the amplified target cDNA can be determined.

[0303] Any method includes a protocol for testing or detecting mRNA, such as a target mRNA, in a tissue or cell sample by microarray technology. Using a nucleic acid microarray, test and control mRNA samples from test and control tissue samples are reverse transcribed and labeled to generate cDNA probes. The probes are then hybridized to an array of nucleic acids immobilized on a solid support. The array is constructed such that the sequence and location of each member of the array is known. For example, a selection of different genes whose expression correlates with increased or decreased clinical usefulness of antiangiogenic therapy can be arrayed on a solid support. Hybridization of a labeled probe with a particular array member indicates that the sample from which the probe was derived expresses that gene.

[0304] According to some embodiments, the presence and / or expression level / amount is measured by observing the protein expression levels of the aforementioned genes. In certain embodiments, the method comprises contacting the biological sample with an antibody against a biomarker described herein (e.g., an anti-PD-L1 antibody) under conditions that allow binding of the biomarker, and detecting whether a complex is formed between the antibody and the biomarker. Such a method may be an in vitro method or an in vivo method. In one embodiment, the antibody is used to select a biomarker for selection of subjects, e.g., individuals, eligible for therapy with a PD-L1 axis binding antagonist.

[0305] In certain embodiments, the presence and / or expression level / amount of biomarker protein in a sample is tested using IHC and staining protocols. IHC staining of tissue sections has been shown to be a reliable method of determining or detecting the presence of a protein in a sample. In some embodiments of any of these methods, assays, and / or kits, the PD-L1 biomarker is PD-L1. In some embodiments, PD-L1 is detected by immunohistochemistry. In some embodiments, an increase in expression of PD-L1 biomarker in a sample from an individual is an increase in protein expression, which in further embodiments is determined using IHC. In one embodiment, the expression level of the biomarker is determined using a method that includes (a) performing an IHC analysis of a sample (such as a cancer sample of interest) using an antibody, and (b) determining the expression level of the biomarker in the sample. In some embodiments, the IHC staining intensity is determined relative to a standard. In some embodiments, the standard is a reference value. In some embodiments, the standard is a reference sample (e.g., a control cell line stained sample or a tissue sample from a non-cancerous patient).

[0306] IHC may be performed in combination with further techniques such as morphological staining and / or fluorescent in situ hybridization. Two general IHC methods are available: direct and indirect assays. According to the first assay, the binding of the antibody to the target antigen is determined directly. This direct assay uses a labeling reagent such as a fluorescent tag or an enzyme-labeled primary antibody that can be visualized without further antibody interaction. In a typical indirect assay, an unconjugated primary antibody binds to the antigen, and then a labeled secondary antibody binds to the primary antibody. If the secondary antibody is conjugated to an enzyme label, a chromogenic or fluorogenic substrate is added to result in the visualization of the antigen. Signal amplification occurs because several secondary antibodies may react with different epitopes of the primary antibody.

[0307] The primary and / or secondary antibodies used in IHC are typically labeled with a detectable moiety. Numerous labels are available, which can generally be grouped into the following categories: (a) 35 S, 14 C. 125 I, 3 H, and 131 These may be grouped into fluorescent labels, including, but not limited to, radioisotopes such as I, (b) colloidal gold particles, (c) rare earth chelates (europium chelates), Texas Red, rhodamine, fluorescein, dansyl, Lissamine, umbelliferone, phycoglycerin, phycocyanin, or commercially available fluorophores (such as SPECTRUM ORANGE7 and SPECTRUM GREEN7), and / or derivatives of any one or more of the above, and (d) a variety of enzyme-substrate labels are available, and U.S. Pat. No. 4,275,149 provides a review of some of these. Examples of enzyme labels include luciferases (e.g., firefly luciferase and bacterial luciferase; see U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidases such as horseradish peroxidase (HRPO), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, sugar oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like.

[0308] Examples of enzyme-substrate combinations include, for example, horseradish peroxidase (HRPO) with hydrogen peroxidase as a substrate, alkaline phosphatase (AP) with para-nitrophenyl phosphate as a chromogenic substrate, and β-D-galactosidase (β-D-Gal) with a chromogenic (e.g., p-nitrophenyl-β-D-galactosidase) or fluorogenic (e.g., 4-methylumbelliferyl-β-D-galactosidase) substrate. For reviews, see U.S. Patent Nos. 4,275,149 and 4,318,980.

[0309] In some embodiments of any of these methods, PD-L1 is detected by immunohistochemistry using an anti-PD-L1 diagnostic antibody (i.e., a primary antibody). In some embodiments, the PD-L1 diagnostic antibody specifically binds to human PD-L1. In some embodiments, the PD-L1 diagnostic antibody is a non-human antibody. In some embodiments, the PD-L1 diagnostic antibody is a rat, mouse, or rabbit antibody. In some embodiments, the PD-L1 diagnostic antibody is a monoclonal antibody. In some embodiments, the PD-L1 diagnostic antibody is directly labeled.

[0310] The specimen thus prepared can be mounted and coverslipped. Slide evaluation can then be determined, for example, using a microscope, and staining intensity criteria commonly used by the art can be used. In one embodiment, when cells and / or tissues from a tumor are examined using IHC, it is understood that staining is generally determined or evaluated in tumor cells and / or tissues (as opposed to stroma or surrounding tissues present in the sample). In some embodiments, when cells and / or tissues from a tumor are examined using IHC, it is understood that staining includes determination or evaluation in tumor-infiltrating immune cells, such as intratumoral or peritumoral immune cells.

[0311] In some embodiments, PDL1 expression is assessed in tumors or tumor samples. As used herein, tumors or tumor samples may include some or all of the tumor area occupied by tumor cells. In some embodiments, tumors or tumor samples further include tumor area occupied by tumor-associated intratumoral cells and / or tumor-associated stroma (e.g., adjacent peritumoral desmoplastic stroma). Tumor-associated intratumoral cells and / or tumor-associated stroma may include areas of immune infiltrates (e.g., tumor-infiltrating immune cells as described herein) that are directly adjacent and / or contiguous with the main tumor mass. In some embodiments, PDL1 expression is assessed in tumor cells. In some embodiments, PDL1 expression is assessed in immune cells within the above-mentioned tumor areas, such as tumor-infiltrating immune cells.

[0312] In an alternative method, the sample may be contacted with an antibody specific for the biomarker under conditions sufficient to form an antibody-biomarker complex, which is then detected. The presence of the biomarker may be detected in a number of ways, for example, by Western blot and ELISA procedures, for assaying a wide variety of tissues and samples, such as plasma or serum. A wide range of immunoassay techniques using such assay formats are available, see, for example, U.S. Patent Nos. 4,016,043, 4,424,279, and 4,018,653. These include both one-site and two-site assays of the non-competitive type, or "sandwich" assays, as well as traditional competitive binding assays. These assays also include direct binding of a labeled antibody to the target biomarker.

[0313] The presence and / or expression level / amount of a selected biomarker in a tissue or cell sample can also be tested by functional or activity-based assays. For example, if the biomarker is an enzyme, assays known in the art can be performed to determine or detect the presence of a given enzymatic activity in a tissue or cell sample.

[0314] In certain embodiments, samples are normalized for both differences in the amount of assayed biomarkers and variations in the quality of samples used, as well as variations between assay runs. Such normalization can be achieved by detecting and incorporating the expression of certain normalizing biomarkers, such as well-known housekeeping genes. Alternatively, normalization can be based on the average or median signal of all of the assayed genes or a large subset thereof (global normalization approach). For each gene, the measured normalized amount of the subject's tumor mRNA or protein is compared to the amount found in the reference set. The normalized expression level of each mRNA or protein for each tested tumor for each subject can be expressed as a percentage of the measured expression level in the reference set. The measured presence and / or expression level / amount in the particular subject sample being analyzed is expressed as a percentage within this range, which can be determined by methods well known in the art.

[0315] In one embodiment, the sample is a clinical sample. In another embodiment, the sample is used in a diagnostic assay. In some embodiments, the sample is obtained from a primary tumor or a metastatic tumor. Tissue biopsy is often used to obtain a representative piece of tumor tissue. Alternatively, tumor cells can be obtained indirectly in the form of tissue or fluid known or believed to contain the tumor cells of interest. For example, lung cancer lesion samples can be obtained by resection, bronchoscopy, fine needle aspiration, bronchial scraping, or from sputum, pleural fluid, or blood. Genes or gene products can be detected from cancer or tumor tissue or from other body samples, such as urine, sputum, serum, or plasma. The same techniques discussed above for the detection of target genes or gene products in cancerous samples can be applied to other body samples. Cancer cells can be shed from cancer lesions and appear in such body samples. By screening such body samples, simple early diagnosis of these cancers can be achieved. In addition, progress of therapeutic approaches can be more easily monitored by testing such body samples for target genes or gene products.

[0316] In certain embodiments, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is a single sample or a combination of multiple samples from the same subject or individual that are obtained at one or more time points different from when the test sample is obtained.For example, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from the same subject or individual at an earlier time point than when the test sample is obtained.Such a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue can be useful when the reference sample is obtained during the initial diagnosis of cancer and the test sample is obtained when the cancer becomes metastatic.

[0317] In certain embodiments, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is a combined sample from one or more healthy individuals that are not the subject or individual. In certain embodiments, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is a combined sample from one or more individuals with a disease or disorder (e.g., cancer) that are not the subject or individual. In certain embodiments, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is a pooled RNA sample from normal tissue, or a pooled plasma or serum sample from one or more individuals that are not the subject or individual. In certain embodiments, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is a pooled RNA sample from tumor tissue, or a pooled plasma or serum sample from one or more individuals with a disease or disorder (e.g., cancer) that are not the subject or individual.

[0318] In some embodiments, the sample is a tissue sample from an individual. In some embodiments, the tissue sample is a tumor tissue sample (e.g., biopsy tissue). In some embodiments, the tissue sample is lung tissue. In some embodiments, the tissue sample is kidney tissue. In some embodiments, the tissue sample is skin tissue. In some embodiments, the tissue sample is pancreatic tissue. In some embodiments, the tissue sample is stomach tissue. In some embodiments, the tissue sample is bladder tissue. In some embodiments, the tissue sample is esophageal tissue. In some embodiments, the tissue sample is mesothelial tissue. In some embodiments, the tissue sample is breast tissue. In some embodiments, the tissue sample is thyroid tissue. In some embodiments, the tissue sample is colorectal tissue. In some embodiments, the tissue sample is head and neck tissue. In some embodiments, the tissue sample is osteosarcoma tissue. In some embodiments, the tissue sample is prostate tissue. In some embodiments, the tissue sample is ovarian tissue, HCC (liver), blood cells, lymph nodes, and / or bone / bone marrow tissue. In some embodiments, the tissue sample is colon tissue. In some embodiments, the tissue sample is endometrial tissue, hi some embodiments, the tissue sample is brain tissue (such as glioblastoma, neuroblastoma, etc.).

[0319] In some embodiments, a tumor tissue sample (the terms "tumor sample" are used interchangeably herein) may include some or all of the tumor area occupied by tumor cells. In some embodiments, the tumor or tumor sample further includes the tumor area occupied by tumor-associated intratumoral cells and / or tumor-associated stroma (e.g., adjacent peritumoral desmoplastic stroma). Tumor-associated intratumoral cells and / or tumor-associated stroma may include an area of ​​immune infiltrate (e.g., tumor-infiltrating immune cells as described herein) that is directly adjacent and / or contiguous with the main tumor mass.

[0320] In some embodiments, the PD-L1 biomarker is detected in the sample using a method selected from the group consisting of FACS, Western blot, ELISA, immunoprecipitation, immunohistochemistry, immunofluorescence, radioimmunoassay, dot blotting, immunodetection methods, HPLC, surface plasmon resonance, optical spectroscopy, mass spectroscopy, HPLC, qPCR, RT-qPCR, multiplex qPCR or RT-qPCR, RNA-seq, microarray analysis, SAGE, MassARRAY techniques, and FISH, and combinations thereof. In some embodiments, the PD-L1 biomarker is detected using FACS analysis. In some embodiments, the PD-L1 biomarker is PD-L1. In some embodiments, PD-L1 expression is detected in a blood sample. In some embodiments, PD-L1 expression is detected on circulating immune cells in the blood sample. In some embodiments, the circulating immune cells are CD3+ / CD8+ T cells. In some embodiments, immune cells are isolated from the blood sample prior to analysis. Any suitable method of isolation / enrichment of such cell populations may be used, including, but not limited to, cell sorting. In some embodiments, PD-L1 expression is elevated in a sample from an individual who responds to treatment with a PD-L1 / PD-1 axis pathway inhibitor, such as an anti-PD-L1 antibody. In some embodiments, PD-L1 expression is elevated on circulating immune cells, such as CD3+ / CD8+ T cells in a blood sample.

[0321] In some embodiments, the anti-PD-L1 rabbit monoclonal primary antibody is detected with a secondary antibody that comprises a detectable label. In some embodiments, the assay used to detect PD-L1 is the VENTANA PD-L1 (SP142) Assay (commercially available from VENTANA®), which is described in more detail in the Examples.

[0322] Certain aspects of the present disclosure relate to measuring the expression levels of one or more genes or one or more proteins in a sample. In some embodiments, the sample may include white blood cells. In some embodiments, the sample may be a peripheral blood sample (e.g., from a patient with a tumor). In some embodiments, the sample is a tumor sample. The tumor sample may include cancer cells, lymphocytes, white blood cells, stroma, blood vessels, connective tissue, basement membrane, and any other cell type associated with a tumor. In some embodiments, the sample is a tumor tissue sample containing tumor-infiltrating white blood cells. In some embodiments, the sample may be processed to separate or isolate one or more cell types (e.g., white blood cells). In some embodiments, the sample may be used without separating or isolating cell types.

[0323] Tumor samples may be obtained from a subject by any method known in the art, including, but not limited to, biopsy, endoscopy, or surgical procedures. In some embodiments, tumor samples may be prepared by methods such as freezing, fixing (e.g., using formalin or a similar fixative), and / or embedding in paraffin wax. In some embodiments, tumor samples may be sectioned. In some embodiments, fresh tumor samples (i.e., tumor samples not prepared by the methods described above) may be used. In some embodiments, tumor samples may be prepared by incubation in solutions to preserve the integrity of mRNA and / or protein.

[0324] In some embodiments, the sample may be a peripheral blood sample. The peripheral blood sample may include white blood cells, PBMCs, etc. Any technique for isolating white blood cells from a peripheral blood sample known in the art may be used. For example, a blood sample may be taken, red blood cells may be lysed, and a white blood cell pellet may be isolated and used for the sample. In another example, density gradient separation may be used to separate white blood cells (e.g., PBMCs) from red blood cells. In some embodiments, a fresh peripheral blood sample (i.e., a peripheral blood sample not prepared by the methods described above) may be used. In some embodiments, the peripheral blood sample may be prepared by incubation in a solution to preserve the integrity of the mRNA and / or protein.

[0325] In some embodiments, responsiveness to treatment may refer to any one or more of: extending survival (including overall survival and progression-free survival), producing an objective response (including complete or partial response), or improving signs or symptoms of cancer. In some embodiments, responsiveness may refer to an improvement in one or more factors according to the published set of RECIST guidelines for determining tumor status in cancer patients, i.e., response, stable, or progression. For a more detailed discussion of these guidelines, see Eisenhauer et al., Eur J Cancer (2009) 45:228-47; Topalian et al., N Engl J Med (2012) 366:2443-54; Wolchok et al., Clin Can Res (2009) 15:7412-20; and Therasse, P. et al., J. Natl. Cancer Inst. 92:205-16 (2000). A responsive subject may refer to a subject whose cancer(s) show improvement according to, for example, one or more factors based on RECIST criteria. A non-responsive subject may refer to a subject whose cancer(s) do not show improvement according to, for example, one or more factors based on RECIST criteria.

[0326] Traditional response criteria may not be adequate to characterize the antitumor activity of immunotherapeutic agents and may result in delayed responses that may be preceded by the first obvious radiological progression, such as the appearance of new lesions. Therefore, modified response criteria have been developed that account for the possibility of new lesion appearance and allow radiological progression to be confirmed at subsequent evaluations. Thus, in some embodiments, responsiveness may refer to an improvement in one of more factors according to the immune-related response criteria 2 (irRC). See, for example, Wolchok et al., Clin Can Res (2009) 15:7412-20. In some embodiments, new lesions are added to the defined tumor burden, e.g., followed by radiological progression at subsequent evaluations. In some embodiments, the presence of non-target lesions is included in the assessment of complete response and not in the assessment of radiological progression. In some embodiments, radiological progression may be determined based only on measurable disease and / or confirmed by consecutive evaluations for 4 weeks or more from the date of first recording.

[0327] In some embodiments, the responsiveness may include immune activation. In some embodiments, the responsiveness may include therapeutic efficacy. In some embodiments, the responsiveness may include immune activation and therapeutic efficacy.

[0328] X. Products or kits In another aspect of the invention, an article of manufacture or kit is provided that includes a PD-1 axis binding antagonist (such as atezolizumab) and / or a platinum agent (such as carboplatin or cisplatin) and / or an antimetabolite (such as pemetrexed). In some embodiments, the article of manufacture or kit further includes a package insert that includes instructions for using the PD-1 axis binding antagonist in combination with a platinum agent (such as carboplatin or cisplatin) and an antimetabolite (such as pemetrexed) to treat or delay cancer in an individual (e.g., lung cancer, such as non-small cell lung cancer (NSCLC), including stage IV non-squamous NSCLC), or to enhance immune function in an individual with cancer (e.g., lung cancer, such as NSCLC, including stage IV non-squamous NSCLC). The PD-1 axis binding antagonist, any of the platinum agents known in the art, can be included in the article of manufacture or kit. In some embodiments, the kit comprises atezolizumab, carboplatin or cisplatin, and pemetrexed.

[0329] In some embodiments, the PD-1 axis binding antagonist (such as atezolizumab), the platinum agent (such as carboplatin or cisplatin), and the antimetabolite (such as pemetrexed) are in the same container or in separate containers. Suitable containers include, for example, bottles, vials, bags, and syringes. The containers can be formed from a variety of materials, such as glass, plastic (such as polyvinyl chloride or polyolefin), or metal alloys (such as stainless steel or Hastelloy). In some embodiments, the container holds the formulation, and a label on or associated with the container can indicate instructions for use. The article of manufacture or kit can further include other materials desirable from a commercial and user standpoint, such as other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. In some embodiments, the article of manufacture further includes one or more of another agent (e.g., a chemotherapeutic agent and an anti-neoplastic agent). Suitable containers for one or more agents include, for example, bottles, vials, bags, and syringes.

[0330] The specification is deemed sufficient to enable one skilled in the art to practice the invention. Various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the foregoing description, which are within the scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes. EXAMPLES

[0331] The present disclosure will be more fully understood by referring to the following examples. However, the examples should not be interpreted as limiting the scope of the present invention. It is understood that the examples and embodiments described herein are for illustrative purposes only, and various modifications or changes taking into account thereof are suggested to those skilled in the art, and should be included within the spirit and scope of this specification and the scope of the appended claims. Example 1: A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + pemetrexed or cisplatin + pemetrexed compared with carboplatin + pemetrexed or cisplatin + pemetrexed in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC).

[0332] This study was designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab in combination with carboplatin + pemetrexed or cisplatin + pemetrexed compared with carboplatin + pemetrexed or cisplatin + pemetrexed in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC). The specific objectives of the study and corresponding endpoints are outlined below. Purpose of the test

[0333] The primary efficacy objectives in this study were: To evaluate the efficacy of atezolizumab plus carboplatin plus pemetrexed compared with carboplatin plus pemetrexed and atezolizumab plus cisplatin plus pemetrexed compared with cisplatin plus pemetrexed in the intent-to-treat (ITT) population, measured by investigator assessment of progression-free survival (PFS) or death from any cause, whichever occurs first, according to RECIST version 1.1 (see, for example, Eisenhauer et al. (2009) New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1), Eur J Cancer. 45:228-47). To assess the efficacy of atezolizumab plus carboplatin plus pemetrexed compared with carboplatin plus pemetrexed, and atezolizumab plus cisplatin plus pemetrexed compared with cisplatin plus pemetrexed, measured by overall survival (OS), defined as the time from randomization to death from any cause.

[0334] The secondary efficacy objectives in this study were: To evaluate the efficacy of atezolizumab plus carboplatin plus pemetrexed compared with carboplatin plus pemetrexed and atezolizumab plus cisplatin plus pemetrexed compared with cisplatin plus pemetrexed, measured by objective response rate (ORR) and defined as partial response (PR) or complete response (CR) according to RECIST version 1.1. To evaluate the efficacy of atezolizumab plus carboplatin plus pemetrexed compared with carboplatin plus pemetrexed and atezolizumab plus cisplatin plus pemetrexed compared with cisplatin plus pemetrexed, as measured by investigator assessment of duration of response (DOR) according to RECIST version 1.1. To assess OS rates at 1 and 2 years. To assess the impact of atezolizumab as measured by change from baseline in patient-reported lung cancer symptoms of cough, dyspnea, chest pain, or arm / shoulder pain using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core30 (QLQ-C30) and supplemental lung cancer module (QLQ-LC13). Time to deterioration (TTD) in symptoms in patients with lung cancer, defined as the time from randomization to progression (a 10-point change) in the EORTC QLQ-30 and EORTC QLQ-LC13, respectively. To determine the effect of atezolizumab as measured by change from baseline in patient-reported lung cancer symptom scores (chest pain, dyspnea, and cough) using the symptom severity score of the Symptoms in Lung Cancer (SILC) scale.

[0335] The safety goals of the study were: To evaluate the safety and tolerability of atezolizumab plus carboplatin plus pemetrexed or atezolizumab plus cisplatin plus pemetrexed, as measured by the incidence, nature, and severity of adverse events classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. To assess changes in vital signs, physical examination findings, and laboratory findings during and after study treatment administration. To evaluate the safety and tolerability of atezolizumab when used in combination with carboplatin and pemetrexed, in combination with cisplatin and pemetrexed, or as maintenance therapy with pemetrexed alone. To assess the incidence and titer of anti-therapeutic antibodies (ATA) to atezolizumab and to examine the potential relationship of immunogenic responses to pharmacokinetics, safety, and efficacy.

[0336] The pharmacokinetic objectives of this study were to: To characterize the pharmacokinetics of atezolizumab in combination with carboplatin and pemetrexed, in combination with cisplatin and pemetrexed, or with pemetrexed alone. · To characterize the pharmacokinetics of carboplatin when combined with atezolizumab + pemetrexed. · To characterize the pharmacokinetics of cisplatin when combined with atezolizumab + pemetrexed. To characterize the pharmacokinetics of pemetrexed in combination with atezolizumab plus carboplatin or in combination with atezolizumab plus cisplatin. Maximum observed serum atezolizumab concentration after infusion (C max ) (Group A). Minimum observed serum atezolizumab concentrations (C) for selected cycles, before infusion, at treatment interruption, and 120 days (± 30 days) after the last dose of atezolizumab min ) (Group A). · To determine the plasma concentrations of carboplatin or cisplatin (Group A). · To determine the plasma concentration of pemetrexed (Group A).

[0337] The exploratory objectives of this study are to: To evaluate progression-free survival (PFS) rates at landmark time points of 6 months and 1 year. To assess the 3-year overall survival (OS) rates in each treatment group. To evaluate the efficacy of atezolizumab, as measured by investigator-assessed OS and PFS per RECIST version 1.1, in subgroups based on demographic and baseline characteristics. To evaluate the efficacy of atezolizumab as measured by milestone survival. Evaluate the relationship between tumor and blood biomarkers defined by immunohistochemistry (IHC), quantitative reverse transcription polymerase chain reaction (qRT-PCR), next generation sequencing, and / or other methods and efficacy measures, including but not limited to programmed cell death-ligand 1 (PD-L1), programmed cell death-1 (PD-1), and somatic mutations. To evaluate predictive, prognostic, and exploratory pharmacodynamic biomarkers in archived and / or fresh tumor tissue and blood and their association with disease state, resistance mechanisms, and / or response to study treatment. To evaluate the association of PD-L1-, immune-related, and NSCLC-associated, as well as other exploratory biomarker status in archived and / or fresh tumor tissue and blood (or blood products) taken before, during, after, or at progression with atezolizumab, with disease status and / or response to atezolizumab in combination with chemotherapy. To evaluate and compare patient health status as assessed by the EuroQoL 5 Dimensions 5-Level (EQ-5D-5L) questionnaire to generate utility scores for use in economic models for reimbursement. To determine the impact of atezolizumab in each of the treatment comparisons, as measured by change from baseline in health-related quality of life, lung cancer-related symptoms, and health status patient-reported outcomes (PROs) assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires EORTC QLQ-C30 and QLQ-LC13. Study design

[0338] Below are details of a randomized, phase III, multicenter, open-label study designed to evaluate the safety and efficacy of (a) atezolizumab + carboplatin + pemetrexed compared to carboplatin + pemetrexed, and (b) atezolizumab + cisplatin + pemetrexed compared to cisplatin + pemetrexed in chemotherapy-naïve patients with stage IV non-squamous NSCLC. Scheme 1 below shows the study design: TIFF2024161372000010.tif143170

[0339] In the above scheme 1, ECOG PS refers to "Eastern Cooperative Oncology Group performance status", NSCLC refers to "non-small cell lung cancer", and RECIST version 1.1 refers to "Response Evaluation Criteria in Solid Tumors (version 1.1)".

[0340] Approximately 568 patients were enrolled in this study across all sites in the international registration phase. Patients were stratified by sex (male vs. female), smoking status (never vs. current and / or former smoker), ECOG (i.e., Eastern Cooperative Oncology Group) performance status (0 vs. 1), and chemotherapy regimen (carboplatin vs. cisplatin), and then randomized in a 1:1 ratio to receive one of the treatment regimens listed below, as shown in Table 5 below. Further details regarding ECOG performance status are provided in Oken et al. (1982) Am J Clin Oncol. 5:649-655. TIFF2024161372000011.tif49170

[0341] The induction phase was administered in 21-day cycles for 4 or 6 cycles. The number of cycles of induction treatment (i.e., 4 or 6) was at the discretion of the investigator and was determined and documented prior to randomization. Induction treatment was administered in 21-day cycles until the occurrence of the following events (first occurring event): (1) administration of 4 or 6 cycles, (2) unacceptable toxicity, or (3) confirmed disease progression.

[0342] After the induction phase, patients who did not experience progression or unacceptable toxicity continued maintenance therapy with either atezolizumab plus pemetrexed (Group A) or pemetrexed alone (Group B). Patients randomized to either Group A or Group B continued treatment with atezolizumab plus pemetrexed maintenance or pemetrexed maintenance until disease progression, unacceptable toxicity, or death. During the induction or maintenance phase, patients randomized to Group A continued treatment with atezolizumab beyond disease progression by RECIST version 1.1 if they had undergone clinical benefit assessed by the investigator as described below.

[0343] For treatment group A: Patients who showed evidence of clinical benefit during treatment (induction or maintenance phase) were permitted to continue atezolizumab if they met all of the following criteria after RECIST v1.1 for disease progression was met: Evidence of clinical benefit as assessed by the investigator. Absence of symptoms and signs of evident progression of the disease, including deterioration of laboratory values ​​(e.g., onset or worsening of hypercalcemia). There was no decline in ECOG performance status due to disease progression. · Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal disease) that cannot be managed with protocol-permitted medical interventions. Patients must have given written consent to defer other treatment options in favor of continuing study treatment at the time of early progression.

[0344] Treatment with chemotherapy (both Group A and Group B) was discontinued in all patients who showed evidence of disease progression by RECIST version 1.1.

[0345] The dosages and administration schedules of the treatment regimen for Group A in Table 5 are shown in Tables 6A and 6B below. TIFF2024161372000012.tif83170TIFF2024161372000013.tif83170

[0346] Patients underwent tumor assessments at baseline and every 6 weeks (± 7 days) for the first 48 weeks after Day 1 of Cycle 1, regardless of dosing delays. After completion of tumor assessments at Week 48, tumor assessments were required every 9 weeks (± 7 days) thereafter, regardless of treatment dosing delays. Patients underwent tumor assessments until radiographic disease progression per RECIST v1.1 or loss of clinical benefit (only for atezolizumab-treated patients who continued treatment after radiographic disease progression per RECIST v1.1), withdrawal of consent, sponsor-initiated study discontinuation, or death, whichever occurred first. Patients who discontinued treatment for reasons other than radiographic disease progression (e.g., toxicity), regardless of whether they initiated new anticancer therapy, continued to have scheduled tumor assessments until radiographic disease progression per RECIST v1.1 or loss of clinical benefit (only for atezolizumab-treated patients who continued treatment after radiographic disease progression per RECIST v1.1), withdrawal of consent, sponsor-initiated study discontinuation, or death, whichever occurred first.

[0347] Patients were encouraged to undergo tumor biopsy sampling at the time of radiographic disease progression, if clinically feasible. These data were used to examine whether radiographic findings were...

Claims

1. 1. A method of treating an individual having lung cancer comprising administering to the individual effective amounts of an anti-PD-L1 antibody, an antimetabolite, and a platinum agent, wherein the treatment extends the progression free survival (PFS) of the individual.

2. 10. The method of claim 1, wherein the treatment extends the overall survival (OS) of the individual.

3. 1. A method of treating an individual having lung cancer comprising administering to said individual effective amounts of an anti-PD-L1 antibody, an antimetabolite, and a platinum drug, wherein said treatment extends the overall survival (OS) of said individual.

4. 10. The method of claim 1, wherein the treatment extends the PFS of the individual by at least about 6 months.

5. 4. The method of claim 2 or 3, wherein the treatment extends the OS of the individual by at least about 15 months.

6. The anti-PD-L1 antibody is as follows: (a) a heavy chain variable region (VH) comprising an HVR-H1 comprising the amino acid sequence of GFTFSDSWIH (SEQ ID NO: 1), an HVR-2 comprising the amino acid sequence of AWISPYGGSTYYADSVKG (SEQ ID NO: 2), and an HVR-3 comprising the amino acid sequence RHWPGGFDY (SEQ ID NO: 3); (b) a light chain variable region (VL) comprising an HVR-L1 comprising the amino acid sequence of RASQDVSTAVA (SEQ ID NO: 4), an HVR-L2 comprising the amino acid sequence of SASFLYS (SEQ ID NO: 5), and an HVR-L3 comprising the amino acid sequence of QQYLYHPAT (SEQ ID NO: 6); The method according to any one of claims 1 to 5.

7. The anti-PD-L1 antibody comprises a heavy chain variable region (V H ) and a light chain variable region (V L 7. The method of claim 1, comprising:

8. The method of any one of claims 1 to 7, wherein the anti-PD-L1 antibody is atezolizumab.

9. The method of any one of claims 1 to 8, wherein the antimetabolite is pemetrexed, 5-fluorouracil, 6-mercaptopurine, capecitabine, cytarabine, floxuridine, fludarabine, hydroxycarbamide, or methotrexate.

10. 10. The method of claim 9, wherein the antimetabolite is pemetrexed.

11. The method according to any one of claims 1 to 10, wherein the platinum agent is carboplatin.

12. The method according to any one of claims 1 to 10, wherein the platinum agent is cisplatin.

13. The anti-PD-L1 antibody is administered at a dose of 1200 mg, where the platinum agent is carboplatin and is administered at a dose sufficient to achieve an AUC=6 mg / mL / min, and where the antimetabolite is pemetrexed and is administered at a dose sufficient to achieve an AUC=500 mg / mL. 2 The method according to any one of claims 1 to 11, wherein the dose is

14. The anti-PD-L1 antibody is administered at a dose of 1200 mg, where the platinum agent is cisplatin and is administered at a dose of 75 mg / m 2 and wherein the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m 2 The method according to any one of claims 1 to 10 and 12, wherein the dose is

15. The anti-PD-L1 antibody, the antimetabolite, and the platinum agent are administered in four 21-day cycles, where the anti-PD-L1 antibody is atezolizumab and is administered on day 1 at a dose of 1200 mg, and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m 2 and wherein the platinum agent is carboplatin and is administered at a dose sufficient to achieve an AUC=6 mg / mL / min on day 1 of each 21-day cycle for cycles 1-4.

16. The anti-PD-L1 antibody, the antimetabolite, and the platinum agent are administered in four 21-day cycles, where the anti-PD-L1 antibody is atezolizumab and is administered on day 1 at a dose of 1200 mg, and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m 2 on day 1, and where the platinum agent is cisplatin and is administered at a dose of 75 mg / m on day 1 of each 21-day cycle for cycles 1-4. 2 The method of any one of claims 1 to 10, 12 and 14, wherein the compound is administered at a dose of

17. 17. The method of any one of claims 15-16, wherein the anti-PD-L1 antibody, the antimetabolite, and the platinum agent are administered consecutively on day 1 of cycles 1-4.

18. 18. The method of claim 17, wherein the anti-PD-L1 antibody is administered prior to the antimetabolite, wherein the antimetabolite is administered prior to the platinum agent on day 1 of cycles 1-4.

19. the anti-PD-L1 antibody and the antimetabolite are further administered after cycle 4, where the anti-PD-L1 antibody is atezolizumab and is administered at a dose of 1200 mg on day 1, and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 4. 2 The method according to any one of claims 15 to 18, wherein the dose is

20. 20. The method of claim 19, wherein the anti-PD-L1 antibody and the antimetabolite are administered consecutively on day 1 of each 21-day cycle for all cycles following cycle 4.

21. 21. The method of claim 20, wherein the anti-PD-L1 antibody is administered prior to the antimetabolite on day 1 after cycle 4.

22. The anti-PD-L1 antibody, the antimetabolite, and the platinum agent are administered in four 21-day cycles, where the anti-PD-L1 antibody is atezolizumab and is administered on day 1 at a dose of 1200 mg, and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m 2 and wherein the platinum agent is carboplatin and is administered at a dose sufficient to achieve an AUC=6 mg / mL / min on day 1 of each 21-day cycle for cycles 1-6.

23. The anti-PD-L1 antibody, the antimetabolite, and the platinum agent are administered in four 21-day cycles, where the anti-PD-L1 antibody is atezolizumab and is administered on day 1 at a dose of 1200 mg, and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m 2 on day 1, and where the platinum agent is cisplatin and is administered at a dose of 75 mg / m on day 1 of each 21-day cycle for cycles 1-6. 2 The method of any one of claims 1 to 10, 12 and 14, wherein the compound is administered at a dose of

24. 24. The method of claim 22 or 23, wherein the anti-PD-L1 antibody, the antimetabolite, and the platinum agent are administered consecutively on day 1 of cycles 1-6.

25. 25. The method of claim 24, wherein the anti-PD-L1 antibody is administered prior to the antimetabolite, wherein the antimetabolite is administered prior to the platinum agent on day 1 of cycles 1-6.

26. the anti-PD-L1 antibody and the antimetabolite are further administered after cycle 6, where the anti-PD-L1 antibody is atezolizumab and is administered at a dose of 1200 mg on day 1, and where the antimetabolite is pemetrexed and is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 6. 2 The method according to any one of claims 22 to 25, wherein the dose is

27. 27. The method of claim 26, wherein the anti-PD-L1 antibody and the antimetabolite are administered consecutively on day 1 of each 21-day cycle for all cycles following cycle 6.

28. 28. The method of claim 27, wherein the anti-PD-L1 antibody is administered prior to the antimetabolite on day 1 of each 21-day cycle for all cycles after cycle 6.

29. The method of any one of claims 1 to 28, wherein the anti-PD-L1 antibody, the platinum agent, and the antimetabolite inhibitor are each administered intravenously.

30. The method according to any one of claims 1 to 29, wherein the lung cancer is non-small cell lung cancer (NSCLC).

31. 31. The method of claim 30, wherein the NSCLC is stage IV non-squamous NSCLC.

32. 32. The method of claim 31, wherein the individual is treatment-naive for stage IV non-squamous NSCLC.

33. 32. The method of claim 31, wherein the individual is chemotherapy naive for stage IV non-squamous NSCLC.

34. The method of any one of claims 1 to 33, wherein the individual is Asian.

35. The method of any one of claims 1 to 34, wherein the individual is at least 65 years old.

36. The method of any one of claims 1 to 35, wherein the individual is a non-smoker.

37. The method of any one of claims 1 to 36, wherein the individual has high PD-L1.

38. The method of any one of claims 1 to 36, wherein the individual is PD-L1 negative.

39. 1. A method of treating an individual with stage IV non-squamous non-small cell lung cancer (NSCLC), comprising administering to the individual effective amounts of atezolizumab, pemetrexed, and carboplatin, wherein the atezolizumab is administered at a dose of 1200 mg and the pemetrexed is administered at a dose of 500 mg / m 2 and said carboplatin is administered at a dose sufficient to achieve an AUC=6 mg / mL / min, wherein said treatment prolongs progression free survival (PFS).

40. 40. The method of claim 39, wherein treatment extends overall survival (OS) of the individual.

41. Atezolizumab, pemetrexed, and carboplatin are administered in four 21-day cycles, and atezolizumab and pemetrexed are further administered in a 21-day cycle after cycle 4, where atezolizumab is administered at a dose of 1200 mg on day 1 of each 21-day cycle for cycles 1-4, and pemetrexed is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for cycles 1-4. 2 and carboplatin is administered at a dose sufficient to achieve an AUC=6 mg / mL / min on day 1 of each 21-day cycle for cycles 1-4, and wherein atezolizumab is further administered at a dose of 1200 mg on day 1 of each 21-day cycle for all cycles after cycle 4, and pemetrexed is administered at a dose of 500 mg / mL on day 1 of each 21-day cycle for all cycles after cycle 4. 2 41. The method of claim 39 or 40, further comprising administering at a dose of

42. 42. The method of claim 41, wherein atezolizumab, pemetrexed, and carboplatin are administered sequentially on day 1 of cycles 1-4.

43. 43. The method of claim 42, wherein atezolizumab is administered prior to pemetrexed, wherein pemetrexed is administered prior to carboplatin on day 1 of cycles 1-4.

44. 44. The method of any one of claims 41-43, wherein atezolizumab and pemetrexed are administered consecutively on day 1 of each 21-day cycle for all cycles after cycle 4.

45. 45. The method of claim 44, wherein atezolizumab is administered prior to pemetrexed on day 1 of each 21-day cycle for all cycles after cycle 4.

46. Atezolizumab, pemetrexed, and carboplatin are administered in six 21-day cycles, and atezolizumab and pemetrexed are further administered in a 21-day cycle after cycle 6, where atezolizumab is administered at a dose of 1200 mg on day 1 of each 21-day cycle for cycles 1-6, and pemetrexed is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for cycles 1-6. 2 and carboplatin is administered at a dose sufficient to achieve an AUC=6 mg / mL / min on day 1 of each 21-day cycle for cycles 1-6, and wherein atezolizumab is further administered at a dose of 1200 mg on day 1 of each 21-day cycle for all cycles after cycle 6, and pemetrexed is further administered at a dose of 500 mg / mL on day 1 of each 21-day cycle for all cycles after cycle 6. 2 41. The method of claim 39 or 40, further comprising administering at a dose of

47. 47. The method of claim 46, wherein atezolizumab, pemetrexed, and carboplatin are administered sequentially on day 1 of cycles 1-6.

48. 48. The method of claim 47, wherein atezolizumab is administered prior to pemetrexed, wherein pemetrexed is administered prior to carboplatin on day 1 of cycles 1-6.

49. 49. The method of any one of claims 46-48, wherein atezolizumab and pemetrexed are administered consecutively on day 1 of each 21-day cycle for all cycles after cycle 6.

50. 50. The method of claim 49, wherein atezolizumab is administered prior to pemetrexed on day 1 of each 21-day cycle for all cycles after cycle 6.

51. 51. The method of any one of claims 39-50, wherein the atezolizumab, the pemetrexed, and the carboplatin are each administered intravenously.

52. 42. The method of any one of claims 39-41, wherein treatment extends the PFS in the individual by at least about 6 months.

53. 53. The method of any one of claims 39-52, wherein treatment extends the OS in the individual by at least about 15 months.

54. 1. A method of treating an individual with stage IV non-squamous non-small cell lung cancer (NSCLC), comprising administering to the individual effective amounts of atezolizumab, pemetrexed, and cisplatin, wherein the atezolizumab is administered at a dose of 1200 mg and the pemetrexed is administered at a dose of 500 mg / m 2 and the cisplatin is administered at a dose of 75 mg / m 2 wherein said treatment extends progression free survival (PFS) of said individual.

55. 55. The method of claim 54, wherein treatment extends the overall survival (OS) of the individual.

56. Atezolizumab, pemetrexed, and cisplatin are administered in four 21-day cycles, and atezolizumab and pemetrexed are further administered in a 21-day cycle after cycle 4, where atezolizumab is administered at a dose of 1200 mg on day 1 of each 21-day cycle for cycles 1-4, and pemetrexed is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for cycles 1-4. 2 and cisplatin was administered at a dose of 75 mg / m on day 1 of each 21-day cycle in cycles 1-4. 2 and where atezolizumab is further administered at a dose of 1200 mg on day 1 of each 21-day cycle for all cycles after cycle 4, and pemetrexed is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 4. 2 56. The method of claim 54 or 55, further comprising administering at a dose of

57. 57. The method of claim 56, wherein atezolizumab, pemetrexed, and cisplatin are administered sequentially on day 1 of cycles 1-4.

58. 58. The method of claim 57, wherein atezolizumab is administered prior to pemetrexed, wherein pemetrexed is administered prior to cisplatin on day 1 of cycles 1-4.

59. 59. The method of any one of claims 56-58, wherein atezolizumab and pemetrexed are administered consecutively on day 1 of each 21-day cycle for all cycles after cycle 4.

60. 60. The method of claim 59, wherein atezolizumab is administered prior to pemetrexed on day 1 of each 21-day cycle for all cycles after cycle 4.

61. Atezolizumab, pemetrexed, and cisplatin are administered in six 21-day cycles, and atezolizumab and pemetrexed are further administered in a 21-day cycle after cycle 6, where atezolizumab is administered at a dose of 1200 mg on day 1 of each 21-day cycle for cycles 1-6, and pemetrexed is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for cycles 1-6. 2 and cisplatin was administered at a dose of 75 mg / m on day 1 of each 21-day cycle in cycles 1-6. 2 and where atezolizumab is further administered at a dose of 1200 mg on day 1 of each 21-day cycle for all cycles after cycle 6, and pemetrexed is administered at a dose of 500 mg / m on day 1 of each 21-day cycle for all cycles after cycle 6. 2 56. The method of claim 54 or 55, further comprising administering at a dose of

62. 62. The method of claim 61, wherein atezolizumab, pemetrexed, and cisplatin are administered sequentially on day 1 of cycles 1-6.

63. 63. The method of claim 62, wherein atezolizumab is administered prior to pemetrexed, wherein pemetrexed is administered prior to cisplatin on day 1 of cycles 1-6.

64. 64. The method of any one of claims 61-63, wherein atezolizumab and pemetrexed are administered consecutively on day 1 of each 21-day cycle for all cycles after cycle 6.

65. 65. The method of claim 64, wherein atezolizumab is administered prior to pemetrexed on day 1 of each 21-day cycle for all cycles after cycle 6.

66. 66. The method of any one of claims 54-65, wherein the atezolizumab, the pemetrexed, and the cisplatin are each administered intravenously.

67. 67. The method of any one of claims 54-66, wherein treatment extends the PFS in the individual by at least about 6 months.

68. 68. The method of any one of claims 54-67, wherein treatment extends the OS in the individual by at least about 15 months.

69. The method of any one of claims 39 to 68, wherein the individual is treatment-naive for stage IV non-squamous NSCLC.

70. 70. The method of any one of claims 39-69, wherein the individual is chemotherapy naive for stage IV non-squamous NSCLC.

71. 71. The method of any one of claims 39 to 70, wherein the individual is Asian.

72. 72. The method of any one of claims 39 to 71, wherein the individual is at least 65 years of age.

73. 73. The method of any one of claims 39 to 72, wherein the individual is a non-smoker.

74. The method of any one of claims 39 to 73, wherein the individual has high PD-L1.

75. The method of any one of claims 39 to 74, wherein the individual is PD-L1 negative.

76. The method of any one of claims 1 to 75, wherein the individual is a human.

77. 77. A kit comprising an anti-PD-L1 antibody for use in combination with an antimetabolite and a platinum agent to treat an individual with lung cancer according to the method of any one of claims 1 to 38 and 76.

78. A kit comprising atezolizumab for use in combination with pemetrexed and carboplatin to treat an individual with lung cancer according to the method of any one of claims 39-53 and 69-76.

79. A kit comprising atezolizumab for use in combination with pemetrexed and cisplatin to treat an individual with lung cancer according to the method of any one of claims 54 to 76.

80. 1. An anti-PD-L1 antibody for use in a method of treating lung cancer in an individual comprising administering to the individual effective amounts of an anti-PD-L1 antibody, an antimetabolite, and a platinum drug, wherein said treatment extends the progression-free survival (PFS) and / or overall survival (OS) of the individual.

81. The anti-PD-L1 antibody of claim 80 for use in the method of any one of claims 1 to 38 and 76.

82. 1. A composition comprising atezolizumab for use in a method of treating stage IV non-squamous non-small cell lung cancer (NSCLC) comprising administering to an individual effective amounts of atezolizumab, pemetrexed, and carboplatin, wherein the atezolizumab is administered at a dose of 1200 mg and the pemetrexed is administered at a dose of 500 mg / m 2 and said carboplatin is administered at a dose sufficient to achieve an AUC=6 mg / mL / min, wherein said treatment extends progression free survival (PFS) and / or overall survival (OS) of said individual.

83. A composition according to claim 82 for use in a method according to any one of claims 39 to 53 and 69 to 76.

84. 1. A composition comprising atezolizumab for use in a method of treating stage IV non-squamous non-small cell lung cancer (NSCLC) comprising administering to an individual effective amounts of atezolizumab, pemetrexed, and cisplatin, wherein the atezolizumab is administered at a dose of 1200 mg and the pemetrexed is administered at a dose of 500 mg / m 2 and the cisplatin is administered at a dose of 75 mg / m 2 wherein said treatment extends the progression free survival (PFS) and / or overall survival (OS) of said individual.

85. A composition according to claim 84 for use in a method according to any one of claims 54 to 76.